What are Datasets?

Datasets are defined file collections, whose access is governed by a Data Access Committee (DAC).

Total number of Datasets: 3709
Displaying 1 - 3709

Dataset Accession Description Technology Samples File Types
EGAD00001001856 100 other
EGAD00001000602 Illumina HiSeq 2000; 1 bam
EGAD00001000393 Illumina HiSeq 2000; 30 vcf
EGAD00001000597 Illumina HiSeq 2000; 212 bam
EGAD00001000601 Illumina HiSeq 2000; 1 bam
EGAD00001000427 Illumina HiSeq 2000; 30 bam
EGAD00001000628 Illumina HiSeq 2000;, Illumina Genome Analyzer IIx; 66 bam
EGAD00001000632 AB SOLiD 4 System; 12 SOLiD_native_csfasta,SOLiD_native_qual,bam
EGAD00001000659 Illumina HiSeq 2000; 12 bam
EGAD00001000642 Illumina HiScanSQ; 2 bam
EGAD00001000643 Illumina HiScanSQ; 2 bam
EGAD00001001260 Illumina HiSeq 2000; 2 fastq
EGAD00001000667 Illumina HiSeq 2000; 72 bam
EGAD00001000714 102 bam
EGAD00001000711 Illumina HiSeq 2000; 42 bam
EGAD00001000713 Illumina HiSeq 2000; 12 bam
EGAD00001000712 Illumina HiSeq 2000; 72 bam
EGAD00001000856 Illumina HiSeq 2000; 1 fastq
EGAD00001000749 Illumina HiSeq 2000; 12 bam
EGAD00001000704 Illumina HiSeq 2000; 44 bam
EGAD00001000779 AB SOLiD 4 System; 2 bam
EGAD00001000724 Illumina HiSeq 2000; 68 bam
EGAD00001000830 Illumina HiSeq 2000; 14 bam
EGAD00001000834 Illumina HiSeq 2000; 20 bam
EGAD00001000833 Illumina HiSeq 2000; 10 bam
EGAD00001000832 Illumina HiSeq 2000; 16 bam
EGAD00001000829 Illumina HiSeq 2000; 16 bam
EGAD00001000831 Illumina HiSeq 2000; 30 bam
EGAD00001000835 Illumina HiSeq 2000; 8 bam
EGAD00001000849 Illumina HiSeq 2000; 50 bam
EGAD00001000876 Illumina HiSeq 2000; 98 fastq
EGAD00001003280 NextSeq 550;ILLUMINA 16
EGAD00001000880 233 bam,vcf
EGAD00001001213 Illumina HiSeq 2000; 88 bam
EGAD00001001270 Illumina HiSeq 2000; 196 bam
EGAD00001001258 Illumina HiSeq 2000; 5 fastq
EGAD00001001259 Illumina HiSeq 2000; 2 fastq
EGAD00001001257 Illumina HiSeq 2000; 3 fastq
EGAD00001000843 Illumina HiSeq 2000; 12 fastq
EGAD00001000844 Illumina HiSeq 2000; 22 fastq
EGAD00001000836 Illumina HiSeq 2000; 49 bam
EGAD00001000780 Illumina HiSeq 2000; 18 fastq
EGAD00001000759 Illumina HiSeq 2000; 86 bam,fastq
EGAD00001003419 Illumina HiSeq 2000;ILLUMINA 50
EGAD00001001001 2 bam
EGAD00001000896 Illumina HiSeq 2000; 12 bam
EGAD00001001860 19 vcf
EGAD00001001036 Illumina HiSeq 2000; 26 fastq
EGAD00001001044 Ion Torrent PGM; 2 bam
EGAD00001001043 Illumina HiSeq 2000; 8 bam
EGAD00001001014 Illumina HiSeq 2000; 2,597 bam
EGAD00001001015 Illumina HiSeq 2000; 76 bam
EGAD00001000845 44 bam
EGAD00001001072 Illumina MiSeq; 5 fastq
EGAD00001001051 Illumina HiSeq 2000; 200 fastq
EGAD00001001113 Illumina HiSeq 2000; 46 bam
EGAD00001001060 Illumina HiSeq 2000; 112 bam
EGAD00001001084 Illumina HiSeq 2000; 209 fastq
EGAD00001001083 Illumina HiSeq 2000; 2 fastq
EGAD00001001126 340 other
EGAD00001001218 10 bam
EGAD00001001217 15 bam
EGAD00001001096 Illumina HiSeq 2000; 419 bam
EGAD00001001221 Illumina HiSeq 2500; 54 fastq
EGAD00001001220 Illumina HiSeq 1000; 10 bam
EGAD00001001302 Illumina HiSeq 2500; 2 bam
EGAD00001001381 Illumina HiSeq 2000; 69 fastq
EGAD00001001391 Illumina HiSeq 2000; 3 bam
EGAD00001001423 Illumina HiSeq 2000; 7 bam
EGAD00001001436 AB 5500 Genetic Analyzer; 4 bam
EGAD00001001272 Illumina HiSeq 2000; 15 fastq
EGAD00001001616 2 bam
EGAD00001001614 26 bam
EGAD00001001613 10 bam
EGAD00001001615 10 bam
EGAD00001001602 Illumina HiSeq 2000; 1 fastq
EGAD00001001628 Illumina MiSeq;, Illumina HiSeq 2500; 142 bam
EGAD00001001631 Illumina MiSeq; 334 fastq
EGAD00001001275 Illumina HiSeq 2000; 1 fastq
EGAD00001001056 Illumina HiSeq 2000; 7 bam
EGAD00001001688 Illumina HiSeq 2500; 34 fastq
EGAD00001001689 Illumina HiSeq 2500; 27 fastq
EGAD00001001687 Illumina HiSeq 2000; 56 bam,fastq
EGAD00001001379 Illumina HiSeq 2000; 29 bam
EGAD00001001674 Illumina MiSeq;, Illumina HiSeq 2500; 299 bam
EGAD00001001857 Illumina HiSeq 2000; 381 fastq
EGAD00001001927 Illumina HiSeq 2000; 27 fastq
EGAD00001001645 Illumina Genome Analyzer II; 28 bam
EGAD00001002191 Illumina HiSeq 2000; 28 bam,cram
EGAD00001002278 58 vcf
EGAD00001002746 Illumina HiSeq 2000;ILLUMINA 13 bam
EGAD00001002745 Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 7 fastq
EGAD00001001874 Illumina HiSeq 2000; 16
EGAD00001003292 Illumina HiSeq 2000;ILLUMINA 520
EGAD00001003297 9
EGAD00001003302 Illumina HiSeq 3000;ILLUMINA 21
EGAD00001003794 8
EGAD00001003387 MinION;OXFORD_NANOPORE 19
EGAD00001003382 MinION;OXFORD_NANOPORE 26
EGAD00001001112 Illumina HiSeq 2000; 46
EGAD00001003593 Complete Genomics;COMPLETE_GENOMICS 24
EGAD00001001111 Illumina HiSeq 2000; 46
EGAD00001001110 Illumina HiSeq 2000; 46
EGAD00001001109 Illumina HiSeq 2000; 46
EGAD00001003778 Illumina HiSeq 2000;ILLUMINA 1
EGAD00001003825 Illumina MiSeq;ILLUMINA, Illumina HiSeq 2000;ILLUMINA 134
EGAD00001003763 15
EGAD00001003831 NextSeq 500;ILLUMINA 6
EGAD00010000572 Imputation-based meta-analysis of severe malaria in Gambia. 2,870
EGAD00010000570 Imputation-based meta-analysis of severe malaria in Kenya. 3,343
EGAD00001000036 "Copy number variant detection in multiple foci of three prostate cancer tumors" Illumina Genome Analyzer II 9 bam
EGAD00001000035 "Single nucleotide variant detection in multiple foci of three prostate cancer tumors" Illumina Genome Analyzer II 9 bam
EGAD00001000033 "SNV detection from formalin fixed paraffin embedded (FFPE) samples" Illumina Genome Analyzer II 6 bam
EGAD00001000034 "Usage of small amounts of DNA for Illumina sequencing" Illumina Genome Analyzer II 3 bam
EGAD00001001889 ***THIS DATA CAN ONLY BE USED FOR NON-COMMERCIAL CANCER RESEARCH*** Sequencing of organoid cell lines derived from oesophageal tumour sections taken from patients diagnosed with primary oesophageal cancer who underwent tumour resection surgery. HiSeq X Ten; 9 cram
EGAD00001002727 1,591 single cells from 11 colorectal cancer patients were profiled using Fluidigm based single cell RNA-seq protocol to characterized cellular heterogeneity of colorectal cancer. 630 single cells from 7 cell lines were profiled similarly to benchmark de novo cell type identification algorithms. Illumina HiSeq 3000;ILLUMINA 2,221
EGAD00001002226 1. Odors are detected, firstly, by olfactory sensory neurons (OSNs) in the olfactory epithelium of the nose. This neurons then project directly to the olfactory bulb in the brain. Olfaction depends on cellular regeneration of the OE, olfactory bulb and hippocampus, and on their continual re-wiring. The olfactory neural pathway includes regions of the frontal, temporal and limbic brain, which in turn overlap with brain areas involved in brain disorders. OSNs are the only aspect of the human brain exposed to the external environment. This not only makes them vulnerable to environmental changes, but also accessible for biomedical studies. We have already sequenced and developed a protocol for analyzing the transcriptome of mouse main olfactory epithelium and single OSNs. We propose here to perform a similar study for samples from the human olfactory epithelium. We have developed a minimally invasive method for obtaining human OSNs, among other cells from the nasal epithelium. In this experiment, we have obtained cell samples from the olfactory epithelium, including OSN, from healthy volunteers. We would like to further characterize them by RNA sequencing. This will give us valuable insight into human olfaction. It will also provide a first step into a new avenue to study, and find biomarkers for, brain diseases though the analysis of these easily available neurons. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/ Illumina HiSeq 2500; 8 cram
EGAD00001003705 10 single-cell placental RNA libraries were generated using the Chromium Single Cell 3′ Reagent Kit (10X Genomics). All single-cell libraries were sequenced with a customized paired end with dual indexing (98/14/8/10-bp) format according to the recommendation by 10X Genomics. The data were aligned using the Cell Ranger Single-Cell Software Suite (version 1.0). Moreover, plasma RNA from 22 samples were extracted using the RNeasy Mini Kit (Qiagen). cDNA reverse transcription, second-strand synthesis, and RNA-sequencing (RNA-seq) library construction were performed using the Ovation RNA-seq System V2 (NuGEN) kit according to the manufacturer’s protocol. For alignment of the plasma RNA library, adaptor sequences and low-quality bases on the fragment ends (i.e., quality score < 5) were trimmed, and reads were aligned to the human reference genome (hg19) using the TopHat (v2.0.4) software. All aligned reads were deposited in bam file format. Illumina HiSeq 2000;ILLUMINA, NextSeq 500;ILLUMINA 32
EGAD00010001422 1000G Phase 3 Imputed cases and controls from NSAID-induced PUD study Illumina Omni 2.5 676
EGAD00001001456 1000Genomes imputed data set of 581 cases and 417 controls for male-pattern baldness 1 vcf
EGAD00001002204 1006 Familial early onset gemrline CRC patients sequenced by the Molecular and Population Genetics group of the Institute of Cancer Research Illumina HiSeq 2500; 1,006 bam
EGAD00001000618 1204 Sardinian males 1,195 bam
EGAD00001001897 15x whole genome sequencing in samples from the Cretan Greek isolate collection HELIC MANOLIS HiSeq X Ten; 1,482 cram
EGAD00001003205 160 WES and 25 WGS for HBV related HCC, and 15 WES for ICC belongs LICA-CN Illumina HiSeq 2000;ILLUMINA 402
EGAD00001003453 16S sequencing of stool samples of LifeLines-DEEP, domain V4 Illumina MiSeq;ILLUMINA 1,010
EGAD00010000248 1958BC control samples Illumina ImmunoBeadChip - Illuminus, GenoSNP 6,812
EGAD00010000294 1958BC control samples only (Hap300) 2,436
EGAD00010000296 1958BC control samples only (Hap550) 2,224
EGAD00001003250 1cm biospies of from patients undergoing bladder cystectomy will be collected. The underlying muscle and stroma will be removed and the remaining epithelia dissected into small sequential areas which will be sent for ultra-deep exome sequencing using a panel of known cancer and viral genes. Sequence analysis using similar methods to Martincorena I et al (Science 2015, 348:880) will provide an idea of the somatic mutational landscape in these patient samples. Individual patient muscle samples will also be sequenced as a reference. Illumina HiSeq 2000;ILLUMINA 55
EGAD00001001846 2 BRAFV600E cell lines that have been made resistance to 1. the BRAF inhibitor PLX4720 and 2. the combination therapy of dabrafenib and trametinib seem to have a internal duplication in the kinase domain. We would like to know if this is caused by a translocation. HiSeq X Ten; 4 cram
EGAD00001000082 20 Matched Pair Breast Cancer Genomes Illumina HiSeq 2000;ILLUMINA, Illumina Genome Analyzer II;ILLUMINA 42 bam
EGAD00001000409 2000 ulcerative colitis cases drawn from the UKIBD Genetics Consortium cohort and whole-genome sequenced at 2X depth. A case control association study using control samples whole-genome sequenced by UK10K will be undertaken to identify common, low-frequency and rare variants associated with ulcerative colitis. Data will be combined with similar data across 3000 Crohn's disease cases from the same cohort to identify inflammatory bowel disease (IBD) loci and better understand the genetic differences and similarities of the two common forms of IBD. Illumina HiSeq 2000; 1,992 bam
EGAD00001000428 204 individuals were genotyped with the Illumina 2.5M Omni chip. Filtered genotypes were imputed into the 1000 genomes project European panel SNPs. Beagle R2 is indicated in VCF files for further filtering. See Materials and Methods in publication for details. 204 vcf
EGAD00010000536 21 unlinked autosomal microsatellite loci for 30 Central Asian populations Applied Biosystems 3100 automated sequencer-GeneMarker v.1.6 (Softgenetics) 1,702
EGAD00001002262 26 cell lines derived from human Diffuse Large B Cell lymphomas (DLBCL) or Burkit Lymphomas (BL) were subjected to whole exome sequencing. Exome capture was carried out using the SeqCap EZ Exome Library 2.0 kit (Roche/Nimblegen) and 100 bp single-read sequencing was performed on a HiSeq2500 (Illumina). 82% of the coding region was covered at least 30x. Illumina HiSeq 2500; 26 bam
EGAD00010000538 28 unlinked autosomal microsatellite loci for 20 African and 4 philippine populations Applied Biosystems 3100 automated sequencer-GeneMarker v.1.6 (Softgenetics) 1,702
EGAD00010000917 399 tumors profiled using Agilent miRNA microarrays (Product Number G4872A, design ID 046064). The arrays are based on miRBase release 19.0 and 2006 human miRNAs are represented. 150 ng total RNA was used as input. Agilent miRNA microarrays 399
EGAD00010000614 40 Druze Trios 120
EGAD00001001358 463 newly diagnosed patients from the UK Myeloma XI clinical trial (NCT01554852) underwent whole exome sequencing plus targeted capture of the IGH/K/L and MYC loci. 200 ng of DNA were processed using NEBNext DNA library prepartion kit and hybridised to the SureSelect Human All Exon V5 Plus. Four samples were pooled and run on one lane of a HiSeq 2000 using 76-bp paired end reads. DNA from CD138+ selected bone marrow cells (myeloma tumour) as well as peripheral white blood cells were analysed and somatic mutations detected. Illumina HiSeq 2000; 926 bam
EGAD00001001847 4C-seq data was generated for regions of interest to confirm enhancer-gene promoter interactions Illumina HiSeq 2000; 1 fastq
EGAD00001002652 50 ng of genomic double stranded DNA was enzymatically sheared to an average size of 200 bp. Further processing was performed using Illumina Nextera Rapid Capture Custom Kit (Illumina) and 100 bp paired-end sequencing was performed with 24 samples per lane on a Illumina HiSeq 2000 (Illumina) to reach a coverage of 100-1000x. 284 bam,bai
EGAD00001001694 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB10_C 1 other
EGAD00001001695 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB10_F 1 other
EGAD00001001696 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB10_M 1 other
EGAD00001001697 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB15_C 1 other
EGAD00001001698 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB15_F 1 other
EGAD00001001699 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB15_M 1 other
EGAD00001001700 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB1_C 1 other
EGAD00001001701 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB1_F 1 other
EGAD00001001702 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB1_M 1 other
EGAD00001001703 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB21_C 1 other
EGAD00001001704 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB21_F 1 other
EGAD00001001705 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB21_M 1 other
EGAD00001001706 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB22_C 1 other
EGAD00001001707 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB22_F 1 other
EGAD00001001708 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB22_M 1 other
EGAD00001001709 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB23_C 1 other
EGAD00001001710 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB23_F 1 other
EGAD00001001711 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB23_M 1 other
EGAD00001001712 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB24_C 1 other
EGAD00001001713 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB24_F 1 other
EGAD00001001714 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB24_M 1 other
EGAD00001001715 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB25_C 1 other
EGAD00001001716 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB25_F 1 other
EGAD00001001717 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB25_M 1 other
EGAD00001001718 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB27_C 1 other
EGAD00001001719 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB27_F 1 other
EGAD00001001720 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB27_M 1 other
EGAD00001001721 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB28_C 1 other
EGAD00001001722 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB28_F 1 other
EGAD00001001723 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB28_M 1 other
EGAD00001001724 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB30_C 1 other
EGAD00001001725 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB30_F 1 other
EGAD00001001726 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB30_M 1 other
EGAD00001001727 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB31_C 1 other
EGAD00001001728 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB31_F 1 other
EGAD00001001729 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB31_M 1 other
EGAD00001001730 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB33_C 1 other
EGAD00001001731 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB33_F 1 other
EGAD00001001732 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB33_M 1 other
EGAD00001001733 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB35_C 1 other
EGAD00001001734 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB35_F 1 other
EGAD00001001735 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB35_M 1 other
EGAD00001001736 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB38_C 1 other
EGAD00001001737 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB38_F 1 other
EGAD00001001738 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB38_M 1 other
EGAD00001001739 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB40_C 1 other
EGAD00001001740 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB40_F 1 other
EGAD00001001741 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB40_M 1 other
EGAD00001001742 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB41_C 1 other
EGAD00001001743 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB41_F 1 other
EGAD00001001744 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB41_M 1 other
EGAD00001001745 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB42_C 1 other
EGAD00001001746 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB42_F 1 other
EGAD00001001747 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB42_M 1 other
EGAD00001001748 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB43_C 1 other
EGAD00001001749 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB43_F 1 other
EGAD00001001750 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB43_M 1 other
EGAD00001001751 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB44_C 1 other
EGAD00001001752 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB44_F 1 other
EGAD00001001753 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB44_M 1 other
EGAD00001001754 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB4_C 1 other
EGAD00001001755 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB4_F 1 other
EGAD00001001756 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB4_M 1 other
EGAD00001001757 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB50_C 1 other
EGAD00001001758 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB50_F 1 other
EGAD00001001759 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB50_M 1 other
EGAD00001001760 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB51_C 1 other
EGAD00001001761 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB51_F 1 other
EGAD00001001762 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB51_M 1 other
EGAD00001001763 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB52_C 1 other
EGAD00001001764 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB52_F 1 other
EGAD00001001765 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB52_M 1 other
EGAD00001001766 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB55_C 1 other
EGAD00001001767 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB55_F 1 other
EGAD00001001768 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB55_M 1 other
EGAD00001001769 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB57_C 1 other
EGAD00001001770 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB57_F 1 other
EGAD00001001771 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB57_M 1 other
EGAD00001001772 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB58_C 1 other
EGAD00001001773 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB58_F 1 other
EGAD00001001774 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB58_M 1 other
EGAD00001001775 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB60_C 1 other
EGAD00001001776 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB60_F 1 other
EGAD00001001777 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB60_M 1 other
EGAD00001001778 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB62_C 1 other
EGAD00001001779 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB62_F 1 other
EGAD00001001780 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB62_M 1 other
EGAD00001001781 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB8_C 1 other
EGAD00001001782 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB8_F 1 other
EGAD00001001783 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: BvB8_M 1 other
EGAD00001001784 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW12_C 1 other
EGAD00001001785 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW12_F 1 other
EGAD00001001786 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW12_M 1 other
EGAD00001001787 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW14_C 1 other
EGAD00001001788 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW14_F 1 other
EGAD00001001789 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW14_M 1 other
EGAD00001001790 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW15_C 1 other
EGAD00001001791 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW15_F 1 other
EGAD00001001792 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW15_M 1 other
EGAD00001001793 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW18_C 1 other
EGAD00001001794 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW18_F 1 other
EGAD00001001795 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW18_M 1 other
EGAD00001001796 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW20_C 1 other
EGAD00001001797 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW20_F 1 other
EGAD00001001798 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW20_M 1 other
EGAD00001001799 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW22_C 1 other
EGAD00001001800 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW22_F 1 other
EGAD00001001801 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW22_M 1 other
EGAD00001001802 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW24_C 1 other
EGAD00001001803 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW24_F 1 other
EGAD00001001804 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW24_M 1 other
EGAD00001001805 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW27_C 1 other
EGAD00001001806 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW27_F 1 other
EGAD00001001807 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW27_M 1 other
EGAD00001001808 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW29_C 1 other
EGAD00001001809 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW29_F 1 other
EGAD00001001810 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW29_M 1 other
EGAD00001001811 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW2_C 1 other
EGAD00001001812 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW2_F 1 other
EGAD00001001813 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW2_M 1 other
EGAD00001001814 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW32_C 1 other
EGAD00001001815 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW32_F 1 other
EGAD00001001816 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW32_M 1 other
EGAD00001001817 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW38_C 1 other
EGAD00001001818 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW38_F 1 other
EGAD00001001819 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW38_M 1 other
EGAD00001001820 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW3_C 1 other
EGAD00001001821 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW3_F 1 other
EGAD00001001822 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW3_M 1 other
EGAD00001001823 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW46_C 1 other
EGAD00001001824 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW46_F 1 other
EGAD00001001825 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW46_M 1 other
EGAD00001001826 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW47_C 1 other
EGAD00001001827 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW47_F 1 other
EGAD00001001828 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW47_M 1 other
EGAD00001001829 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW49_C 1 other
EGAD00001001830 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW49_F 1 other
EGAD00001001831 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW49_M 1 other
EGAD00001001833 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW4_F 1 other
EGAD00001001834 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW4_M 1 other
EGAD00001001835 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW50_C 1 other
EGAD00001001836 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW50_F 1 other
EGAD00001001837 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW50_M 1 other
EGAD00001001838 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW51_C 1 other
EGAD00001001839 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW51_F 1 other
EGAD00001001840 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW51_M 1 other
EGAD00001001841 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW52_C 1 other
EGAD00001001842 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW52_F 1 other
EGAD00001001843 50 trios were whole genome sequenced with Complete Genomics to a depth of 80x. For each trio the child was affected with severe ID, and the parents were unaffected. All trios were negative for array, targeted gene and whole exome screening. Dataset consists of sample: MW52_M 1 other
EGAD00001003583 516 DNA samples were collected from individuals upon enrollment into the European Prospective Investigation into Cancer and Nutrition study between 1993 and 1998 across 17 different centers. 126bp pair-end reads sequencing data from the Illumina platform were converted to fastq format, the 2bp molecular barcode information at each read of the pair was trimmed and was written in the reads name. The Thymine nucleotide required for ligation was removed from the sequences. Burroughs-Wheeler Aligner (BWA-mem) was used for alignment of the processed fastq files to the reference hg19 genome, following indel-re-alignment using GATK. An in-house algorithm was written to collapse read families that share the same molecular barcode sequence 516
EGAD00010000704 610k genotyping imputed on Hapmap 3 and 1000G Phase 1 CEU 714
EGAD00001000975 65 prostate cancer cases transcriptome sequencing Illumina HiSeq 2000; 130
EGAD00001001004 65 prostate cancer cases wgs sequencing Illumina HiSeq 2000; 130
EGAD00001000983 65 prostate cancer cases wgs sequencing Illumina HiSeq 2000; 10
EGAD00000000020 685 families where both parents have been genotyped together with the child with severe malaria 0
EGAD00001002111 70 Whole exome sequencing from 9 patients with DIPG for project Spatial and Temporal Homogeneity of Driver Mutations in Diffuse Intrinsic Pointine Glioma Illumina HiSeq 2500; 70 bam
EGAD00000000019 840 families where both parents have been genotyped together with the child with severe malaria 0
EGAD00001003854 A ADMSC01_ChIP-Seq(H3K27me3) paired end data for adipose-derived mesenchymal stem cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003867 A ADMSC01_smRNA-Seq single end data for adipose-derived mesenchymal stem cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003878 A ADMSC01_WGBS paired end data for adipose-derived mesenchymal stem cells HiSeq X Ten;ILLUMINA 1
EGAD00001003855 A ADMSC02_ChIP-Seq(H3K27me3) paired end data for adipose-derived mesenchymal stem cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003868 A ADMSC02_smRNA-Seq single end data for adipose-derived mesenchymal stem cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003879 A ADMSC02_WGBS paired end data for adipose-derived mesenchymal stem cells HiSeq X Ten;ILLUMINA 1
EGAD00001003856 A ADMSC03_ChIP-Seq(H3K27me3) paired end data for adipose-derived mesenchymal stem cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003869 A ADMSC03_smRNA-Seq single end data for adipose-derived mesenchymal stem cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003880 A ADMSC03_WGBS paired end data for adipose-derived mesenchymal stem cells HiSeq X Ten;ILLUMINA 1
EGAD00001003857 A ADMSC04_ChIP-Seq(H3K27me3) paired end data for adipose-derived mesenchymal stem cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003870 A ADMSC04_smRNA-Seq single end data for adipose-derived mesenchymal stem cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003881 A ADMSC04_WGBS paired end data for adipose-derived mesenchymal stem cells HiSeq X Ten;ILLUMINA 1
EGAD00001000620 A bespoke targeted pulldown experiment will be performed on patients with Angiosarcoma. the resulting products will be sequenced to determine the prevalence of previously found mutations in these patients. Illumina HiSeq 2000; 14 bam
EGAD00001000679 A bespoke targeted pulldown experiment will be performed on patients with Angiosarcoma. the resulting products will be sequenced to determine the prevalence of previously found mutations in these patients. Illumina HiSeq 2000; 107 bam
EGAD00001003248 A BRAF V600E colorectal organoid which is sensitive to MAP kinase inhibition was mutagenised with the chemical mutagen ENU and then drug selected using a combination of Trametinib, Dabrafenib and Cetuximab. Single cell derived organoids were then manually picked and expanded in drug. Resistance was confirmed in a 14 day assay and DNA was collected. These then underwent targeted amplicon-based sequencing to confirm candidate resistance effectors from a screen in 2 2D BRAF V600E colorectal cell lines. Pools of resistant clones were also sequenced. Illumina MiSeq;ILLUMINA 36
EGAD00001003481 A CKD23_C_Mesan_mRNA-Seq paired end data for Mesangial cells(kidney) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003497 A CKD23_C_Mesan_smRNA-Seq single end data for Mesangial cells(kidney) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003468 A CKD23_C_Mesan_WGBS paired end data for Mesangial cells(kidney) HiSeq X Ten;ILLUMINA 1
EGAD00001003482 A CKD24_C_Podo_mRNA-Seq paired end data for Podocytes(CD90(-) Podocalyxin(+), kidney) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003498 A CKD24_C_Podo_smRNA-Seq single end data for Podocytes(CD90(-) Podocalyxin(+), kidney) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003469 A CKD24_C_Podo_WGBS paired end data for Podocytes(CD90(-) Podocalyxin(+), kidney) HiSeq X Ten;ILLUMINA 1
EGAD00001003483 A CKD25_C_Podo_mRNA-Seq paired end data for Podocytes(CD90(-) Podocalyxin(+), kidney) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003499 A CKD25_C_Podo_smRNA-Seq single end data for Podocytes(CD90(-) Podocalyxin(+), kidney) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003470 A CKD25_C_Podo_WGBS paired end data for Podocytes(CD90(-) Podocalyxin(+), kidney) HiSeq X Ten;ILLUMINA 1
EGAD00001003484 A CKD27_C_Mesan_mRNA-Seq paired end data for Mesangial cells(kidney) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003500 A CKD27_C_Mesan_smRNA-Seq single end data for Mesangial cells(kidney) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003471 A CKD27_C_Mesan_WGBS paired end data for Mesangial cells(kidney) HiSeq X Ten;ILLUMINA 1
EGAD00001000948 A comparison of the somatic variation present in a primary colorectal tumour and three different liver metastases from the same patient. Illumina HiSeq 2000; 6 cram
EGAD00001000149 A Comprehensive Catalogue of Somatic Mutations from a Human Cancer Genome Illumina HiSeq 2000 2 srf
EGAD00001001323 A comprehensive characterisation and analysis of human breast cancers through genome-wide approaches through transcriptomics. Illumina HiSeq 2000; 59 bam
EGAD00001001322 A comprehensive characterisation and analysis of human breast cancers through whole-genome sequencing. Illumina HiSeq 2000; 196 bam
EGAD00001000301 A couple of previously characterized and sequenced libraries will be repeated using a couple of differing size selection criteria and skim sequenced using an Illumina HiSeq. The resulting sequence will be analyzed to determine the optimal DNA library size for our specific downstream analysis. Illumina HiSeq 2000; 1 bam
EGAD00001003138 A dataset consisting of Multi-regional Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) data for 54 samples from 9 patients with hepatocellular carcinoma. The dataset includes 45 tumor samples and 9 normal blood samples. Selected somatic variants were validated by Sequenom. Patients covered are: Patient 1, Patient 2, Patient 3, Patient 4, Patient 5, Patient 6, Patient 7, Patient 8, Patient 9 and Patient 10. Illumina HiSeq 2500;ILLUMINA 54
EGAD00001003485 A DB31_N_Alpha_mRNA-Seq paired end data for alpha cells(PSA-NCAM(-), pancreas) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003494 A DB31_N_Alpha_smRNA-Seq single end data for alpha cells(PSA-NCAM(-), pancreas) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003472 A DB31_N_Alpha_WGBS paired end data for alpha cells(PSA-NCAM(-), pancreas) HiSeq X Ten;ILLUMINA 1
EGAD00010001396 A discovery cohort of 856 adult survivors of pediatric ALL Genome-Wide Human SNP Array 6.0 - Thermo Fisher Scientific 856
EGAD00001003425 A EGFR mutant NSCLC cell line which is sensitive to AZD9291 inhibition was mutagenised with the chemical mutagen ENU and then drug selected using a AZD9291. Single cell derived colonies were then manually picked and expanded in drug. Resistance was confirmed in a 14 day assay and DNA was collected. These then underwent targeted amplicon-based sequencing to confirm candidate resistance effectors hypothesised from currently available literature. This dataset contains all the data available for this study on 2017-07-05. Illumina MiSeq;ILLUMINA 177
EGAD00001002683 A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases 22 bam
EGAD00001003488 A IPS01_N_Fibroblast_mRNA-Seq paired end data for iPSC(Oct4) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003501 A IPS01_N_Fibroblast_smRNA-Seq single end data for iPSC(Oct4) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003473 A IPS01_N_Fibroblast_WGBS paired end data for iPSC(Oct4) HiSeq X Ten;ILLUMINA 1
EGAD00001003489 A IPS02_N_NPC_mRNA-Seq paired end data for Neural progenitor cells(Nestin) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003502 A IPS02_N_NPC_smRNA-Seq single end data for Neural progenitor cells(Nestin) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003474 A IPS02_N_NPC_WGBS paired end data for Neural progenitor cells(Nestin) HiSeq X Ten;ILLUMINA 1
EGAD00001003490 A IPS03_N_ENeuron_mRNA-Seq paired end data for Early neuron cells(Tuj1) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003503 A IPS03_N_ENeuron_smRNA-Seq single end data for Early neuron cells(Tuj1) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003475 A IPS03_N_ENeuron_WGBS paired end data for Early neuron cells(Tuj1) HiSeq X Ten;ILLUMINA 1
EGAD00001003491 A IPS04_X_Fibroblast_mRNA-Seq paired end data for iPSC(Oct4) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003504 A IPS04_X_Fibroblast_smRNA-Seq single end data for iPSC(Oct4) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003476 A IPS04_X_Fibroblast_WGBS paired end data for iPSC(Oct4) HiSeq X Ten;ILLUMINA 1
EGAD00001003492 A IPS05_X_NPC_mRNA-Seq paired end data for Neural progenitor cells(Nestin) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003505 A IPS05_X_NPC_smRNA-Seq single end data for Neural progenitor cells(Nestin) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003477 A IPS05_X_NPC_WGBS paired end data for Neural progenitor cells(Nestin) HiSeq X Ten;ILLUMINA 1
EGAD00001003493 A IPS06_X_ENeuron_mRNA-Seq paired end data for Early neuron cells(Tuj1) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003506 A IPS06_X_ENeuron_smRNA-Seq single end data for Early neuron cells(Tuj1) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003478 A IPS06_X_ENeuron_WGBS paired end data for Early neuron cells(Tuj1) HiSeq X Ten;ILLUMINA 1
EGAD00001002760 A KNIH001 miRNA-seq single end data for islet cells Illumina HiSeq 2500;ILLUMINA 1 fastq
EGAD00001002167 A KNIH001 mRNA-seq paired end data for islet cells Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002749 A KNIH001 Whole-Genome Bisulfite Sequencing(WGBS) paired end data for islet cells Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002761 A KNIH002 miRNA-seq single end data for islet cells Illumina HiSeq 2500;ILLUMINA 1 fastq
EGAD00001002168 A KNIH002 mRNA-seq paired end data for islet cells Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002750 A KNIH002 Whole-Genome Bisulfite Sequencing(WGBS) paired end data for islet cells Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002762 A KNIH003 miRNA-seq single end data for islet cells Illumina HiSeq 2500;ILLUMINA 1 fastq
EGAD00001002169 A KNIH003 mRNA-seq paired end data for islet cells Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002751 A KNIH003 Whole-Genome Bisulfite Sequencing(WGBS) paired end data for islet cells Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002763 A KNIH004 miRNA-seq single end data for islet cells Illumina HiSeq 2500;ILLUMINA 1 fastq
EGAD00001002170 A KNIH004 mRNA-seq paired end data for islet cells Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002752 A KNIH004 Whole-Genome Bisulfite Sequencing(WGBS) paired end data for islet cells Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002764 A KNIH005 miRNA-seq single end data for islet cells Illumina HiSeq 2500;ILLUMINA 1 fastq
EGAD00001002171 A KNIH005 mRNA-seq paired end data for islet cells Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002753 A KNIH005 Whole-Genome Bisulfite Sequencing(WGBS) paired end data for islet cells Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002765 A KNIH006 miRNA-seq single end data for beta cells Illumina HiSeq 2500;ILLUMINA 1 fastq
EGAD00001002172 A KNIH006 mRNA-seq paired end data for beta cells Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002754 A KNIH006 Whole-Genome Bisulfite Sequencing(WGBS) paired end data for beta cells Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002766 A KNIH007 miRNA-seq single end data for adipocytes Illumina HiSeq 2500;ILLUMINA 1 fastq
EGAD00001002173 A KNIH007 mRNA-seq paired end data for adipocytes Illumina HiSeq 2000;, Illumina HiSeq 2500; 1 fastq
EGAD00001002755 A KNIH007 Whole-Genome Bisulfite Sequencing(WGBS) paired end data for adipocytes Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002767 A KNIH008 miRNA-seq single end data for adipocytes Illumina HiSeq 2500;ILLUMINA 1 fastq
EGAD00001002174 A KNIH008 mRNA-seq paired end data for adipocytes Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002756 A KNIH008 Whole-Genome Bisulfite Sequencing(WGBS) paired end data for adipocytes Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002768 A KNIH009 miRNA-seq single end data for preadipocytes Illumina HiSeq 2500;ILLUMINA 1 fastq
EGAD00001002175 A KNIH009 mRNA-seq paired end data for preadipocytes Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002757 A KNIH009 Whole-Genome Bisulfite Sequencing(WGBS) paired end data for preadipocytes Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002769 A KNIH010 miRNA-seq single end data for podocytes Illumina HiSeq 2500;ILLUMINA 1 fastq
EGAD00001002176 A KNIH010 mRNA-seq paired end data for podocytes Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002758 A KNIH010 Whole-Genome Bisulfite Sequencing(WGBS) paired end data for podocytes Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002770 A KNIH011 miRNA-seq single end data for podocytes Illumina HiSeq 2500;ILLUMINA 1 fastq
EGAD00001002177 A KNIH011 mRNA-seq paired end data for podocytes Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00001002759 A KNIH011 Whole-Genome Bisulfite Sequencing(WGBS) paired end data for podocytes Illumina HiSeq 2000;ILLUMINA 1 fastq
EGAD00010000626 A new beta-globin mutation responsible of a beta-thalassemia (HbVar database ID 2928) was observed in 8 unrelated French families. The mutation carriers originated from Nord-Pas-de-Calais, a Northern French region where the chief town is Lille. 5 unrelated mutation carriers were genotyped for a set of 12 microsatellites from chromosome 11, around the beta-globin gene. Among the 5 mutation carriers, 4 were genotyped for 97 European Ancestry Informative SNPs (EAIMs). 37
EGAD00010000624 A new beta-globin mutation responsible of a beta-thalassemia (HbVar database ID 2928) was observed in 8 unrelated French families. The mutation carriers originated from Nord-Pas-de-Calais, a Northern French region where the chief town is Lille. 5 unrelated mutation carriers were genotyped for a set of 12 microsatellites from chromosome 11, around the beta-globin gene. Among the 5 mutation carriers, 4 were genotyped for 97 European Ancestry Informative SNPs (EAIMs). 0
EGAD00001003486 A OB56_N_PreA_mRNA-Seq paired end data for Preadipocytes(fat) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003495 A OB56_N_PreA_smRNA-Seq single end data for Preadipocytes(fat) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003479 A OB56_N_PreA_WGBS paired end data for Preadipocytes(fat) HiSeq X Ten;ILLUMINA 1
EGAD00001003487 A OB57_D_PreA_mRNA-Seq paired end data for Preadipocyte(fat) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003496 A OB57_D_PreA_smRNA-Seq single end data for Preadipocyte(fat) Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003480 A OB57_D_PreA_WGBS paired end data for Preadipocyte(fat) HiSeq X Ten;ILLUMINA 1
EGAD00001001879 A pilot to establish the feasability of using a custom Agilent targeted pulldown of 110 genes implicated in colorectal tumourigensis to sequence for driver mutations in a set of 30 FFPE colorectal adenomas. If successful, we propose to sequence an additional 350 adenomas as part of a MRC research study in order to define the pattern of driver mutations across the spectrum of pathological subtypes including coventional adenomas, serrated adenomas and hyperplastic polyps Illumina HiSeq 2000; 30 cram
EGAD00001000670 A potential and very serious side effect of treating IBD with antiTNFa therapies (the current gold standard) is the development of systemic lupus erythematosis (SLE). This side effect is rare and unpredictable. Out of several thousand cases having received treatment, the University of Calgary have accumulated 12 individuals with full phenotyping and novel serological antibody discovery panel data. We propose to exome sequence these samples in an effort to identify rare highly-penetrant variants that could be underlying this severe phenotype. Illumina HiSeq 2000; 15 bam
EGAD00001002265 A pulldown experiment with Agilent SureSelect probes designed on regions that were more likely to contain de novo mutations. 266 candidate sites were selected based on whole genome sequencing data. The probes also included the exons of genes that have been identified as neurodevelopmental disorder genes in DDD (the DDG2P genes) 1,336 targets. In addition, the design included the standard iPLEX sites. 4 bam,bai
EGAD00010001395 A replication cohort consisting of 1428 adult survivors of any non-ALL pediatric cancer Genome-Wide Human SNP Array 6.0 - Thermo Fisher Scientific 1,428
EGAD00001003335 A resource for assessment of exon CNV calling methods in targeted NGS data, we here present the ICR96 exon CNV validation series. The dataset includes high-quality sequencing data from a targeted NGS assay (the TruSight Cancer Panel) together with Multiplex Ligation-dependent Probe Amplification (MLPA) results for 96 independent samples. 66 samples contain at least one validated exon CNV and 30 samples have validated negative results for exon CNVs in 26 genes. The dataset includes 46 exon CNVs in BRCA1, BRCA2, TP53, MLH1, MSH2, MSH6, PMS2, EPCAM and PTEN, giving excellent representation of the cancer predisposition genes most frequently tested in clinical practice. Moreover, the validated exon CNVs include 25 single exon CNVs the most difficult exon CNV to detect. Illumina HiSeq 2500;ILLUMINA 96
EGAD00001000646 A selection of human cancers harbours somatic driver mutations in genes encoding histones, most notably childhood brain tumours with K27M substitutions of the histone 3.3 gene, H3F3A. We performed whole genome sequencing of the benign cartilage tumour, chondroblastoma, and targeted sequencing of histone 3.3 genes, H3F3A and H3F3B, in seven further skeletal tumour types. We identified an exceptionally high prevalence of novel histone 3.3 driver mutations at glycine 34 and at lysine 36. Histone 3.3 gene mutations were found in 91% in giant cell tumours of bone (48/53), mainly H3F3A G34W variants, and in 92% of chondroblastoma (73/79), predominantly K36M mutations in H3F3B. H3F3B is paralogous to the cancer gene H3F3A. However, H3F3B driver variants have not previously been reported in human cancer. Our observation demonstrate remarkable tumour-specificity of mutations, with respect to which histone 3.3 gene and residue is mutated, indicating that the advantage these mutations confer is tumour dependent. Moreover, tumour-specific mutation of H3F3A and H3F3B suggests, that although both genes encode identical proteins, they are likely non-redundant and employed differentially during skeletal development. Illumina HiSeq 2000; 14 bam
EGAD00001003845 A SMC01_ChIP-Seq(H3K27me3) paired end data for skletal muscle cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003858 A SMC01_smRNA-Seq single end data for skletal muscle cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003871 A SMC01_WGBS paired end data for skletal muscle cells HiSeq X Ten;ILLUMINA 1
EGAD00001003846 A SMC02_ChIP-Seq(H3K27me3) paired end data for skletal muscle cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003859 A SMC02_smRNA-Seq single end data for skletal muscle cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003872 A SMC02_WGBS paired end data for skletal muscle cells HiSeq X Ten;ILLUMINA 1
EGAD00001003847 A SMC03_ChIP-Seq(H3K27me3) paired end data for skletal muscle cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003860 A SMC03_smRNA-Seq single end data for skletal muscle cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003848 A SMC04_ChIP-Seq(H3K27me3) paired end data for skletal muscle cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003861 A SMC04_smRNA-Seq single end data for skletal muscle cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003849 A SMC05_ChIP-Seq(H3K27me3) paired end data for skletal muscle cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003862 A SMC05_smRNA-Seq single end data for skletal muscle cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003873 A SMC05_WGBS paired end data for skletal muscle cells HiSeq X Ten;ILLUMINA 1
EGAD00001003850 A SMC06_ChIP-Seq(H3K27me3) paired end data for skletal muscle cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003863 A SMC06_smRNA-Seq single end data for skletal muscle cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003874 A SMC06_WGBS paired end data for skletal muscle cells HiSeq X Ten;ILLUMINA 1
EGAD00001003851 A SMC07_ChIP-Seq(H3K27me3) paired end data for skletal muscle cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003864 A SMC07_smRNA-Seq single end data for skletal muscle cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003875 A SMC07_WGBS paired end data for skletal muscle cells HiSeq X Ten;ILLUMINA 1
EGAD00001003852 A SMC08_ChIP-Seq(H3K27me3) paired end data for skletal muscle cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003865 A SMC08_smRNA-Seq single end data for skletal muscle cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003876 A SMC08_WGBS paired end data for skletal muscle cells HiSeq X Ten;ILLUMINA 1
EGAD00001003853 A SMC09_ChIP-Seq(H3K27me3) paired end data for skletal muscle cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003866 A SMC09_smRNA-Seq single end data for skletal muscle cells Illumina HiSeq 2500;ILLUMINA 1
EGAD00001003877 A SMC09_WGBS paired end data for skletal muscle cells HiSeq X Ten;ILLUMINA 1
EGAD00001001037 A total of 395 couples were subjected to IVF-PGD treatment, including 129 couples with NGS-based test and 266 couples with SNP array based test for the detection of embryonic chromosomal abnormalities. The NGS test was performed using low coverage whole genome sequencing with HiSeq 2000 platform. And the SNP array test was using Affymetrix Gene Chip Mapping Nsp I 262K. The average age of patients was 32.1 years (age range 20-44 years). Illumina HiSeq 2000; 188 fastq
EGAD00001003805 A whole genome mutation analysis of cortical kidney tissue, an early passage kidney organoid culture derived from the kidney tissue sample, and a late passage of the same organoid culture. HiSeq X Ten (ILLUMINA) 3
EGAD00010000736 AAD case and control samples from UK and Norway 117
EGAD00010000937 ACGH 180K dataset Agilent 180K 5
EGAD00010000935 ACGH 244K dataset Agilent 244K 10
EGAD00010000858 Achalasia cases & controls 8,151
EGAD00001000061 Acral melanoma study whole exomes Illumina Genome Analyzer IIx 3 fastq
EGAD00001000060 Acral melanoma study whole genomes Complete Genomics 3 CompleteGenomics_native
EGAD00001000089 Acute Lymphoblastic Leukemia Exome sequencing Illumina Genome Analyzer II 20 bam
EGAD00001000104 Acute Lymphoblastic Leukemia Exome sequencing 2 Illumina Genome Analyzer II 97 bam
EGAD00001000116 Acute Lymphoblastic Leukemia Sequencing Illumina HiSeq 2000, Illumina Genome Analyzer II, Illumina HiSeq 2000; 61 bam,srf
EGAD00001000404 Acute myeloid leukaemia (AML) is an aggressive and molecularly diverse disease with a poor overall survival of 20-25%. With an annual incidence of 2.9 per 100,000, AML is currently the commonest myeloid malignancy in Europe, yet the two main therapeutic options for this disease, anthracyclines and purine analogues, have remained unchanged for over 20 years. Currently patients are stratified at diagnosis according to a series of clinicopathological parameters (e.g. age, white cell count and presence/absence of previous clonal haematological disease) and molecular markers (e.g. chromosomal translocations/deletions, aneuploidy and mutations in genes such as FLT3 and NPM1). Patients with adverse prognostic features, whose prognosis is particularly poor (e.g. <15% long-term survival) are offered treatment with allogeneic bone marrow transplantation (allo-BMT) if a sibling or unrelated donor is available. This can significantly improve survival (e.g. up to 40% long-term survival in some contexts), albeit at the expense of significant toxicity and transplant-related mortality (TRM). Allo-BMT is thought to work in part by allowing the delivery of large doses of chemotherapy followed by haemopoietic "rescue" with donor haemopoietic stem cells (haemopoietic failure would otherwise ensue). However, potentially the most potent effect of allo-BMT is the cytotoxic effect of donor lymphocytes against AML blasts, a phenomenon known as graft-vs-leukaemia (GVL) effect. Increasingly, transplants using reduced chemotherapy intensity (mini-allografts) are being used that partially circumvent the toxicity from chemotherapy and rely on GVL to effect cure. Nevertheless, AML relapse after allo-BMT still occurs at a significant rate of up to 80% depending on the type of transplant. There is accumulating evidence that genetic events in residual leukaemic cells enable them to evade immunodetection and therefore survive the GVL effect and expand to cause relapse. The most striking example of this is the loss of HLA antigens after transplants in which donor and recipient are not fully HLA-matched. In these cases, the leukaemia "deletes" the genomic region containing the disparate HLA antigen which was preferentially targeted as "foreign" by the GVL effect. However, the genetic basis of immune evasion in the majority of transplants, which are fully HLA matched, is not known. One possibility is that loss of genes coding for antigens outside the HLA locus but which are also targets of GVL may operate, alternatively genetic events that affect processes downstream of immunological cytotoxicity may be responsible. The identification of genetic events that mediate immune evasion would not only facilitate the understanding of this process but can help plan therapeutic interventions that improve the outcomes of allogeneic transplantation for AML and other disorders. We intend to study this by conducting exome sequencing on 6 cases of AMLs from patients that attend my clinic at Addenbrooke's hospital and have relapsed after allogeneic transplantation. Samples from AML diagnosis, remission/normal and AML relapse (total n=18) will be studied to identify somatic mutations in the primary AML and those acquired by the relapsed clone. The 18 samples will also be studied by array CGH to detect regions of genomic amplification or deletion. Illumina HiSeq 2000; 25 bam
EGAD00001000095 Acute Myeloid Leukemia Sequencing Illumina Genome Analyzer II 9 bam
EGAD00001000101 ADCC Exome Sequencing Illumina Genome Analyzer II, Illumina HiSeq 2000; 125 bam
EGAD00001000062 ADCC Rearrangement Screen Illumina HiSeq 2000, Illumina Genome Analyzer II 14 bam,srf
EGAD00001002667 Additional files for "The Genomic Landscape of Core-Binding Factor Acute Myeloid Leukemias" (EGAS00001000349). This dataset includes the processed Excap data referenced in this paper. Illumina HiSeq 2000;ILLUMINA 327 bam
EGAD00001002530 Additional files for "The Genomic Landscape of Core-Binding Factor Acute Myeloid Leukemias" (EGAS00001000349). This dataset includes the processed RNASeq data referenced in this paper. Illumina HiSeq 2000;ILLUMINA 36 bam
EGAD00001002192 Additional sequencing data for 173 donors in EGAS00001000154, a study of Pancreatic Ductal Adenocarcinoma. WGS libraries were used for high-cellularity cases, WXS sequencing to high depth on low-cellularity cases. HiSeq 2xxx platform was used in all cases. The analysis files associated with this dataset are merged, de-duplicated bams aligned against GRCh37, one tumour and one normal bam per donor. 346 bam
EGAD00001002741 Additional Xenograph files for PCGP SJERG Illumina HiSeq 2000;ILLUMINA 11 bam
EGAD00001000764 Adrenocortical carcinomas (ACC) are aggressive cancers originating in the cortex of the adrenal glands. Despite the overall poor prognosis, ACC outcome is heterogeneous. CTNNB1 and TP53 mutations are frequent in these tumors, but the complete spectrum of genetic changes remains undefined. Exome sequencing and SNP array analysis of 45 ACC revealed recurrent alterations in known drivers (CTNNB1, TP53, CDKN2A, RB1, MEN1) and genes not previously reported to be altered in ACC (ZNRF3, DAXX, TERT and MED12), which were validated in an independent cohort of 77 ACC. The cell-surface transmembrane E3 ubiquitin ligase ZNRF36 was the gene the most frequently altered (21%), and appears as a potential novel tumor suppressor gene related to the ß-catenin pathway. Our integrated genomic analyses led to the identification of two distinct molecular subgroups with opposite outcome. The C1A group of poor outcome ACC was characterized by numerous mutations and DNA methylation alterations, whereas the C1B group with good prognosis displayed a specific deregulation of two miRNA clusters. Thus, aggressive and indolent ACC correspond to two distinct molecular entities, driven by different oncogenic alterations. Illumina HiSeq 2000; 45 bam
EGAD00010000164 Affymetrix 6.0 CEL files Affymetrix SNP 6.0 1,992
EGAD00010000158 Affymetrix 6.0 cel files Affymetrix SNP 6.0 1,001
EGAD00010000936 Affymetrix Exon Array dataset Affymetrix GeneChip Human Exon 1.0 ST 2
EGAD00010001275 Affymetrix GeneChip® Human Transcriptome Array 2.0 Affymetrix GeneChip® Human Transcriptome Array 2.0 34
EGAD00010001273 Affymetrix GeneChip® Human Transcriptome Array 2.0 Affymetrix GeneChip® Human Transcriptome Array 2.0 34
EGAD00010000490 Affymetrix Genome-Wide Human SNP Array 6.0 data Affymetrix 6.0- 19
EGAD00010000442 Affymetrix SNP 6.0 CEL files Affymetrix_SNP6_raw 1,302
EGAD00010001079 Affymetrix SNP6.0 array breast cancer data Affymetrix SNP6.0 66
EGAD00010000915 Affymetrix SNP6.0 breast cancer genome sequencing data Affymetrix SNP6.0 344
EGAD00010000644 Affymetrix SNP6.0 cancer cell line exome sequencing data 1,022
EGAD00010000498 Affymetrix SNP6.0 genotype data for prostate cancer patients Affymetrix_SNP6- 18
EGAD00001001612 After overexpression and knockdown of both described novel miRs nmiR-1 and nmiR-2 in BL cell lines (SU-DHL4 for nmiR-1 and Raji for nmiR-2), we performed regular RNA-Seq (including Mock controls for all cell lines) to identify their direct and indirect downstream mRNA targets. Illumina HiSeq 2500; 16 fastq
EGAD00000000058 Aggregate results from 22 Carbamazepine-induced hypersensitivity syndrome patients and 2691 UK National Blood Service (NBS) control samples Illumina Infinium 1.2M 2,713
EGAD00000000059 Aggregate results from 43 Carbamazepine-induced hypersensitivity syndrome patients and 1296 1958 British Birth Cohort control samples Affymetrix 500K, Illumina 610K Quad 1,339
EGAD00000000029 Aggregate results from a case-control study on stroke and ischemic stroke. 19,602
EGAD00000000028 Aggregate results from a GWAS study on 3352 cases abd 3145 controls iSelect Beadchip 6,497
EGAD00010000934 Agilent miRNA dataset Agilent SurePrint Human miRNA Microarray 2
EGAD00010000444 Agilent ncRNA 60k txt files Agilent ncRNA 60k 1,480
EGAD00001000289 Agilent whole exome hybridisation capture was performed on genomic DNA derived from cancer and matched normal DNA from the same patients. Next Generation sequencing performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes. Now we aim to re find and validate the findings of those exome libraries using bespoke pulldown methods and sequencing the products. Illumina HiSeq 2000; 12 bam
EGAD00001000392 Agilent whole exome hybridisation capture was performed on genomic DNA derived from Chondrosarcoma cancer and matched normal DNA from the same patients. Next Generation sequencing performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes. Now we aim to re find and validate the findings of those exome libraries using bespoke pulldown methods and sequencing the products. Illumina MiSeq; 60 bam
EGAD00001000283 Agilent whole exome hybridisation capture was performed on genomic DNA derived from MDS and matched normal DNA from the same patients. Next Generation sequencing performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes. Now we aim to discover the prevalence of our findings using bespoke pulldown methods and sequencing the products from a larger set of patient DNA. Illumina HiSeq 2000; 764 bam
EGAD00001000287 Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 25 renal cancers and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 50 exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes. Illumina Genome Analyzer II; 54 bam,srf
EGAD00001000014 Agilent whole exome hybridisation capture will be performed on genomic DNA derived from 25 renal cancers and matched normal DNA from the same patients. Three lanes of Illumina GA sequencing will be performed on the resulting 50 exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes. Illumina Genome Analyzer II;, Illumina Genome Analyzer II 54 bam,srf
EGAD00001003203 Aligned (hg19) sequencing data from 16 participants with FL/DLBCL. 37
EGAD00001001608 Aligned BAM files of whole exome sequencing of 20 syCRCs and 10 normal counterparts. Each sample of 4 patients (S13, S3, S12 and S6) underwent two sequencing rounds. Illumina HiSeq 2000;, Illumina HiSeq 2500; 42 bam
EGAD00001001329 Aligned Sequence (bam format), Duplicates removed 28 bam
EGAD00001003139 Aligned sequence data for 124 CPCGene Tumour/Normal Pairs from the 200PG Study 262
EGAD00001002739 Aligned sequence data from 14 Prostate cancer samples with BRCA2 mutations 49 bam
EGAD00001001435 Aligned whole genome bisulfite sequencing data for reference epigenomes generated at Centre for Epigenome Mapping Technologies, Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. 30 bam
EGAD00001003234 Aligned whole genome sequence from AML relapse project 33
EGAD00001003221 Aligned, merged and deduplicated BAM files from BGISeq-500 sequencing of six samples: matched tumour-normal pairs from three melanoma patients. 6
EGAD00001003357 Aligned, merged and deduplicated BAM files from HiSeq whole exome sequencing of 106 samples: matched tumour-normal pairs from 53 melanoma patients. 106
EGAD00001003388 Aligned, merged and deduplicated BAM files from HiSeq whole genome sequencing of 366 samples: matched tumour-normal pairs from 183 melanoma patients. 366
EGAD00001003222 Aligned, merged and deduplicated BAM files from HiSeqXTen sequencing of six samples: matched tumour-normal pairs from three melanoma patients. 6
EGAD00001003157 Alignment of Genome Denmark Phase II dataset to GRCh38. The dataset consists of 150 Danish individuals (50 trios) sequenced to 80X. The BAM-file contains data from multiple libraries created from one individual with libraries of 180, 500, 800, 2000, 5000, 10000 and 20000 bp. The libraries were created using standard Illumina protocols for paired end reads (180-800bp libraries) and mate pair libraries (2kb-20kb). 150
EGAD00001000078 ALK inhibitors in the context of ALK-dependent cancer cell lines Illumina HiSeq 2000, Illumina HiSeq 2000; 16 bam,cram
EGAD00010000298 All cases and controls (Hap300) 13,761
EGAD00010000286 All cases and controls (Hap550) Illumina (various) 11,950
EGAD00010000292 All cases and Finnish, Dutch, Italian control samples (Hap300) 10,339
EGAD00010000288 All cases and Finnish, Dutch, Italian control samples (Hap550) 6,313
EGAD00001001380 All humans outside Africa are descendants of the same single exit, usually dated at 50-70 thousand years ago. However, the route taken out of Africa is still debated. The two main candidates are a northern route via Egypt and the Levant, or a southern route via Ethiopia and the Arabian Peninsula. We are generating genetic data to evaluate these two possibilities. In this study we propose to generate high-coverage sequencing data for 3 Egyptian samples. Illumina HiSeq 2000; 3 cram
EGAD00001001372 All humans outside Africa are descendants of the same single exit, usually dated at 50-70 thousand years ago. However, the route taken out of Africa is still debated. The two main candidates are a northern route via Egypt and the Levant, or a southern route via Ethiopia and the Arabian Peninsula. We are generating genetic data to evaluate these two possibilities. In this study we propose to generate low-coverage sequencing data for 100 Egyptian samples. Illumina HiSeq 2000; 100 cram
EGAD00001001921 All pituitary samples Illumina HiSeq 2500; 84 bam
EGAD00001001457 All samples from the "100" project Illumina HiSeq 2000; 238 bam
EGAD00001001210 Altered translation response to stress by medulloblastoma-associated DDX3X mutations 28 bam
EGAD00001000817 Alternative splicing plays critical roles in differentiation, development, and cancer (Pettigrew et al., 2008; Chen and Manley, 2009). The recent identification of specific spliceosome inhibitors has generated interest in the therapeutic potential of targeting this cellular process (van Alphen et al., 2009). Using an integrated genomic approach, we have identified PRPF6, an RNA binding component of the pre-mRNA spliceosome, as an essential driver of oncogenesis in colon cancer. Importantly, PRPF6 is both amplified and overexpressed in colon cancer, and only colon cancer cells with high PRPF6 levels are sensitive to its loss. Our data clearly point to an important role for PRPF6 in colon cancer growth and suggest that a better understanding of its role in alternative splicing in colon cancer is warranted. To determine the specific alternative splice forms that PRPF6 regulates in colon cancer, we plan three experiments: 1. The first involves knocking down expression of PRPF6 in two different cancer cell lines with 3 different siRNAs, and then completing RNA-seq to determine the gene expression changes that occur relative to a non-targeting control siRNA. Because of the role for PRPF6 in pre-mRNA splicing, we especially want to quantify the changes in splice-specific forms of all genes genome-wide to identify genes whose splicing is altered upon PRPF6 knockdown. 2. The second involves immunoprecipitating PRPF6 from two different cancer cell lines and isolating any RNA that is bound to PRPF6, since PRPF6 is an RNA-binding protein. We then want to carry out RNA-seq to identify which RNA molecules co-immunoprecipitated with PRPF6. This will help us determine possible functions for PRPF6 in regulating colon cancer growth. 3. The third involves overexpressing PRPF6 in cell lines and then carrying out RNA-seq to identify any changes in splice-specific gene expression. This will allow us to determine whether increased PRPF6 expression is sufficient to drive alternative splicing changes. Illumina HiSeq 2000; 34 fastq
EGAD00001001873 AML emerges as a consequence of accumulating independent genetic aberrations that direct regulation and/or dysfunction of genes resulting in aberrant activation of signalling pathways, resistance to apoptosis and uncontrolled proliferation. Given the significant heterogeneity of AML genomes, AML patients demonstrate a highly variable response rate and poor median survival in response to current chemotherapy regimens. For the past 4 years we have conducted gene expression profiling on purified bone marrow populations equating to normal haematopoietic stem and progenitor cells from healthy subjects and patients with de novo AML in order to identify AML signatures of aberrantly expressed genes in cancer versus normal. We are now applying a series of bioinformatic methodologies combined with clinical and conventional diagnostic data to establish novel genomics strategies for improved prognostication of AML. Additionally, we use our AML signatures to unravel oncogenic signalling pathway activities in AML patients and test inhibitory drugs for these pathways inn preclinical therapeutic programmes. We consider that superimposing GEP and clinical data for our AML patient cohort with additional data on their mutational status will significantly improve the prognostic power of the study as well as unravel yet unknown mutations associated with aberrant signalling activities of oncogenic pathways. Illumina HiSeq 2000; 215 cram
EGAD00001000253 AML targeted resequencing study Illumina HiSeq 2000; 1,972 bam
EGAD00001002896 Amplicon sequencing libraries from the study "Histological Transformation and Progression in Follicular Lymphoma: a Clonal Evolution Study". These are Illumina amplicon deep sequencing libraries (n = 118) to validate somatic predictions made in the whole genome sequencing libraries. Specifically, there are 72 tumor libraries and 46 normal libraries. Some patients may have multiple amplicon libraries sequenced. Illumina HiSeq 2000;ILLUMINA 118
EGAD00001003196 Amplicon-based fungal metagenomic sequencing for the identification of fungal species in brain tissue from Alzheimer's disease. The study consists in 14 samples, sequenced using Illumina's paired-end technology. Illumina MiSeq;ILLUMINA 14
EGAD00001003409 Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are part of a clinical, pathological and genetic continuum. The purpose of the present study was to assess the mutation burden that is present in ALS and/or FTD known disease-causing genes in 54 patients (16 with available postmortem neuropathological diagnosis) with concurrent ALS and FTD (ALS/FTD) not-carrying the C9orf72 hexanucleotide repeat expansion, the most important genetic cause in both diseases. Illumina HiSeq 2500;ILLUMINA 54
EGAD00001000037 An evaluation of different strategies for large-scale pooled sequencing study design. Illumina Genome Analyzer II 7 bam,srf
EGAD00001003810 An RNA Seq study of the effects of HDAC inhibitor Quisinostat on six different synovial sarcoma cell lines NextSeq 500;ILLUMINA 12
EGAD00001000660 Analysis .bam files from HiSeq sequencing of Australian ICGC PDAC study samples, submitted 20130826 353 bam
EGAD00001000030 Analysis of genomic integrity of disease-corrected human induced pluripotent stem cells by exome sequencing Illumina HiSeq 2000 4 bam
EGAD00001000086 Analysis of genomic integrity of disease-corrected human induced pluripotent stem cells by exome sequencing Illumina HiSeq 2000 16 bam
EGAD00001003282 Analysis scripts and output 37
EGAD00001001267 Anaplastic meningiomas are a rare, malignant variant of meningioma. At present there is no effective treatment for this cancer. The aim of the study is to identify somatic mutations in anaplastic meningiomas. We plan to sequence a set of 500 known cancer genes in 50 anaplastic meningioma and corresponding peripheral blood DNA samples. Bioinformatics will be used to analyse the results to assess the probability of these mutations being causal and so likely of critical importance for the tumour growth. Identification of these mutations will guide selection of appropriate compounds to effectively treat the disease. HiSeq X Ten; 60 cram
EGAD00001001452 Anaplastic oligodendrogliomas (AOs) are rare primary brain tumors which are generally incurable, with heterogeneous prognosis and few treatment targets identified. Most oligodendrogliomas have chromosome 1p/19q co-deletion and IDH mutation. We analyzed 51 AOs by whole-exome sequencing, identifying previously reported frequent somatic mutations in CIC and FUBP1. We also identified recurrent mutations in TCF12 and in an additional series of 83 AO. Overall 7.5% of AO are mutated for TCF12, which encodes an oligodendrocyte-related transcription factor. 80% of TCF12 mutations identified were in either the bHLH domain, which is important for TCF12 function as a transcription factor, or were frame shift mutations leading to TCF12 truncated for this domain. We show that these mutations compromise TCF12 transcriptional activity and are associated with a more aggressive tumor type. Our analysis provides further insights into the unique and shared pathways driving AO. Illumina HiSeq 2000; 102 bam
EGAD00010001055 APCDR AGV Project: Array data from 100 Baganda. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2.5-4v1_B and HumanOmni2-5_8v1_A 100
EGAD00010001053 APCDR AGV Project: Array data from 100 Banyarwanda. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2.5-4v1_B and HumanOmni2-5_8v1_A 100
EGAD00010001058 APCDR AGV Project: Array data from 100 Ga-Adangbe. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2.5-4v1_B and HumanOmni2-5_8v1_A 100
EGAD00010001052 APCDR AGV Project: Array data from 100 Kalenjin. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2.5-4v1_B 100
EGAD00010001056 APCDR AGV Project: Array data from 100 Zulu. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2.5-4v1_B and HumanOmni2-5_8v1_A 100
EGAD00010001047 APCDR AGV Project: Array data from 107 Ethiopians (Amhara, Oromo, Somali; subset of Ethiopian Genome Project Genotyping). Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2-5_8v1_A 107
EGAD00010001054 APCDR AGV Project: Array data from 74 Fula Illumina HumanOmni2-5_8v1_A 74
EGAD00010001050 APCDR AGV Project: Array data from 78 Wolof. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2-5_8v1_A 78
EGAD00010001048 APCDR AGV Project: Array data from 79 Jola. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2-5_8v1_A 79
EGAD00010001046 APCDR AGV Project: Array data from 86 Sotho. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2-5_8v1_A 86
EGAD00010001057 APCDR AGV Project: Array data from 88 Mandinka. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2-5_8v1_A 88
EGAD00010001051 APCDR AGV Project: Array data from 97 Barundi. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2-5_8v1_A 97
EGAD00010001045 APCDR AGV Project: Array data from 99 Igbo. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2.5-4v1_B 99
EGAD00010001049 APCDR AGV Project: Array data from 99 Kikuyu. Raw data, intensity files and post-QC Plink files. Illumina HumanOmni2.5-4v1_B 99
EGAD00010000714 aplastic anemia samples tumor using 250K Affymetrix 250K Nsp-GTYPE 440
EGAD00001001092 Approximately 80% of clinically clearly diagnosed patients suffering from primary ciliary dyskinesia (PCD) cannot be assigned to a specific gene defect. Despite extensive research on PCD and despite the increasing number of PCD genes and knowledge about their sites of action as e.g structural component or cytoplasmic pre-assembly factor, the biology of motile cilia and the pathomechanism leading to PCD is largely unknown. The aim of this study is to identify novel PCD related genes and processes relevant for motile cilia function. We will perform exome sequencing, aiming on the analysis of family trios. In these families, the diagnosis of PCD is secured, but the underlying gene defects has so far not been identified. Illumina HiSeq 2000; 150 cram
EGAD00010001075 Argentine samples using 250K Illumina Exome 250K 391
EGAD00001002186 Around 10% of patients who present in melanoma clinics have a first degree relative with a previous diagnosis of melanoma. While around 3% have three or more relatives who have been diagnosed with the disease. In this project we will whole genome sequence patients from large Dutch familial melanoma pedigrees to identify mutations in genes that drive melanomagenesis. The identification of these genes will facilitate the management of familial melanoma patients and their families. Illumina HiSeq 2000;, Illumina HiSeq 2500; 38 cram
EGAD00001001271 Around 50 samples of pre-invasive lung cancer lesions showing subsequent clinical and pathological progression or regression HiSeq X Ten; 50 cram
EGAD00010000965 Array data from 4778 individuals from general population of rural Uganda Illumina HumanOmni2.5-8 BeadChip 4,778
EGAD00010001287 Array methylation profiling of knee osteoarthritis patients who have undergone total joint replacement Illumina HumanMethylation450K 68
EGAD00010001447 Array-based association data Illumina Omni Express/Illumina Core Exome 784
EGAD00001002773 As part of the International Parkinson Disease Genomics Consortium, exomes of Parkinson disease (PD) patients and healthy controls were sequenced to study the genetic etiology of PD. The Dutch cohort consists of 175 patients with a young age of onset below 50 years. Researchers can apply for access to fastq files for this cohort. Illumina HiSeq 2000;ILLUMINA 211 fastq
EGAD00001003096 As part of the International Parkinson's Disease Genomics Consortium, exomes of Parkinson's disease (PD) patients and healthy controls were sequenced to study the genetic etiology of PD. This UK cohort consists of 70 PD patients. Researchers can apply for access to fastq files for this cohort. Illumina HiSeq 2000;ILLUMINA 77 fastq
EGAD00001002911 ATAC-seq data for 1 sample(s) for germinal center B cell from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002906 ATAC-seq data for 1 sample(s) for monocyte RPMI_BG_T=1hr from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002909 ATAC-seq data for 1 sample(s) for monocyte RPMI_BG_T=24hrs from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002904 ATAC-seq data for 1 sample(s) for monocyte RPMI_BG_T=24hrs_RPMI_T=5days from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002915 ATAC-seq data for 1 sample(s) for monocyte RPMI_BG_T=24hrs_RPMI_T=5days_LPS_T=4hrs from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002910 ATAC-seq data for 1 sample(s) for monocyte RPMI_BG_T=4hrs from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002913 ATAC-seq data for 1 sample(s) for monocyte RPMI_LPS_T=1hr from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002900 ATAC-seq data for 1 sample(s) for monocyte RPMI_LPS_T=24hrs from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002922 ATAC-seq data for 1 sample(s) for monocyte RPMI_LPS_T=4hrs from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002919 ATAC-seq data for 1 sample(s) for monocyte RPMI_T=1hr from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002921 ATAC-seq data for 1 sample(s) for monocyte RPMI_T=24hrs from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002899 ATAC-seq data for 1 sample(s) for monocyte RPMI_T=4hrs from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002914 ATAC-seq data for 1 sample(s) for monocyte RPMI_T=6days from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002916 ATAC-seq data for 106 sample(s) Chronic Lymphocytic Leukemia from venous blood, on Genome GRCh38. 111 run(s), 109 experiment(s), 109 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 106 bam,fastq
EGAD00001002709 ATAC-seq data for 136 sample(s) from venous blood, on Genome GRCh38. 141 run(s), 139 experiment(s), 139 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 136 bam,fastq
EGAD00001002908 ATAC-seq data for 2 sample(s) for class switched memory B cell from venous blood, on Genome GRCh38. 2 run(s), 2 experiment(s), 2 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002917 ATAC-seq data for 2 sample(s) for germinal center B cell from tonsil, on Genome GRCh38. 2 run(s), 2 experiment(s), 2 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002901 ATAC-seq data for 2 sample(s) for monocyte RPMI_LPS_T=24hrs_RPMI_T=5days from venous blood, on Genome GRCh38. 2 run(s), 2 experiment(s), 2 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002907 ATAC-seq data for 2 sample(s) for osteoclast from venous blood, on Genome GRCh38. 2 run(s), 2 experiment(s), 2 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002912 ATAC-seq data for 2 sample(s) for plasma cell from tonsil, on Genome GRCh38. 2 run(s), 2 experiment(s), 2 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002903 ATAC-seq data for 3 sample(s) for naive B cell from tonsil, on Genome GRCh38. 3 run(s), 3 experiment(s), 3 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 3 bam,fastq
EGAD00001002902 ATAC-seq data for 3 sample(s) for naive B cell from venous blood, on Genome GRCh38. 3 run(s), 3 experiment(s), 3 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 3 bam,fastq
EGAD00001002905 ATAC-seq data for 3 sample(s) for unswitched memory B cell from venous blood, on Genome GRCh38. 3 run(s), 3 experiment(s), 3 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 3 bam,fastq
EGAD00001002710 ATAC-seq data for 4 sample(s) from bone marrow, on Genome GRCh38. 4 run(s), 4 experiment(s), 4 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 4 bam,fastq
EGAD00001002920 ATAC-seq data for 4 sample(s) Multiple Myeloma for plasma cell from bone marrow, on Genome GRCh38. 4 run(s), 4 experiment(s), 4 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 4 bam,fastq
EGAD00001003759 ATAC-seq data for 5 non-diabetic human pancreatic islet samples Illumina HiSeq 2500;ILLUMINA 5
EGAD00001002918 ATAC-seq data for 5 sample(s) Mantle Cell Lymphoma from venous blood, on Genome GRCh38. 5 run(s), 5 experiment(s), 5 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 5 bam,fastq
EGAD00001002708 ATAC-seq data for 7 sample(s) from tonsil, on Genome GRCh38. 7 run(s), 7 experiment(s), 7 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 7 bam,fastq
EGAD00010000815 ATL tumor samples using Affymetrix 250K SNP array 1
EGAD00010000813 ATL tumor samples using Illumina 450K Methylation array 1
EGAD00010000811 ATL tumor samples using Illumina 610K SNP array 1
EGAD00001000799 Atrio-ventricular septal defects (AVSD) are a specific form of congenital heart structural defect that result from abnormal or inadequate fusion of endocardial cushions during cardiac development. This project is focused on identifying rare coding variation that substantially increases risk of AVSD, by exome sequencing of AVSD patients and some of their family members, and comparing to control datasets from other sources. The exome sequencing is performed using Agilent SureSelect 50Mb exome v3 and Hiseq 75bp paired reads with an mean sequencing coverage target of 50X. Illumina HiSeq 2000; 95 bam
EGAD00010000789 ATRT expression Illumina Human HT6-v3 Array 4
EGAD00010000790 ATRT expression Illumina Human HT6-v3 Array 41
EGAD00010000712 ATRT genotyping 0
EGAD00010000710 ATRT genotyping blood 0
EGAD00001001444 Atypical teratoid/rhabdoid tumor (ATRT) is one of the most common brain tumors in infants and young children. Although the prognosis of ATRT patients is poor, some patients respond very well to current treatments, suggesting inter-tumor molecular heterogeneity. To investigate this further, we genetically and epigenetically analyzed a large cohort of ATRTs (n = 170). Three distinct molecular subgroups of ATRTs, associated with differences in demographics, tumor location and type of SMARCB1 alterations, were identified using DNA-methylation or gene expression analyses. Whole genome DNA- and RNA-sequencing found no other recurrent mutations explaining the differences between subgroups. However, whole genome bisulfite-sequencing and H3K27Ac ChIP-sequencing of primary tumors revealed clear differences in methylation patterns and enhancer landscapes, leading to the identification of subgroup-specific regulatory networks. Illumina HiSeq 2000;, Illumina HiSeq 2500; 55 fastq
EGAD00001002725 Autism spectrum disorder (ASD) is a collection of neuro-developmental disorders characterized by deficits in social interaction and social communication, along with restricted and repetitive behaviour patterns. we globally interrogated the histone acetylomes of enhancers in a large cohort of ASD and control samples by analyzing tissue from three brain regions postmortem: prefrontal cortex (PFC), temporal cortex (TC) and cerebellum (CB). H3K27ac was selected as the representative acetylation mark and 288 ChIP-seq were performed on these postmortem samples. Illumina HiSeq 2000;ILLUMINA 291 bam
EGAD00010001255 Autosomal STR genotypes using 15 Identifiler loci Applied Biosystems 990
EGAD00001000708 AZIN1 amplicon sequencing data of the EGAS00001000495 project. 454 GS FLX Titanium; 69 fastq
EGAD00001003326 Azoospermia, characterized by the absence of spermatozoa in the ejaculate is a common cause of male infertility with a poorly characterized etiology. Exome sequencing analysis of two azoospermic brothers allowed the identification of a homozygous splice mutation in SPINK2, encoding a serine protease inhibitor believed to target acrosin, the main sperm acrosomal protease. In accord with these findings we observed that homozygous Spink2 KO male mice had azoospermia. Moreover, despite normal fertility, heterozygous male mice had a high rate of morphologically abnormal spermatozoa and a reduced sperm motility. Further analysis demonstrated that in the absence of Spink2, protease-induced stress initiates Golgi fragmentation and prevents acrosome biogenesis leading to spermatid differentiation arrest. We also observed a deleterious effect of acrosin overexpression in HEK cells, effect that was alleviated by SPINK2 coexpression confirming its role as acrosin inhibitor. These results demonstrate that SPINK2 is necessary to neutralize proteases during their cellular transit towards the acrosome and that its deficiency induces a pathological continuum ranging from oligoasthenoteratozoospermia in heterozygotes to azoospermia in homozygotes. Illumina HiSeq 2000;ILLUMINA 2
EGAD00001003206 BACKGROUND TRACERx (TRAcking Cancer Evolution through therapy (Rx)) is a prospective cohort study designed to investigate intratumor heterogeneity (ITH) in relation to clinical outcome, and to determine the clonal nature of driver events and evolutionary processes in early stage non-small cell lung cancer (NSCLC). METHODS Multiregion high-depth whole-exome sequencing (M-seq) was performed on 100 early stage NSCLC tumors resected prior to systemic therapy. A total of 327 tumor regions were sequenced and analyzed to define evolutionary histories, obtain a census of clonal and subclonal events, and assess the relationship between ITH and recurrence-free survival (RFS). RESULTS Widespread ITH was observed for both somatic copy number alterations (median 48% [0.03-88%]) and mutations (median 30% [0.5-93%]). Driver mutations in EGFR, MET, BRAF and TP53 were almost always clonal. However, heterogeneous driver alterations occurring later in evolution were found in over 75% of tumors and were common in PIK3CA, NF1 and genes involved in chromatin modification and DNA response and repair. Genome doubling and ongoing dynamic chromosomal instability (CIN), illustrated by mirrored subclonal allelic imbalance, were identified as causes of ITH resulting in parallel evolution of driver copy number events, including amplifications of CDK4, FOXA1, and BCL11A. Elevated copy number heterogeneity was associated with shorter RFS (HR=4.9, P=0.00044), which remained significant in a multivariate analysis. CONCLUSIONS ITH mediated through CIN, rather than point mutational heterogeneity, was associated with increased risk of relapse, supporting its value as a prognostic predictor, and the need to target this high-risk phenotype. 427
EGAD00001000606 Background Massively parallel sequencing technology has transformed cancer genomics. It is now feasible, in a clinically relevant time-frame, for a clinically manageable cost, to screen DNA from patient tumours for mutations essentially genome-wide. The challenge for personalised medicine will be to increase the sample size to thousands or tens of thousands of well-characterised cases in order to attain sufficient statistical power to stratify patients accurately across the complexity and genomic heterogeneity expected for most of the common tumour types. Currently, whole genome sequencing on this scale is not feasible, and targeted sequencing of relevant portions of the genome will be required. Pilot data We have developed protocols for large-scale, multiplexed sequencing of 100-200 genes in thousands of samples. Essentially, using robotic technology, genomic DNA from the cancer specimen is processed into sequencing libraries with unique DNA barcodes, thereby allowing sequencing reads to be attributed to the sample they derive from. Currently, these sequencing libraries can be generated in a 96-well format using fully automated protocols, and we are exploring methods to expand this to a 384-well format. The sequencing libraries are pooled and hybridized to custom sets of RNA baits representing the genomic regions of interest. Sequencing of the pulled-down libraries is done in pools of 48-96 samples per lane of an Illumina Hi-Seq. This protocol is already implemented at the Sanger Institute. We have published proof that somatic mutations in novel cancer genes can be identified from exome-wide sequencing. In unpublished pilot data, we have established the feasibility of robotic library production, custom pull-down, and multiplexed sequencing of barcoded libraries for 100 known myeloid cancer genes across 760 myelodysplasia samples. Highlights of the data thus far analysed reveal that the coverage is remarkably even between samples; when 96 samples are run, average coverage per lane of sequencing is ~250, with 90-95% of targeted exons covered by >25 reads; known mutations can be discovered in the data set; and the protocol is amenable to whole genome amplified DNA. The bioinformatic algorithms for identification of substitutions and indels in pull-down data are well-established; we have pilot data proving that copy number changes, LOH and genomic rearrangements in specific regions of interest can also be identified by tiling of baits across the relevant loci. Proposal We propose to apply this methodology to 10000 samples from patients with AML enrolled in clinical trials over the last 10-20 years. Oncogenic point mutations and potentially genomic rearrangements will be identified, and linked to clinical outcome data, with a view to undertaking the following sorts of analyses: ? Identification of co-occurrence, mutual exclusivity and clusters of driver mutations. ? Correlation of prognosis with driver mutations and potentially gene-gene interactions ? Exploration of genomic markers of drug response Ultimately, we would like to be in a position to release the mutation data together with matched clinical outcome data to genuine medical researchers via a controlled access approach, possibly within the COSMIC framework (www.sanger.ac.uk/genetics/CGP/cosmic/). The vision here is to generate a portal whereby a clinician faced with an AML patient and his / her mutational profile can obtain a ?personalised? prediction of outcome, together with a fair assessment of the uncertainty of the estimate. With a sufficient sample size, there would also be the potential to develop decision support algorithms for therapeutic choices based on such data. Illumina MiSeq; 38 bam
EGAD00001002179 Background: A rare subgroup of HIV infected individuals naturally controls infection without treatment. These ?elite controllers? constitute an important model for the natural control of HIV infection. Indeed, the study of these individuals may provide insights into strategies for the development of HIV vaccines. Although several HLA and chemokine alleles are known to be over-represented in elite controllers, only a small portion of HIV phenotypic variation is explained by known genetic variants. The elite controller phenotype is rare and distinct, representing the extreme of an infectious disease trait. As such, this phenotype may be partly explained by variation in host immune control, which may be characterized by differences in rare functional genetic variants. Genomic regions underlying elite control can be potentially identified by comparing the presence or frequency of variants in this group to that representing the opposite extreme. In this context, ?rapid progressors? is a group defined by its rapid immunological and clinical disease progression. Aim: To extend an existing study, in order to identify DNA sequence variants involved in the control of HIV infection with greater statistical resolution. Specifically, we aim to sequence up to 200 exomes from multiple cohort studies within the EuroCoord CASCADE collaboration (a collaboration of 25 HIV seroconversion cohort studies across Europe). Illumina HiSeq 2000; 183 cram
EGAD00001002738 Background: In follicular lymphoma (FL), studies addressing the prognostic value of microenvironment-related immunohistochemical (IHC) markers and tumor cell-related genetic markers have yielded conflicting results, precluding implementation in practice. Therefore, the Lunenburg Lymphoma Biomarker Consortium (LLBC) performed a validation study for published markers. Methods: To maximize sensitivity, an end-of-spectrum design was applied for 122 uniformly immunochemotherapy-treated FL patients retrieved from international trials and registries; early failure (EF): progression or lymphoma-related death <2 years versus long remission: response duration of >5 years. IHC staining for T-cells and macrophages was performed on tissue microarrays from initial biopsy and scored with a validated computer-assisted protocol. Shallow whole-genome and deep targeted sequencing was performed on the same samples. Results: 96/122 cases with complete molecular and immunohistochemical data were included in the analysis. EZH2 wild-type (p=0.006), gain of chromosome 18 (p=0.002), low percentages of CD8+ cells (p=0.011) and CD163+ areas (p=0.038) were associated with EF. No significant differences in other markers were observed, thereby refuting previous claims on their prognostic significance. Conclusion: Using an optimized study design, this LLBC study validates wild-type EZH2 status, gain of chromosome 18, low percentages of CD8+ cells and CD163+ area as predictors of EF to immunochemotherapy in FL. Illumina HiSeq 2000;ILLUMINA 96
EGAD00001001395 Background: Invasive lobular breast cancer (ILBC) is the second most common histological subtype after ductal breast cancer (IDBC). In spite of significant clinical and pathological differences, ILBC is still treated as IDBC. Here, we aimed at identifying recurrent genomic alterations in ILBC with potential clinical implications. Methods: Starting from 630 ILBC primary tumors with a median follow up of 10 years, we interrogated oncogenic substitutions and indels of 360 cancer genes and genome-wide copy number alterations in 413 and 170 ILBC samples, respectively, and correlated those findings with clinical, pathological, and outcome features. The Cancer Genome Atlas database was used for comparison of frequency estimates. Results: Besides the high mutation frequency of CDH1 in 65% of the tumors, alterations in one of the three key genes of the PI3K pathway, PIK3CA, PTEN and AKT1, were present in more than half of the cases. ERBB2 and ERBB3 were mutated in 5.1 and 3.6% of the tumors. FOXA1 mutations and ESR1 copy number gains were detected in 9% and 25% of the samples. All these alterations were more frequent in ILBC than IDBC. The histological diversity of ILBC was associated with specific genomic alterations, such as enrichment for ERBB2 mutations in the mixed, non-classic subtype, and for ARID1A mutations and ESR1 gains in the solid subtype. Finally, ERBB2 and AKT1 mutations were associated with short-term risk of relapse, and chromosome 1q and 11p gain with increased and decreased breast cancer free survival, respectively. Conclusion: ERBB2, ERBB3 and AKT1 mutations represent high prevalence therapeutic targets in ILBC. FOXA1 mutations and ESR1 gains urgently deserve dedicated clinical investigation, especially in the context of endocrine treatment. Illumina HiSeq 2000; 541 bam,cram
EGAD00001001000 Background: The disease course of patients with diffuse low-grade glioma is notoriously unpredictable. Temporal and spatially distinct samples may provide insight into the evolution of clinically relevant copy number aberrations (CNAs). The purpose of this study is to identify CNAs that are indicative of aggressive tumor behaviour and can thereby complement the prognostically favorable 1p/19q co-deletion. Results: Genome-wide, 50 base pair single-end, sequencing was performed to detect CNAs in a clinically well-characterized cohort of 98 formalin-fixed paraffin-embedded low-grade gliomas. CNAs are correlated with overall survival as an endpoint. Seventy-five additional samples from spatially distinct regions and paired recurrent tumors of the discovery cohort were analysed to interrogate the intratumoral heterogeneity and spatial evolution. Loss of 10q25.2-qter is a frequent subclonal event and significantly correlates with an unfavorable prognosis. A significant correlation is furthermore observed in a validation set of 126 and confirmation set of 184 patients. Loss of 10q25.2-qter arises in a longitudinal manner in paired recurrent tumor specimens, whereas the prognostically favorable 1p/ 19q co-deletion is the only CNA that is stable across spatial regions and recurrent tumors. Conclusions: CNAs in low-grade gliomas display extensive intratumoral heterogeneity. Distal loss of 10q is a late onset event and a marker for reduced overall survival in low-grade glioma patients. Intratumoral heterogeneity and higher frequencies of distal 10q loss in recurrences suggest this event is involved in outgrowth to the recurrent tumor. Illumina HiSeq 2000; 175 fastq
EGAD00001003158 Bam files consisting of aligned MeDIP-seq reads from cord blood cells and cord blood mononuclear cells of twins conceived through in vitro fertilisation Illumina Genome Analyzer II;ILLUMINA 75
EGAD00001003159 Bam files consisting of aligned MeDIP-seq reads from cord blood cells and cord blood mononuclear cells of twins not conceived through in vitro fertilisation Illumina Genome Analyzer II;ILLUMINA 105
EGAD00001003360 Bam files containing mitochondrial alignments, extracted from CPCGene Whole Genome Alignments 432
EGAD00001001055 Bam files for the whole exome sequencing from the study on Spatial homogeneity in pediatric brain tumors. Illumina HiSeq 2000; 53
EGAD00001001633 BAM files for two WES TRAIP patients Illumina HiSeq 2000; 2 bam
EGAD00001003818 BAM files of targeted next-generation DNA sequencing data of 13 chordoid gliomas of the third ventricle (2 paired tumor-normal samples and 11 tumor-only samples). Genomic DNA was extracted from formalin-fixed, paraffin-embedded blocks of tumor tissue from 13 patients with chordoid glioma of the third ventricle using the QIAamp DNA FFPE Tissue Kit (Qiagen). Genomic DNA was also extracted from leukocytes in a peripheral blood sample from one of the patients and a non-neoplastic gastric biopsy specimen from one of the patients. Capture-based next-generation DNA sequencing was performed at the University of California, San Francisco Clinical Cancer Genomics Laboratory, using an assay that targets all coding exons of approximately 500 cancer-related genes, select introns of 47 genes, and TERT promoter with a total sequencing footprint of 2.8 Mb (UCSF500 Cancer Panel). Sequencing libraries were prepared from genomic DNA, and target enrichment was performed by hybrid capture using a custom oligonucleotide library (Nimblegen SeqCap EZ Choice). Captured libraries were sequenced as paired-end 100 bp reads on an Illumina HiSeq 2500 instrument. Duplicate sequencing reads were removed computationally to allow for accurate allele frequency determination and copy number calling. Illumina HiSeq 2500;ILLUMINA 15
EGAD00001003510 BAM files with sequencing reads derived from Illumina whole genome sequencing of two DNA samples from lymphoblastoid cell lines from two patients with congenital disease. Whole genome sequencing was performed using Illumina HiSeq X Ten and samples were prepared using TruSeq library prep. HiSeq X Ten;ILLUMINA 2
EGAD00001003511 BAM files with sequencing reads derived from Oxford Nanopore MinION whole genome sequencing of two DNA samples from lymphoblastoid cell lines from two patients with congenital disease. Samples were prepared using 1D and 2D library preps. MinION;OXFORD_NANOPORE 2
EGAD00001003336 BAM outputs from RSEM (https://deweylab.github.io/RSEM/) analysis of RNASeq sequencing on HiSeq platform of tumour samples from 29 pancreatic neuroendocrine cases. 29
EGAD00001003298 BAM outputs from RSEM (https://deweylab.github.io/RSEM/) analysis of RNASeq sequencing on HiSeq platform of tumour samples from 95 pancreatic adenocarcinoma cases. 96
EGAD00001003353 BAM outputs from STAR (https://github.com/alexdobin/STAR) analysis of RNASeq sequencing on HiSeq platform of 56 tumour samples from 46 melanoma cases. Gene model = Ensembl version 70 56
EGAD00001002181 Barrett?s oesophagus is common in the UK affecting 2 % of the population. Family history has been recorded among the 4000 Barrett's cases collected so far and have 241 families. Among them we have assessed 6 multiplex families with proven Barrett?s and defined as having 1 pro band and at least 3 affected first degree members. We propose to exome sequence the probands of these six families to assess the presence of pathogenic rare coding variants. Illumina HiSeq 2000; 6 cram
EGAD00010000916 BASIS breast cancer DNA methylation Illumina 450k Illumina 450k 457
EGAD00001001623 BBMRI - BIOS project - Freeze 1 - Bam files 2,117 bam,contig_fasta
EGAD00001001622 BBMRI - BIOS project - Freeze 1 - Fastq files Illumina HiSeq 2000; 2,199 fastq
EGAD00001003758 BBMRI - BIOS project - Freeze 2 - Bam files Illumina HiSeq 2000;ILLUMINA 3,686
EGAD00001003786 BBMRI - BIOS project - Freeze 2 - Bam files - GoNL samples Illumina HiSeq 2000;ILLUMINA 420
EGAD00001003784 BBMRI - BIOS project - Freeze 2 - Bam files - unrelated samples Illumina HiSeq 2000;ILLUMINA 3,559
EGAD00001003757 BBMRI - BIOS project - Freeze 2 - Fastq files Illumina HiSeq 2000;ILLUMINA 3,686
EGAD00001003787 BBMRI - BIOS project - Freeze 2 - Fastq files - GoNL samples Illumina HiSeq 2000;ILLUMINA 420
EGAD00001003785 BBMRI - BIOS project - Freeze 2 - Fastq files - unrelated samples Illumina HiSeq 2000;ILLUMINA 3,559
EGAD00010001416 BBMRI - BIOS project - Freeze 2 - methylation Illumina Human Methylation 450k BeadChip 4,386
EGAD00001003116 Benchmark data set containing five tumor/normal pairs of non-small cell lung cancer (NSCLC) patients. Tissue pairs were screened with bisulfite (BS) sequencing, MeDIP methylation enrichment sequencing and RNA sequencing in order to identify differentially methylated and expressed spots in the genomes. Illumina HiSeq 2500;ILLUMINA 10
EGAD00001000661 Bespoke validation experiments will be performed on ER+ Breast Cancer cases to confirm the presence of mutations found in whole genome sequencing. Illumina HiSeq 2000; 46 bam
EGAD00001001530 Bisulfite-Seq data for 1 Acute Myeloid Leukemia - CTR sample(s). 18 run(s), 1 experiment(s), 1 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 1 bam
EGAD00001001162 Bisulfite-Seq data for 1 Acute myeloid leukemia sample(s). 18 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 1 bam
EGAD00001002472 Bisulfite-Seq data for 1 Acute Promyelocytic Leukemia - ATRA sample(s). 9 run(s), 1 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 1 bam,bcf
EGAD00001000920 Bisulfite-Seq data for 1 alternatively activated macrophage sample(s). 10 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT release August 2014. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 1 bam,readme_file
EGAD00001001509 Bisulfite-Seq data for 1 CD34-negative, CD41-positive, CD42-positive megakaryocyte cell sample(s). 14 run(s), 1 experiment(s), 1 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 1 bam
EGAD00001000932 Bisulfite-Seq data for 1 CD34-negative, CD41-positive, CD42-positive megakaryocyte cell sample(s). 14 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT release August 2014. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 1 bam
EGAD00001001150 Bisulfite-Seq data for 1 CD34-negative, CD41-positive, CD42-positive megakaryocyte cell sample(s). 14 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 1 bam
EGAD00001000921 Bisulfite-Seq data for 1 CD8-positive, alpha-beta T cell sample(s). 14 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT release August 2014. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 1 bam,readme_file
EGAD00001001563 Bisulfite-Seq data for 1 central memory CD4-positive, alpha-beta T cell sample(s). 15 run(s), 1 experiment(s), 1 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 1 bam
EGAD00001001553 Bisulfite-Seq data for 1 central memory CD8-positive, alpha-beta T cell sample(s). 13 run(s), 1 experiment(s), 1 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 1 bam
EGAD00001001176 Bisulfite-Seq data for 1 class switched memory B cell sample(s). 20 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 1 bam
EGAD00001001567 Bisulfite-Seq data for 1 effector memory CD4-positive, alpha-beta T cell sample(s). 15 run(s), 1 experiment(s), 1 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 1 bam
EGAD00001001583 Bisulfite-Seq data for 1 effector memory CD8-positive, alpha-beta T cell sample(s). 11 run(s), 1 experiment(s), 1 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 1 bam
EGAD00001001200 Bisulfite-Seq data for 1 effector memory CD8-positive, alpha-beta T cell sample(s). 11 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 1 bam
EGAD00001001541 Bisulfite-Seq data for 1 effector memory CD8-positive, alpha-beta T cell, terminally differentiated sample(s). 15 run(s), 1 experiment(s), 1 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 1 bam
EGAD00001001151 Bisulfite-Seq data for 1 endothelial cell of umbilical vein (proliferating) sample(s). 21 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 1 bam
EGAD00001000909 Bisulfite-Seq data for 1 erythroblast sample(s). 14 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT release August 2014. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 1 bam,readme_file
EGAD00001001587 Bisulfite-Seq data for 1 germinal center B cell sample(s). 6 run(s), 1 experiment(s), 1 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 1 bam
EGAD00001000943 Bisulfite-Seq data for 1 germinal center B cell sample(s). 8 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT release August 2014. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 1 bam,readme_file
EGAD00001001203 Bisulfite-Seq data for 1 germinal center B cell sample(s). 8 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 1 bam,readme_file
EGAD00001001493 Bisulfite-Seq data for 1 hematopoietic multipotent progenitor cell sample(s). 5 run(s), 1 experiment(s), 1 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 1 bam
EGAD00001000917 Bisulfite-Seq data for 1 hematopoietic multipotent progenitor cell sample(s). 8 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT release August 2014. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 1 bam,readme_file
EGAD00001001141 Bisulfite-Seq data for 1 hematopoietic multipotent progenitor cell sample(s). 8 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 1 bam,readme_file
EGAD00001002410 Bisulfite-Seq data for 1 macrophage - T=6days B-glucan sample(s). 15 run(s), 1 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,bcf
EGAD00001002373 Bisulfite-Seq data for 1 macrophage - T=6days untreated sample(s). 15 run(s), 1 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,bcf
EGAD00001000923 Bisulfite-Seq data for 1 macrophage sample(s). 14 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT release August 2014. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 1 bam,readme_file
EGAD00001001507 Bisulfite-Seq data for 1 mature eosinophil sample(s). 15 run(s), 1 experiment(s), 1 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 1 bam
EGAD00001001479 Bisulfite-Seq data for 1 memory B cell sample(s). 20 run(s), 1 experiment(s), 1 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 1 bam
EGAD00001001131 Bisulfite-Seq data for 1 memory B cell sample(s). 20 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 1 bam
EGAD00001001494 Bisulfite-Seq data for 1 memory B cells sample(s). 1 run(s), 1 experiment(s), 1 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 1 bam
EGAD00001002475 Bisulfite-Seq data for 1 monocyte - Attached_T=1hr sample(s). 23 run(s), 2 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 1 bam,bcf
EGAD00001002327 Bisulfite-Seq data for 1 monocyte - RPMI_BG_T=1hr sample(s). 14 run(s), 1 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,bcf
EGAD00001002441 Bisulfite-Seq data for 1 monocyte - RPMI_BG_T=24hrs sample(s). 21 run(s), 2 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 1 bam,bcf
EGAD00001002385 Bisulfite-Seq data for 1 monocyte - RPMI_BG_T=24hrs_RPMI_T=5days sample(s). 18 run(s), 2 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,bcf
EGAD00001002301 Bisulfite-Seq data for 1 monocyte - RPMI_BG_T=4hrs sample(s). 14 run(s), 1 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 1 bam,bcf
EGAD00001002502 Bisulfite-Seq data for 1 monocyte - RPMI_LPS_T=1hr sample(s). 14 run(s), 1 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 1 bam,bcf
EGAD00001002302 Bisulfite-Seq data for 1 monocyte - RPMI_LPS_T=24hrs sample(s). 22 run(s), 2 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,bcf
EGAD00001002324 Bisulfite-Seq data for 1 monocyte - RPMI_LPS_T=24hrs_RPMI_T=5days sample(s). 15 run(s), 1 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,bcf
EGAD00001002432 Bisulfite-Seq data for 1 monocyte - RPMI_LPS_T=4hrs sample(s). 18 run(s), 2 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,bcf
EGAD00001002447 Bisulfite-Seq data for 1 monocyte - RPMI_T=1hr sample(s). 15 run(s), 1 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,bcf
EGAD00001002335 Bisulfite-Seq data for 1 monocyte - RPMI_T=24hrs sample(s). 14 run(s), 1 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,bcf
EGAD00001002394 Bisulfite-Seq data for 1 monocyte - RPMI_T=4hrs sample(s). 15 run(s), 1 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 1 bam,bcf
EGAD00001002371 Bisulfite-Seq data for 1 monocyte - RPMI_T=6days sample(s). 14 run(s), 1 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,bcf
EGAD00001002405 Bisulfite-Seq data for 1 monocyte - T=0days sample(s). 15 run(s), 1 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,bcf
EGAD00001001565 Bisulfite-Seq data for 1 monocytes - T=0days sample(s). 15 run(s), 1 experiment(s), 1 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 1 bam
EGAD00001001556 Bisulfite-Seq data for 1 naive B cell sample(s). 5 run(s), 1 experiment(s), 1 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 1 bam
EGAD00001000927 Bisulfite-Seq data for 1 Plasma cell sample(s). 11 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT release August 2014. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 1 bam,readme_file
EGAD00001001160 Bisulfite-Seq data for 1 plasma cell sample(s). 11 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 1 bam,readme_file
EGAD00001001529 Bisulfite-Seq data for 1 precursor B cell sample(s). 6 run(s), 1 experiment(s), 1 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 1 bam
EGAD00001002330 Bisulfite-Seq data for 1 precursor B cell sample(s). 6 run(s), 1 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,bcf
EGAD00001002291 Bisulfite-Seq data for 1 precursor lymphocyte of B lineage sample(s). 11 run(s), 2 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,bcf
EGAD00001000910 Bisulfite-Seq data for 1 precursor lymphocyte of B lineage sample(s). 8 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT release August 2014. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 1 bam,readme_file
EGAD00001001134 Bisulfite-Seq data for 1 precursor lymphocyte of B lineage sample(s). 8 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 1 bam,readme_file
EGAD00001001564 Bisulfite-Seq data for 1 regulatory T cell sample(s). 15 run(s), 1 experiment(s), 1 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 1 bam
EGAD00001002969 Bisulfite-Seq data for 1 sample(s) Acute Lymphocytic Leukemia for precursor B cell from bone marrow, on Genome GRCh38. 3 run(s), 1 experiment(s), 0 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000;ILLUMINA 1 bam
EGAD00001002440 Bisulfite-Seq data for 1 thymocyte sample(s). 14 run(s), 1 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,bcf
EGAD00001002419 Bisulfite-Seq data for 19 Acute Myeloid Leukemia sample(s). 338 run(s), 32 experiment(s), 38 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2000; 19 bcf,bam
EGAD00001002333 Bisulfite-Seq data for 2 Acute Myeloid Leukemia - CTR sample(s). 28 run(s), 2 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 2 bcf,bam
EGAD00001002407 Bisulfite-Seq data for 2 Acute Promyelocytic Leukemia - CTR sample(s). 27 run(s), 3 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 2 bcf,bam
EGAD00001002404 Bisulfite-Seq data for 2 adult endothelial progenitor cell sample(s). 38 run(s), 3 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 2 bcf,bam
EGAD00001002464 Bisulfite-Seq data for 2 CD3-negative, CD4-positive, CD8-positive, double positive thymocyte sample(s). 29 run(s), 2 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 2 bcf,bam
EGAD00001002325 Bisulfite-Seq data for 2 CD3-positive, CD4-positive, CD8-positive, double positive thymocyte sample(s). 29 run(s), 2 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 2 bcf,bam
EGAD00001002311 Bisulfite-Seq data for 2 CD34-negative, CD41-positive, CD42-positive megakaryocyte cell sample(s). 29 run(s), 2 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2000; 2 bcf,bam
EGAD00001002483 Bisulfite-Seq data for 2 CD4-positive, alpha-beta thymocyte sample(s). 29 run(s), 2 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 2 bcf,bam
EGAD00001002370 Bisulfite-Seq data for 2 CD8-positive, alpha-beta thymocyte sample(s). 28 run(s), 2 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 2 bcf,bam
EGAD00001002364 Bisulfite-Seq data for 2 central memory CD4-positive, alpha-beta T cell sample(s). 41 run(s), 3 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 2 bcf,bam
EGAD00001001180 Bisulfite-Seq data for 2 central memory CD8-positive, alpha-beta T cell sample(s). 27 run(s), 2 experiment(s), 2 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 2 bam
EGAD00001002486 Bisulfite-Seq data for 2 central memory CD8-positive, alpha-beta T cell sample(s). 36 run(s), 3 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 2 bcf,bam
EGAD00001001548 Bisulfite-Seq data for 2 class switched memory B cell sample(s). 21 run(s), 2 experiment(s), 2 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 2 bam
EGAD00001001497 Bisulfite-Seq data for 2 conventional dendritic cell sample(s). 30 run(s), 2 experiment(s), 2 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 2 bam
EGAD00001002437 Bisulfite-Seq data for 2 conventional dendritic cell sample(s). 30 run(s), 2 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 2 bcf,bam
EGAD00001001473 Bisulfite-Seq data for 2 cytotoxic CD56-dim natural killer cell sample(s). 24 run(s), 2 experiment(s), 2 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000;ILLUMINA 2 bam
EGAD00001002367 Bisulfite-Seq data for 2 effector memory CD4-positive, alpha-beta T cell sample(s). 34 run(s), 3 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2000; 2 bcf,bam
EGAD00001002383 Bisulfite-Seq data for 2 effector memory CD8-positive, alpha-beta T cell sample(s). 30 run(s), 3 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 2 bcf,bam
EGAD00001002346 Bisulfite-Seq data for 2 effector memory CD8-positive, alpha-beta T cell, terminally differentiated sample(s). 34 run(s), 3 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 2 bcf,bam
EGAD00001001510 Bisulfite-Seq data for 2 endothelial cell of umbilical vein (proliferating) sample(s). 36 run(s), 2 experiment(s), 2 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 2 bam
EGAD00001002451 Bisulfite-Seq data for 2 endothelial cell of umbilical vein (proliferating) sample(s). 36 run(s), 2 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 2 bcf,bam
EGAD00001001486 Bisulfite-Seq data for 2 endothelial cell of umbilical vein (resting) sample(s). 2 run(s), 2 experiment(s), 2 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 2 bam
EGAD00001001135 Bisulfite-Seq data for 2 endothelial cell of umbilical vein (resting) sample(s). 2 run(s), 2 experiment(s), 2 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 2 bam
EGAD00001002294 Bisulfite-Seq data for 2 endothelial cell of umbilical vein (resting) sample(s). 35 run(s), 4 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 2 bcf,bam
EGAD00001001484 Bisulfite-Seq data for 2 erythroblast sample(s). 35 run(s), 2 experiment(s), 2 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 2 bam
EGAD00001001133 Bisulfite-Seq data for 2 erythroblast sample(s). 35 run(s), 2 experiment(s), 2 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 2 bam,readme_file
EGAD00001002423 Bisulfite-Seq data for 2 erythroblast sample(s). 35 run(s), 2 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 2 bcf,bam
EGAD00001002434 Bisulfite-Seq data for 2 hematopoietic multipotent progenitor cell sample(s). 16 run(s), 3 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 2 bcf,bam
EGAD00001002309 Bisulfite-Seq data for 2 mature eosinophil sample(s). 23 run(s), 2 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 2 bcf,bam
EGAD00001002519 Bisulfite-Seq data for 2 mesenchymal stem cell of the bone marrow sample(s). 39 run(s), 4 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 2 bcf,bam
EGAD00001002395 Bisulfite-Seq data for 2 monocyte - None sample(s). 70 run(s), 4 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2000; 2 bcf,bam
EGAD00001000934 Bisulfite-Seq data for 2 Multiple myeloma sample(s). 16 run(s), 2 experiment(s), 2 alignment(s). Part of BLUEPRINT release August 2014. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 2 bam,readme_file
EGAD00001001152 Bisulfite-Seq data for 2 Multiple myeloma sample(s). 16 run(s), 2 experiment(s), 2 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 2 bam,readme_file
EGAD00001002427 Bisulfite-Seq data for 2 osteoclast sample(s). 88 run(s), 4 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 2 bcf,bam
EGAD00001001522 Bisulfite-Seq data for 2 plasma cell sample(s). 17 run(s), 2 experiment(s), 2 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 2 bam
EGAD00001002492 Bisulfite-Seq data for 2 regulatory T cell sample(s). 41 run(s), 3 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 2 bcf,bam
EGAD00001001537 Bisulfite-Seq data for 3 Acute promyelocytic leukemia sample(s). 24 run(s), 3 experiment(s), 3 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 3 bam
EGAD00001001167 Bisulfite-Seq data for 3 Acute promyelocytic leukemia sample(s). 24 run(s), 3 experiment(s), 3 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 3 bam
EGAD00001002378 Bisulfite-Seq data for 3 band form neutrophil sample(s). 34 run(s), 3 experiment(s), 6 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 3 bcf,bam
EGAD00001001205 Bisulfite-Seq data for 3 CD38-negative naive B cell sample(s). 29 run(s), 3 experiment(s), 3 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 3 bam
EGAD00001001516 Bisulfite-Seq data for 3 CD4-positive, alpha-beta T cell sample(s). 61 run(s), 3 experiment(s), 3 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 3 bam
EGAD00001001157 Bisulfite-Seq data for 3 CD4-positive, alpha-beta T cell sample(s). 61 run(s), 3 experiment(s), 3 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 3 bam
EGAD00001002354 Bisulfite-Seq data for 3 class switched memory B cell sample(s). 43 run(s), 4 experiment(s), 6 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 3 bcf,bam
EGAD00001001128 Bisulfite-Seq data for 3 cytotoxic CD56-dim natural killer cell sample(s). 38 run(s), 3 experiment(s), 3 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 3 bam
EGAD00001002511 Bisulfite-Seq data for 3 germinal center B cell sample(s). 37 run(s), 4 experiment(s), 6 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 3 bcf,bam
EGAD00001002284 Bisulfite-Seq data for 3 immature conventional dendritic cell - GM-CSF_IL4_T=6_days sample(s). 61 run(s), 4 experiment(s), 6 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 3 bcf,bam
EGAD00001000914 Bisulfite-Seq data for 3 inflammatory macrophage sample(s). 38 run(s), 3 experiment(s), 3 alignment(s). Part of BLUEPRINT release August 2014. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 3 bam,readme_file
EGAD00001001139 Bisulfite-Seq data for 3 inflammatory macrophage sample(s). 38 run(s), 3 experiment(s), 3 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 3 bam,readme_file
EGAD00001002428 Bisulfite-Seq data for 3 mature conventional dendritic cell - GM-CSF_IL4_T=6_days_R848_T=24hrs sample(s). 60 run(s), 4 experiment(s), 6 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 3 bcf,bam
EGAD00001002412 Bisulfite-Seq data for 3 mature neutrophil - G-CSF/Dex. Treatment (16-20 hrs) sample(s). 33 run(s), 3 experiment(s), 6 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 3 bcf,bam
EGAD00001002416 Bisulfite-Seq data for 3 memory B cell sample(s). 47 run(s), 4 experiment(s), 6 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 3 bcf,bam
EGAD00001002361 Bisulfite-Seq data for 3 naive B cell sample(s). 39 run(s), 3 experiment(s), 6 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 3 bcf,bam
EGAD00001002497 Bisulfite-Seq data for 3 neutrophilic metamyelocyte sample(s). 32 run(s), 3 experiment(s), 6 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 3 bcf,bam
EGAD00001002331 Bisulfite-Seq data for 3 neutrophilic myelocyte sample(s). 31 run(s), 3 experiment(s), 6 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 3 bcf,bam
EGAD00001002393 Bisulfite-Seq data for 3 segmented neutrophil of bone marrow sample(s). 34 run(s), 3 experiment(s), 6 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 3 bcf,bam
EGAD00001002303 Bisulfite-Seq data for 3 T-cell Prolymphocytic Leukemia sample(s). 45 run(s), 3 experiment(s), 6 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 3 bcf,bam
EGAD00001001143 Bisulfite-Seq data for 4 alternatively activated macrophage sample(s). 64 run(s), 4 experiment(s), 4 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 4 bam,readme_file
EGAD00001001590 Bisulfite-Seq data for 4 CD38-negative naive B cell sample(s). 44 run(s), 4 experiment(s), 4 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 4 bam
EGAD00001002520 Bisulfite-Seq data for 4 CD38-negative naive B cell sample(s). 51 run(s), 5 experiment(s), 8 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 4 bcf,bam
EGAD00001001571 Bisulfite-Seq data for 4 CD8-positive, alpha-beta T cell sample(s). 56 run(s), 4 experiment(s), 4 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 4 bam
EGAD00001001189 Bisulfite-Seq data for 4 CD8-positive, alpha-beta T cell sample(s). 56 run(s), 4 experiment(s), 4 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 4 bam,readme_file
EGAD00001002496 Bisulfite-Seq data for 4 CD8-positive, alpha-beta T cell sample(s). 57 run(s), 5 experiment(s), 8 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 4 bcf,bam
EGAD00001002403 Bisulfite-Seq data for 4 cytotoxic CD56-dim natural killer cell sample(s). 54 run(s), 5 experiment(s), 8 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 4 bcf,bam
EGAD00001002392 Bisulfite-Seq data for 4 Type 1 diabetes mellitus sample(s). 32 run(s), 4 experiment(s), 8 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 4 bcf,bam
EGAD00001001498 Bisulfite-Seq data for 5 alternatively activated macrophage sample(s). 79 run(s), 5 experiment(s), 5 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 5 bam
EGAD00001001192 Bisulfite-Seq data for 5 macrophage sample(s). 72 run(s), 5 experiment(s), 5 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 5 bam,readme_file
EGAD00001002505 Bisulfite-Seq data for 5 Mantle Cell Lymphoma sample(s). 65 run(s), 5 experiment(s), 10 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 5 bcf,bam
EGAD00001002521 Bisulfite-Seq data for 5 Multiple Myeloma sample(s). 63 run(s), 7 experiment(s), 10 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 5 bcf,bam
EGAD00001002322 Bisulfite-Seq data for 5 plasma cell sample(s). 77 run(s), 5 experiment(s), 10 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 5 bcf,bam
EGAD00001001482 Bisulfite-Seq data for 6 Acute Myeloid Leukemia sample(s). 66 run(s), 6 experiment(s), 6 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 6 bam
EGAD00001002305 Bisulfite-Seq data for 6 alternatively activated macrophage sample(s). 94 run(s), 7 experiment(s), 12 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 6 bcf,bam
EGAD00001002523 Bisulfite-Seq data for 6 CD14-positive, CD16-negative classical monocyte sample(s). 86 run(s), 6 experiment(s), 12 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 6 bcf,bam
EGAD00001000941 Bisulfite-Seq data for 6 CD14-positive, CD16-negative classical monocyte sample(s). 86 run(s), 6 experiment(s), 6 alignment(s). Part of BLUEPRINT release August 2014. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 6 bam,readme_file
EGAD00001001206 Bisulfite-Seq data for 6 CD14-positive, CD16-negative classical monocyte sample(s). 86 run(s), 6 experiment(s), 6 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 6 bam,readme_file
EGAD00001002396 Bisulfite-Seq data for 6 Chronic Lymphocytic Leukemia sample(s). 84 run(s), 6 experiment(s), 12 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 6 bcf,bam
EGAD00001002429 Bisulfite-Seq data for 6 inflammatory macrophage sample(s). 83 run(s), 6 experiment(s), 12 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 6 bcf,bam
EGAD00001001491 Bisulfite-Seq data for 6 inflammatory macrophage sample(s). 83 run(s), 6 experiment(s), 6 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 6 bam
EGAD00001002501 Bisulfite-Seq data for 6 macrophage sample(s). 88 run(s), 7 experiment(s), 12 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 6 bcf,bam
EGAD00001001585 Bisulfite-Seq data for 6 mature neutrophil sample(s). 79 run(s), 6 experiment(s), 6 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 6 bam
EGAD00001000935 Bisulfite-Seq data for 6 mature neutrophil sample(s). 79 run(s), 6 experiment(s), 6 alignment(s). Part of BLUEPRINT release August 2014. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 6 bam,readme_file
EGAD00001001201 Bisulfite-Seq data for 6 mature neutrophil sample(s). 79 run(s), 6 experiment(s), 6 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_bisulphite_analysis_CNAG_20140811 Illumina HiSeq 2000; 6 bam,readme_file
EGAD00001002313 Bisulfite-Seq data for 7 Acute Lymphocytic Leukemia sample(s). 132 run(s), 9 experiment(s), 14 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000;ILLUMINA 7 bcf,bam
EGAD00001001591 Bisulfite-Seq data for 7 CD14-positive, CD16-negative classical monocyte sample(s). 101 run(s), 7 experiment(s), 7 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 7 bam
EGAD00001002460 Bisulfite-Seq data for 8 CD4-positive, alpha-beta T cell sample(s). 108 run(s), 8 experiment(s), 16 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 8 bcf,bam
EGAD00001001575 Bisulfite-Seq data for 8 macrophage sample(s). 117 run(s), 8 experiment(s), 8 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820 Illumina HiSeq 2000; 8 bam
EGAD00001002508 Bisulfite-Seq data for 9 mature neutrophil sample(s). 116 run(s), 9 experiment(s), 18 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816 Illumina HiSeq 2000; 9 bcf,bam
EGAD00001001261 Bisulfite-Seq of CD14-positive, CD16-negative classical monocyte samples for methylome saturation and COMET analysis Illumina HiSeq 2000; 2 bam,readme_file
EGAD00001000406 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive haematological malignancy derived from precursors of plasmacytoid dendritic cells. Due to the rarity of BPDCNs our knowledge of their molecular pathogenesis was until recently confined to observations describing reccurent chromosomal deletions involving chromosomes 5q, 12p, 13q, 6q, 15q and 9. A recent publication went on to delineate the common deleted regions using aCGH and demonstrated that these centred around known tumour suppressor genes including CDKN2A/B (9p21.3), RB1 (12p13.2-14.3), CDKN1B (13q11-q12) and IKZF1 (7p12.2). These mutations are found recurrently in several different cancers and in most cases are thought to be involved in tumour progression rather than initiation. However, the well-defined nature and cellular ontogeny of these neoplasms suggests strongly that they share one or a few characteristic mutations as has been demonstrated for other uncommon but well-defined neoplasms such as Hairy Cell Leukemia (BRAF) and ovarian Granulosa Cell tumours (FOXL2). Illumina HiSeq 2000; 14 bam
EGAD00001000040 Bleeding Illumina Genome Analyzer II 6 bam
EGAD00001000140 Blood sample of serious ovarian carcinoma patient Complete Genomics 1 CompleteGenomics_native
EGAD00010001412 Blood transcriptome from women participating in the Norwegian Women and Cancer study (NOWAC) Illumina HumanWG-6 version 3 or Illumina HumanHT-12 expression bead chip, combined on identical nucleotide universal identifier 920
EGAD00010001063 blood-based gene expression from breast cancer cases IlluminaHuman AWG-6 and HT12 173
EGAD00010001062 blood-based gene expression from breast cancer cases and age-matched controls IlluminaHuman AWG-6 and HT12 455
EGAD00010000476 blood-based gene expression from breast cancer cases and age-matched controls in case-control serie 1 (CC1) Illumina 110
EGAD00010000474 blood-based gene expression from breast cancer cases and age-matched controls in case-control serie 2 (CC2) Illumina 98
EGAD00010000478 blood-based gene expression from breast cancer cases and age-matched controls in case-control serie 3 (CC3) Illumina 118
EGAD00001001892 BLUEPRINT Bisulfite-seq and Whole Genome Sequencing of mantle cell lymphoma Illumina HiSeq 2000; 4 bam
EGAD00001002655 BLUEPRINT ChIP-Seq from two mantle cell lymphoma patients Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2000; 2 fastq
EGAD00010001012 BLUEPRINT DNA Methylation 450K data of mantle cell lymphoma Illumina HumanMethylation 450K 86
EGAD00010000716 BLUEPRINT DNA Methylation of different B-cell subpopulations 35
EGAD00010000850 BLUEPRINT DNA methylation profiles of monocytes, neutrophils and T cells from healthy donors Illumina 450K 525
EGAD00010001025 BLUEPRINT DNA methylation profiles of monocytes, T cells and B cells in type 1 diabetes-discordant monozygotic twins Illumina 450K 302
EGAD00001002682 BLUEPRINT DNA methylation profiles of T cells in type 1 diabetes-discordant monozygotic twins Bisulfite-Seq 8 bam
EGAD00010000831 BLUEPRINT EpiMatch: harnessing epigenetics for hematopoietic stem cell transplantation Illumina Infinium HumanMethylation450 BeadChips 85
EGAD00010000718 BLUEPRINT Gene expression of different B-cell subpopulations 42
EGAD00001002663 BLUEPRINT: A human variation panel of genetic influences on epigenomes and transcriptomes in three immune cells (WGS) Illumina HiSeq 2000;ILLUMINA 197 vcf,cram
EGAD00001000205 BRAF and MEK resistant cell line clones Illumina HiSeq 2000; 3
EGAD00001002051 BRAF V600E colorectal cancers do not respond to the only currently FDA approved targeted therapy for CRC. There is currently a trial underway in the UK recruiting V600E CRC patients for treatment with a triple therapy combination of Cetuximab, Trametinib and Dabrafenib. We have mutagenized a pool of V600E CRC cell lines and treated with this triple therapy to select out drug resistant clones. We will now sequence these drug resistant clones with the aim of identifying common point mutations engendering resistance to this new therapy. Illumina HiSeq 2500; 20 cram
EGAD00001001274 Brain samples for this dataset were provided by the Medical Research Council Sudden Death Brain and Tissue Bank (Edinburgh, UK). All four individuals sampled were of European descent, neurologically normal during life and confirmed to be neuropathologically normal by a consultant neuropathologist using histology performed on sections prepared from paraffin-embedded tissue blocks. Twelve regions of the central nervous system were sampled from each individual. The regions studied were: cerebellar cortex, frontal cortex, temporal cortex, occipital cortex, hippocampus, the inferior olivary nucleus (sub-dissected from the medulla), putamen, substantia nigra, thalamus, hypothalamus, intralobular white matter and cervical spinal cord. Illumina HiSeq 2000; 48 bam
EGAD00001000093 Breast Cancer Exome Resequencing Illumina Genome Analyzer II 21 bam
EGAD00001000110 Breast Cancer Exome Sequencing Illumina HiSeq 2000, Illumina Genome Analyzer II 179 bam
EGAD00001000066 Breast Cancer Follow Up Series Illumina Genome Analyzer II 288 bam
EGAD00001000130 Breast Cancer Matched Pair Cell Line Whole Genomes Illumina HiSeq 2000, Illumina HiSeq 2000; 22 bam
EGAD00001002685 Breast cancer PDTX sequencing data from Bruna et al, Cell 2016 - Exome Sequencing - Shallow Whole Genome Sequencing - RRBS Methylation Sequencing Illumina HiSeq 2500;ILLUMINA, Illumina HiSeq 2500; 393 bam
EGAD00010001406 Breast cancer tissue and controls Exiqon 7th generation miRCURY LNA microRNA microarray system 149
EGAD00001000121 Breast Cancer Whole Genome Sequencing Illumina HiSeq 2000 6 bam
EGAD00010000942 Breast lesions assayed with Affymetrix SNP 6.0 Affymetrix SNP 6.0 125
EGAD00001003151 Bulk whole-genome BAM files for 184-hTERT-L2, SA501X3F, and SA501X4F. Illumina HiSeq 2500;ILLUMINA 3
EGAD00001000127 Burden of Disease in Sarcoma Illumina HiSeq 2000, Illumina HiSeq 2000; 220 bam,cram
EGAD00001003793 By differential gene expression analysis followed by protein expression and functional studies, we define that the naive T cells having divided the least since thymic emigration express complement receptors (CR1 and CR2) known to bind complement C3b- and C3d-decorated microbial products and, following activation, produce IL-8 (CXCL8), a major chemoattractant for neutrophils in bacterial defense. We also observed an IL-8–producing memory T cell subpopulation coexpressing CR1 and CR2 and with a gene expression signature resembling that of RTEs. JCI Insight. 2017;2(16):e93739. https://doi.org/10.1172/jci.insight.93739 Illumina HiSeq 2500;ILLUMINA 24
EGAD00010000387 Cambridge control samples using a 1.2M genotyping chip from Illumina Illumina Human 1.2M Duo custom BeadChips v1 - Genome Studio 188
EGAD00010000389 Cambridge control samples using a 24k expression array from Illumina Illumina Human-Ref 8 v3.0 expression array 395
EGAD00010000391 Cambridge control samples using a 660K genotyping chip from Illumina Illumina Human 660K Quad BeadChips - Illuminus 232
EGAD00001001935 Cancer amplicon reads consisting of BAM paired end reads from primary multiple myeloma samples. Illumina MiSeq; 88 bam
EGAD00001001058 Cancer exome reads consisting of FASTQ paired end reads from bone marrow samples Illumina HiSeq 2000; 42 fastq
EGAD00001000092 Cancer Exome Resequencing Illumina Genome Analyzer II 58 bam
EGAD00001001930 Cancer genes can affect ribosomal RNA processing and this can underlie their essentiality to cells, making them cell-essential in the same way as ribosomal genes themselves. We want to confirm this, in order to understand the results of our CRISPR drop-out screens. NOTE FROM BESPOKE TEAM: Run a single read 1 (forward read) of 30 bases, then an index 1 read as normal. This would fit a 50cycle kit Illumina MiSeq; 6 cram
EGAD00001000094 Cancer Genome Libraries Tests Illumina Genome Analyzer II 16 bam
EGAD00001000308 Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing 1 bam
EGAD00001000284 Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing Illumina Genome Analyzer IIx; 1
EGAD00001000290 Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing Illumina Genome Analyzer IIx; 1
EGAD00001000389 Cancer is driven by mutations in the genome. We will uncover the mutations that give rise to Ewing's sarcoma, a bone tumour that largely affects children. We will use second generation Illumina massively parallel sequencing, and bespoke software, to characterise the genomes and transcriptomes of Ewing's sarcoma tumours. Illumina HiSeq 2000; 20 bam
EGAD00001000333 Cancer is driven by mutations in the genome. We will uncover the mutations that give rise to Ewing's sarcoma, a bone tumour that largely affects children. We will use second generation Illumina massively parallel sequencing, and bespoke software, to characterise the genomes and transcriptomes of Ewing,s sarcoma tumours. Illumina HiSeq 2000; 58
EGAD00001000444 Cancer is driven my mutations in the genome. We will uncover the mutations that give rise to Ewing's sarcoma, a bone tumour that largely affects children. We will use second generation Illumina massively parallel sequencing, and bespoke software, to characterise the genomes and transcriptomes of Ewing's sarcoma tumours. Illumina HiSeq 2000; 3 bam
EGAD00001000067 Cancer Single Cell Sequencing Illumina HiSeq 2000, Illumina HiSeq 2000; 16 bam,srf
EGAD00001000898 Cancers are ecosystems of genetically related clones, competing across space and time for limited resources. To understand the clonal structure of primary breast cancer, we applied genome and targeted sequencing to 295 samples from 49 patients’ tumors. The extent of subclonal diversification varied considerably among patients and encompassed many spatial patterns, including local growth, intraductal dissemination and clonal intermixture. Landmarks of disease progression, such as acquiring invasive or metastatic potential, arose within detectable subclones of antecedent lesions, suggesting that subclonal mutations could be relevant if actionable. No defined temporal order of mutation was evident, with the commonest genes, including PIK3CA, TP53, BRCA2, PTEN and MYC, mutated early in some, late in others, often exhibiting parallel evolution across subclones. Signatures of homologous recombination deficiency correlated with response to neoadjuvant chemotherapy. Thus, the interplay of mutation, growth and competition drives clonal structures of breast cancer that are complex, variable across patients and clinically relevant. Illumina HiSeq 2000; 42 bam
EGAD00001000965 Cancers are ecosystems of genetically related clones, competing across space and time for limited resources. To understand the clonal structure of primary breast cancer, we applied genome and targeted sequencing to 295 samples from 49 patients’ tumors. The extent of subclonal diversification varied considerably among patients and encompassed many spatial patterns, including local growth, intraductal dissemination and clonal intermixture. Landmarks of disease progression, such as acquiring invasive or metastatic potential, arose within detectable subclones of antecedent lesions, suggesting that subclonal mutations could be relevant if actionable. No defined temporal order of mutation was evident, with the commonest genes, including PIK3CA, TP53, BRCA2, PTEN and MYC, mutated early in some, late in others, often exhibiting parallel evolution across subclones. Signatures of homologous recombination deficiency correlated with response to neoadjuvant chemotherapy. Thus, the interplay of mutation, growth and competition drives clonal structures of breast cancer that are complex, variable across patients and clinically relevant. Illumina HiSeq 2000; 331 bam,cram
EGAD00001001243 Capture Hi-C identifies the chromatin interactome of colorectal cancer risk loci. Illumina HiSeq 2000; 9 bam,fastq
EGAD00010001427 Cardio-Metabochip genotypes for B99 cohort Illumina 1,336
EGAD00010001428 Cardio-Metabochip genotypes for IHIT cohort Illumina 2,791
EGAD00010000371 Case and control samples (Genotypes) Infinium_370k - GenomeStudio 170
EGAD00010001198 Case control samples using Infinium Omni2.5 Infinium Omni2.5M 274
EGAD00010000202 Case samples (Illumina_660K & Illumina_670K) Illumina_660K/Illumina_670K 1,478
EGAD00010000512 Case samples using HumanOmni1-Quad GenomeWideSNP_6-BirdseedV2 12
EGAD00010000514 Case samples using SNP 6.0 Array GenomeWideSNP_6-BirdseedV2 12
EGAD00010000656 Case samples using SNP 6.0 Array 0
EGAD00010000502 Case samples using SNP Array 6.0 Affymetrix_U133plus2- 35
EGAD00010000500 Case samples using U133 Plus 2.0 Array Affymetrix_U133plus2- 35
EGAD00010000492 Cases_Human660W-Quad_v1_A Illumina_Human660W-Quad_v1_A-Not supplied 4
EGAD00001001994 CCA targeted sequencing Illumina HiSeq 2500; 376
EGAD00010000480 ccRCC case samples using 250K Nsp Affymetrix_250K(Nsp) - gtype 240
EGAD00010000486 ccRCC case samples using expression array Agilent Human Whole Genome 4x44k v2 - Feature Extraction 101
EGAD00010000482 ccRCC case samples using methylation array Illumina Infinium HumanMethylation 450K - GenomeStudio 1
EGAD00010000484 ccRCC control samples using 250K Nsp Affymetrix_250K(Nsp) - gtype 234
EGAD00001002686 CD4 T-Cell ChIP-Seq Illumina HiSeq 2000;ILLUMINA 42
EGAD00001002687 CD4 T-Cell RNA-Seq Illumina HiSeq 2000;ILLUMINA 4
EGAD00001003806 cDNA depleted RNA (500ng total RNA input) was fragmented to 150-200 nucleotides in first strand buffer for 3 minutes at 94°C. Random hexamer primed first strand was generated in presence of dATP, dGTP, dCTP and cTTP. Second strand was generated using dUTP instead of dTTP to tag the second strand. Subsequent steps to generate the sequencing libraries were performed with the KAPA HTP Library Preparation Kit for Illumina sequencing with minor modifications, i.e., after indexed adapter ligation to the dsDNA fragments, the library was treated with USER enzyme (NEB_M5505L) in order to digest the second strand derived fragments. After amplification of the libraries, samples with unique sample indexes were pooled and sequenced paired-end 2x50bp on a HiSeq2500 system following standard Illumina guidelines. Illumina HiSeq 2500;ILLUMINA 36
EGAD00010000612 Celiac disease North Indian samples using Immunochip 0
EGAD00010000051 Cell line derived from microdissected primary pancreatic ductal adenocarcinoma tissues Affymetrix SNP 6.0 15
EGAD00001003550 Cell line exome sequencing Illumina HiSeq 2500;ILLUMINA 176
EGAD00001000064 Cell Line Sub Clone Rearrangement Screen Illumina Genome Analyzer II 6 bam
EGAD00010000130 Cerebellar ataxia, mental retardation, and disequilibrium syndrome (CAMRQ) samples Illumina 300 Duo V2 - Bead Studio, Illumina 2
EGAD00001002065 Cetuximab is a targeted monoclonal antibody against the epidermal growth factor receptor (EGFR) which is used therapeutically for the treatment of KRAS wild-type colorectal cancer (CRC). The Cetuximab sensitive KRAS wild-type CRC cell line NCI-H508 has been treated with a fixed concentration of ENU for 24 hours and then selected with Cetuximab until drug resistant clones were ready to be picked and grown up as sub-clones of the parental cell line. These will have genes causally implicated in cancer sequenced to identify common point mutations in multiple independently derived drug resistant clones as a forward genetic screen for mechanisms of resistance to Cetuximab in CRC Illumina HiSeq 2500; 50 cram
EGAD00001001948 Cetuximab is a targeted monoclonal antibody against the epidermal growth factor receptor (EGFR) which is used therapeutically for the treatment of KRAS wild-type colorectal cancer (CRC). The Cetuximab sensitive KRAS wild-type CRC cell line NCI-H508 has been treated with a fixed concentration of ENU for 24 hours and then selected with Cetuximab until drug resistant clones were ready to be picked and grown up as sub-clones of the parental cell line. These will have genes causally implicated in cancer sequenced to identify common point mutations in multiple independently derived drug resistant clones as a forward genetic screen for mechanisms of resistance to Cetuximab in CRC Illumina HiSeq 2000; 16 cram
EGAD00001001947 Cetuximab is a targeted monoclonal antibody against the epidermal growth factor receptor (EGFR) which is used therapeutically for the treatment of KRAS wild-type colorectal cancer (CRC). The Cetuximab sensitive KRAS wild-type CRC cell line NCI-H508 has been treated with a fixed concentration of ENU for 24 hours and then selected with Cetuximab until drug resistant clones were ready to be picked and grown up as sub-clones of the parental cell line. These will have genes causally implicated in cancer sequenced to identify common point mutations in multiple independently derived drug resistant clones as a forward genetic screen for mechanisms of resistance to Cetuximab in CRC. Illumina HiSeq 2000; 16 cram
EGAD00001000658 Changes in gene dosage are a major driver of cancer1, engineered from a finite, but increasingly well annotated, repertoire of mutational mechanisms2-6. These processes operate over levels ranging from individual exons to whole chromosomes, often generating correlated copy number alterations across hundreds of linked genes. An example of the latter is the 2% of childhood acute lymphoblastic leukemia (ALL) characterized by recurrent intrachromosomal amplification of megabase regions of chromosome 21 (iAMP21)7,8 To dissect the interplay between mutational processes and selection on this scale, we used genomic, cytogenetic and transcriptional analysis, coupled with novel bioinformatic approaches, to reconstruct the evolution of iAMP21 ALL. We find that individuals born with the rare constitutional Robertsonian translocation between chromosomes 15 and 21, rob(15;21)(q10;q10)c, have ~2700-fold increased risk of developing iAMP21 ALL compared to the general population. In such cases, amplification is initiated by chromothripsis involving both sister chromatids of the dicentric Robertsonian chromosome. In contrast, sporadic iAMP21 is typically initiated by breakage-fusion-bridge (BFB) events, often followed by chromothripsis or other rearrangements. In both sporadic and iAMP21 in rob(15;21)c individuals, the final stages of amplification frequently involve large-scale duplications of the abnormal chromosome. The end-product is a derivative chromosome 21 or a derivative originating from the rob(15;21)c chromosome, der(15;21), respectively, with gene dosage optimised for leukemic potential, showing constrained copy number levels over multiple linked genes. In summary, the constitutional translocation, rob(15;21)c, predisposes to leukemia through a novel mechanism, namely a propensity to undergo chromothripsis, likely related to its dicentric nature. More generally, our data illustrate that several cancer-specific mutational processes, applied sequentially, can co-ordinate to fashion copy number profiles over large genomic scales, incrementally refining the fitness benefits of aggregated gene dosage changes. Illumina Genome Analyzer II;, Illumina HiSeq 2000; 9 bam
EGAD00001001229 ChIP-Seq (H3K27ac) assays for reference epigenomes generated by Centre for Epigenome Mapping Technologies at Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2000;ILLUMINA 48 bam
EGAD00001001230 ChIP-Seq (H3K27me3) assays for reference epigenomes generated by Centre for Epigenome Mapping Technologies at Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2000;ILLUMINA 48 bam
EGAD00001001231 ChIP-Seq (H3K36me3) assays for reference epigenomes generated by Centre for Epigenome Mapping Technologies at Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2000;ILLUMINA 48 bam
EGAD00001001232 ChIP-Seq (H3K4me1) assays for reference epigenomes generated by Centre for Epigenome Mapping Technologies at Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2000;ILLUMINA 48 bam
EGAD00001001233 ChIP-Seq (H3K4me3) assays for reference epigenomes generated by Centre for Epigenome Mapping Technologies at Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2000;ILLUMINA 48 bam
EGAD00001002238 ChIP-Seq (H3K4me3, H3K4me1, H3K9me3, H3K27ac, H3K27me3, H3K36me3, Input) data for HL60 cell line generated at Centre for Epigenome Mapping Technologies, Genome Sciences Center, B.C. Cancer Agency. Illumina HiSeq 2000; 1 bam,fastq
EGAD00001001234 ChIP-Seq (H3K9me3) assays for reference epigenomes generated by Centre for Epigenome Mapping Technologies at Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2000;ILLUMINA 48 bam
EGAD00001001235 ChIP-Seq (Input) assays for reference epigenomes generated by Centre for Epigenome Mapping Technologies at Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. 48 bam
EGAD00001003349 ChIP-seq data (H3K4Me1, H3K4Me3, H3K27Ac histone modifications) in experimental triplicates on multiple myeloma cell line KMS11 and plasma cell leukaemia cell lines L363 and JJN3. ChIP reactions were performed on a Diagenode SX-8G IP-Star Compact using Diagenode automated Ideal Kit. ChIP libraries were generated using HTP Illumina library preparation kit, and sequenced using Illumina HiSeq 2000 with 100 bp single-ended reads. ChIP-seq files are in BED format. Illumina HiSeq 2000;ILLUMINA 9
EGAD00001001569 ChIP-Seq data for 1 Acute lymphocytic leukemia - CTR sample(s). 7 run(s), 7 experiment(s), 7 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 1 fastq,bam
EGAD00001002280 ChIP-Seq data for 1 Acute Lymphocytic Leukemia - CTR sample(s). 7 run(s), 7 experiment(s), 7 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001001536 ChIP-Seq data for 1 Acute Myeloid Leukemia - MC2884 sample(s). 2 run(s), 2 experiment(s), 2 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 1 fastq,bam
EGAD00001002344 ChIP-Seq data for 1 Acute Myeloid Leukemia - MC2884 sample(s). 3 run(s), 3 experiment(s), 3 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001002516 ChIP-Seq data for 1 Acute Promyelocytic Leukemia - MC2494 sample(s). 2 run(s), 1 experiment(s), 1 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 1 bam,fastq
EGAD00001002312 ChIP-Seq data for 1 Acute Promyelocytic Leukemia - MC2884 (24h) sample(s). 6 run(s), 6 experiment(s), 6 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001002372 ChIP-Seq data for 1 Acute Promyelocytic Leukemia - MC2884 (4h) sample(s). 6 run(s), 6 experiment(s), 6 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001002357 ChIP-Seq data for 1 Acute Promyelocytic Leukemia - MC2884 sample(s). 8 run(s), 8 experiment(s), 8 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001002431 ChIP-Seq data for 1 Acute Promyelocytic Leukemia - MC3324 sample(s). 2 run(s), 1 experiment(s), 1 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001002493 ChIP-Seq data for 1 Acute Promyelocytic Leukemia - MS-275 (20h) sample(s). 5 run(s), 5 experiment(s), 5 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 1 bam,fastq
EGAD00001002342 ChIP-Seq data for 1 Acute Promyelocytic Leukemia - MS275 sample(s). 7 run(s), 7 experiment(s), 7 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001002298 ChIP-Seq data for 1 Acute Promyelocytic Leukemia - SAHA sample(s). 1 run(s), 1 experiment(s), 1 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001002304 ChIP-Seq data for 1 Acute Promyelocytic Leukemia sample(s). 7 run(s), 7 experiment(s), 7 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001001554 ChIP-Seq data for 1 adult endothelial progenitor cell sample(s). 8 run(s), 7 experiment(s), 7 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 1 fastq,bam
EGAD00001001570 ChIP-Seq data for 1 CD3-negative, CD4-positive, CD8-positive, double positive thymocyte sample(s). 2 run(s), 2 experiment(s), 2 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 1 fastq,bam
EGAD00001001503 ChIP-Seq data for 1 CD3-positive, CD4-positive, CD8-positive, double positive thymocyte sample(s). 3 run(s), 3 experiment(s), 3 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 1 fastq,bam
EGAD00001001557 ChIP-Seq data for 1 CD34-negative, CD41-positive, CD42-positive megakaryocyte cell sample(s). 7 run(s), 6 experiment(s), 6 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 1 fastq,bam
EGAD00001000916 ChIP-Seq data for 1 CD34-negative, CD41-positive, CD42-positive megakaryocyte cell sample(s). 7 run(s), 7 experiment(s), 7 alignment(s). Part of BLUEPRINT release August 2014. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 1 fastq
EGAD00001001182 ChIP-Seq data for 1 CD34-negative, CD41-positive, CD42-positive megakaryocyte cell sample(s). 7 run(s), 7 experiment(s), 7 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 1 fastq,bam
EGAD00001001584 ChIP-Seq data for 1 CD4-positive, alpha-beta thymocyte sample(s). 2 run(s), 2 experiment(s), 2 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 1 fastq,bam
EGAD00001002386 ChIP-Seq data for 1 CD4-positive, alpha-beta thymocyte sample(s). 3 run(s), 3 experiment(s), 3 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001001568 ChIP-Seq data for 1 CD8-positive, alpha-beta thymocyte sample(s). 2 run(s), 2 experiment(s), 2 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 1 fastq,bam
EGAD00001002494 ChIP-Seq data for 1 CD8-positive, alpha-beta thymocyte sample(s). 2 run(s), 2 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 1 bam,fastq
EGAD00001001144 ChIP-Seq data for 1 central memory CD4-positive, alpha-beta T cell sample(s). 6 run(s), 6 experiment(s), 6 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 1 fastq,bam
EGAD00001001499 ChIP-Seq data for 1 central memory CD4-positive, alpha-beta T cell sample(s). 9 run(s), 7 experiment(s), 7 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 1 fastq,bam
EGAD00001002310 ChIP-Seq data for 1 conventional dendritic cell sample(s). 4 run(s), 4 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001001577 ChIP-Seq data for 1 effector memory CD8-positive, alpha-beta T cell, terminally differentiated sample(s). 4 run(s), 4 experiment(s), 4 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 1 fastq,bam
EGAD00001001195 ChIP-Seq data for 1 effector memory CD8-positive, alpha-beta T cell, terminally differentiated sample(s). 4 run(s), 4 experiment(s), 4 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 1 fastq,bam
EGAD00001001528 ChIP-Seq data for 1 Leukemia sample(s). 2 run(s), 2 experiment(s), 2 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 1 fastq,bam
EGAD00001000929 ChIP-Seq data for 1 macrophage sample(s). 6 run(s), 6 experiment(s), 6 alignment(s). Part of BLUEPRINT release August 2014. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 1 fastq
EGAD00001000906 ChIP-Seq data for 1 mature eosinophil sample(s). 7 run(s), 7 experiment(s), 7 alignment(s). Part of BLUEPRINT release August 2014. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 1 fastq
EGAD00001002510 ChIP-Seq data for 1 memory B cell sample(s). 1 run(s), 1 experiment(s), 1 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 1 bam,fastq
EGAD00001001578 ChIP-Seq data for 1 mesenchymal stem cell of the bone marrow sample(s). 9 run(s), 7 experiment(s), 7 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 1 fastq,bam
EGAD00001002420 ChIP-Seq data for 1 monocyte - T=10day_RANK_M-CSF sample(s). 2 run(s), 2 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001002949 ChIP-Seq data for 1 sample(s) Acute Lymphocytic Leukemia for precursor B cell from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001002951 ChIP-Seq data for 1 sample(s) for class switched memory B cell from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001002948 ChIP-Seq data for 1 sample(s) for conventional dendritic cell from cord blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001002950 ChIP-Seq data for 1 sample(s) for memory B cell from venous blood, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001002282 ChIP-Seq data for 1 unswitched memory B cell sample(s). 7 run(s), 7 experiment(s), 7 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001001179 ChIP-Seq data for 10 CD14-positive, CD16-negative classical monocyte sample(s). 73 run(s), 69 experiment(s), 69 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 10 fastq,readme_file,bam
EGAD00001002484 ChIP-Seq data for 10 CD14-positive, CD16-negative classical monocyte sample(s). 80 run(s), 76 experiment(s), 76 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 10 bam,fastq
EGAD00001002449 ChIP-Seq data for 10 mature neutrophil sample(s). 105 run(s), 86 experiment(s), 86 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 10 bam,fastq
EGAD00001002384 ChIP-Seq data for 106 Chronic Lymphocytic Leukemia sample(s). 173 run(s), 162 experiment(s), 162 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 106 bam,fastq
EGAD00001001576 ChIP-Seq data for 12 macrophage sample(s). 49 run(s), 49 experiment(s), 49 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000;, NextSeq 500; 12 fastq,bam
EGAD00001001196 ChIP-Seq data for 13 macrophage sample(s). 55 run(s), 55 experiment(s), 55 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000;, NextSeq 500; 13 fastq,readme_file,bam
EGAD00001002421 ChIP-Seq data for 15 Acute Lymphocytic Leukemia sample(s). 79 run(s), 78 experiment(s), 78 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 15 bam,fastq
EGAD00001001481 ChIP-Seq data for 15 Acute Myeloid Leukemia sample(s). 75 run(s), 72 experiment(s), 72 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 16 fastq,bam
EGAD00001002466 ChIP-Seq data for 15 naive B cell sample(s). 67 run(s), 59 experiment(s), 59 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 15 bam,fastq
EGAD00001002673 ChIP-Seq data for 154 CD4-positive, alpha-beta T cell sample(s). 355 run(s), 265 experiment(s), 250 analysis(s) on human genome GRCh37. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/blueprint_Epivar/protocols/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 158 bam,fastq
EGAD00001002672 ChIP-Seq data for 172 CD14-positive, CD16-negative classical monocyte sample(s). 572 run(s), 345 experiment(s), 340 analysis(s) on human genome GRCh37. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/blueprint_Epivar/protocols/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 174 bam,fastq
EGAD00001002670 ChIP-Seq data for 182 mature neutrophil sample(s). 2847 run(s), 366 experiment(s), 355 analysis(s) on human genome GRCh37. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/blueprint_Epivar/protocols/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 186 fastq,cram,bam
EGAD00001002406 ChIP-Seq data for 2 Acute Promyelocytic Leukemia - MC2392 sample(s). 14 run(s), 12 experiment(s), 12 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 2 bam,fastq
EGAD00001002487 ChIP-Seq data for 2 adult endothelial progenitor cell sample(s). 16 run(s), 14 experiment(s), 14 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 2 bam,fastq
EGAD00001002369 ChIP-Seq data for 2 CD3-negative, CD4-positive, CD8-positive, double positive thymocyte sample(s). 7 run(s), 5 experiment(s), 5 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 2 bam,fastq
EGAD00001000936 ChIP-Seq data for 2 CD8-positive, alpha-beta T cell sample(s). 13 run(s), 13 experiment(s), 13 alignment(s). Part of BLUEPRINT release August 2014. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 2 fastq
EGAD00001002514 ChIP-Seq data for 2 effector memory CD4-positive, alpha-beta T cell sample(s). 8 run(s), 7 experiment(s), 7 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 2 bam,fastq
EGAD00001001472 ChIP-Seq data for 2 effector memory CD8-positive, alpha-beta T cell sample(s). 10 run(s), 10 experiment(s), 10 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 2 fastq,bam
EGAD00001001127 ChIP-Seq data for 2 effector memory CD8-positive, alpha-beta T cell sample(s). 10 run(s), 10 experiment(s), 10 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 2 fastq,bam
EGAD00001002503 ChIP-Seq data for 2 effector memory CD8-positive, alpha-beta T cell, terminally differentiated sample(s). 6 run(s), 6 experiment(s), 6 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 2 bam,fastq
EGAD00001001487 ChIP-Seq data for 2 endothelial cell of umbilical vein (proliferating) sample(s). 12 run(s), 12 experiment(s), 12 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 2 fastq,bam
EGAD00001001136 ChIP-Seq data for 2 endothelial cell of umbilical vein (proliferating) sample(s). 13 run(s), 13 experiment(s), 13 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 2 fastq,bam
EGAD00001002424 ChIP-Seq data for 2 endothelial cell of umbilical vein (proliferating) sample(s). 14 run(s), 14 experiment(s), 14 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 2 bam,fastq
EGAD00001001183 ChIP-Seq data for 2 endothelial cell of umbilical vein (resting) sample(s). 10 run(s), 10 experiment(s), 10 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 2 fastq,bam
EGAD00001001559 ChIP-Seq data for 2 endothelial cell of umbilical vein (resting) sample(s). 11 run(s), 11 experiment(s), 11 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 2 fastq,bam
EGAD00001002488 ChIP-Seq data for 2 endothelial cell of umbilical vein (resting) sample(s). 13 run(s), 13 experiment(s), 13 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 2 bam,fastq
EGAD00001001574 ChIP-Seq data for 2 erythroblast sample(s). 12 run(s), 12 experiment(s), 12 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 2 fastq,bam
EGAD00001000924 ChIP-Seq data for 2 erythroblast sample(s). 14 run(s), 14 experiment(s), 14 alignment(s). Part of BLUEPRINT release August 2014. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 2 fastq
EGAD00001001194 ChIP-Seq data for 2 erythroblast sample(s). 14 run(s), 14 experiment(s), 14 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 2 fastq,bam,readme_file
EGAD00001002377 ChIP-Seq data for 2 erythroblast sample(s). 14 run(s), 14 experiment(s), 14 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 2 bam,fastq
EGAD00001001502 ChIP-Seq data for 2 germinal center B cell sample(s). 12 run(s), 11 experiment(s), 11 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 2 fastq,bam
EGAD00001002314 ChIP-Seq data for 2 macrophage - T=6days B-glucan sample(s). 6 run(s), 6 experiment(s), 6 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA, NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002498 ChIP-Seq data for 2 macrophage - T=6days LPS sample(s). 6 run(s), 6 experiment(s), 6 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;, NextSeq 500; 2 bam,fastq
EGAD00001002458 ChIP-Seq data for 2 macrophage - T=6days untreated sample(s). 6 run(s), 6 experiment(s), 6 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;, NextSeq 500; 2 bam,fastq
EGAD00001001539 ChIP-Seq data for 2 mature eosinophil sample(s). 12 run(s), 12 experiment(s), 12 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 2 fastq,bam
EGAD00001001168 ChIP-Seq data for 2 mature eosinophil sample(s). 12 run(s), 12 experiment(s), 12 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 2 fastq,bam
EGAD00001002477 ChIP-Seq data for 2 mature eosinophil sample(s). 14 run(s), 14 experiment(s), 14 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 2 bam,fastq
EGAD00001002381 ChIP-Seq data for 2 mesenchymal stem cell of the bone marrow sample(s). 16 run(s), 14 experiment(s), 14 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 2 bam,fastq
EGAD00001002297 ChIP-Seq data for 2 monocyte - RPMI_BG_T=1hr sample(s). 6 run(s), 6 experiment(s), 6 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA, unspecified;ILLUMINA 2 bam,fastq
EGAD00001002376 ChIP-Seq data for 2 monocyte - RPMI_LPS_T=1hr sample(s). 8 run(s), 6 experiment(s), 6 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA, unspecified;ILLUMINA 2 bam,fastq
EGAD00001002399 ChIP-Seq data for 2 monocyte - RPMI_LPS_T=4hrs sample(s). 5 run(s), 5 experiment(s), 5 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 2 bam,fastq
EGAD00001002453 ChIP-Seq data for 2 monocyte - RPMI_T=1hr sample(s). 4 run(s), 4 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 unspecified;, Illumina HiSeq 2000; 2 bam,fastq
EGAD00001002491 ChIP-Seq data for 2 monocyte - T=0days sample(s). 7 run(s), 7 experiment(s), 7 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;, NextSeq 500; 2 bam,fastq
EGAD00001001580 ChIP-Seq data for 2 monocyte sample(s). 6 run(s), 6 experiment(s), 6 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000;, NextSeq 500; 2 fastq,bam
EGAD00001001197 ChIP-Seq data for 2 monocyte sample(s). 7 run(s), 7 experiment(s), 7 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000;, NextSeq 500; 2 fastq,bam
EGAD00001001592 ChIP-Seq data for 2 Multiple myeloma sample(s). 16 run(s), 14 experiment(s), 14 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 2 fastq,bam
EGAD00001002391 ChIP-Seq data for 2 osteoclast sample(s). 17 run(s), 14 experiment(s), 14 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 2 bam,fastq
EGAD00001001470 ChIP-Seq data for 2 plasma cell sample(s). 13 run(s), 12 experiment(s), 12 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 2 fastq,bam
EGAD00001002293 ChIP-Seq data for 2 regulatory T cell sample(s). 2 run(s), 2 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 2 bam,fastq
EGAD00001002307 ChIP-Seq data for 3 Activated B-Cell-Like Diffuse Large B-Cell Lymphoma sample(s). 12 run(s), 12 experiment(s), 12 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 3 bam,fastq
EGAD00001001485 ChIP-Seq data for 3 Acute Myeloid Leukemia - SAHA sample(s). 11 run(s), 11 experiment(s), 11 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 3 fastq,bam
EGAD00001002292 ChIP-Seq data for 3 Acute Myeloid Leukemia - SAHA sample(s). 14 run(s), 14 experiment(s), 14 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 3 bam,fastq
EGAD00001002319 ChIP-Seq data for 3 Acute Promyelocytic Leukemia - ATRA sample(s). 21 run(s), 20 experiment(s), 20 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 3 bam,fastq
EGAD00001002490 ChIP-Seq data for 3 Acute Promyelocytic Leukemia - CTR sample(s). 22 run(s), 21 experiment(s), 21 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 3 bam,fastq
EGAD00001002329 ChIP-Seq data for 3 Burkitt Lymphoma sample(s). 13 run(s), 13 experiment(s), 13 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 3 bam,fastq
EGAD00001002445 ChIP-Seq data for 3 CD3-positive, CD4-positive, CD8-positive, double positive thymocyte sample(s). 11 run(s), 11 experiment(s), 11 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 3 bam,fastq
EGAD00001002362 ChIP-Seq data for 3 CD34-negative, CD41-positive, CD42-positive megakaryocyte cell sample(s). 19 run(s), 18 experiment(s), 18 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 3 bam,fastq
EGAD00001000925 ChIP-Seq data for 3 CD4-positive, alpha-beta T cell sample(s). 21 run(s), 21 experiment(s), 21 alignment(s). Part of BLUEPRINT release August 2014. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 3 fastq
EGAD00001002439 ChIP-Seq data for 3 central memory CD4-positive, alpha-beta T cell sample(s). 11 run(s), 9 experiment(s), 9 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 3 bam,fastq
EGAD00001002450 ChIP-Seq data for 3 central memory CD8-positive, alpha-beta T cell sample(s). 4 run(s), 4 experiment(s), 4 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 3 bam,fastq
EGAD00001001187 ChIP-Seq data for 3 Chronic lymphocytic leukemia sample(s). 6 run(s), 6 experiment(s), 6 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 3 fastq,bam
EGAD00001002430 ChIP-Seq data for 3 class switched memory B cell sample(s). 21 run(s), 21 experiment(s), 21 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 3
EGAD00001002283 ChIP-Seq data for 3 effector memory CD8-positive, alpha-beta T cell sample(s). 16 run(s), 15 experiment(s), 15 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 3 bam,fastq
EGAD00001002506 ChIP-Seq data for 3 Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma sample(s). 10 run(s), 10 experiment(s), 10 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 3 bam,fastq
EGAD00001002485 ChIP-Seq data for 3 immature conventional dendritic cell - GM-CSF_IL4_T=6_days sample(s). 20 run(s), 20 experiment(s), 20 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 3 bam,fastq
EGAD00001000940 ChIP-Seq data for 3 inflammatory macrophage sample(s). 21 run(s), 21 experiment(s), 21 alignment(s). Part of BLUEPRINT release August 2014. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 3 fastq
EGAD00001002389 ChIP-Seq data for 3 Lymphoma_Follicular sample(s). 11 run(s), 11 experiment(s), 11 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 3 bam,fastq
EGAD00001002462 ChIP-Seq data for 3 mature conventional dendritic cell - GM-CSF_IL4_T=6_days_R848_T=24hrs sample(s). 20 run(s), 19 experiment(s), 19 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 3 bam,fastq
EGAD00001001527 ChIP-Seq data for 3 mature neutrophil - G-CSF/Dex. Treatment (16-20 hrs) sample(s). 18 run(s), 18 experiment(s), 18 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 3 fastq,bam
EGAD00001002470 ChIP-Seq data for 3 mature neutrophil - G-CSF/Dex. Treatment (16-20 hrs) sample(s). 23 run(s), 23 experiment(s), 23 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 3 bam,fastq
EGAD00001002415 ChIP-Seq data for 3 monocyte - Attached_T=1hr sample(s). 8 run(s), 7 experiment(s), 7 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA, unspecified;ILLUMINA 3 bam,fastq
EGAD00001002279 ChIP-Seq data for 3 monocyte - None sample(s). 17 run(s), 17 experiment(s), 17 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 3 bam,fastq
EGAD00001002408 ChIP-Seq data for 3 monocyte - RPMI_BG_T=24hrs sample(s). 8 run(s), 8 experiment(s), 8 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 3 bam,fastq
EGAD00001002517 ChIP-Seq data for 3 monocyte - RPMI_BG_T=24hrs_RPMI_T=5days sample(s). 7 run(s), 7 experiment(s), 7 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 3 bam,fastq
EGAD00001002512 ChIP-Seq data for 3 monocyte - RPMI_BG_T=24hrs_RPMI_T=5days_LPS_T=4hrs sample(s). 7 run(s), 7 experiment(s), 7 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 3 bam,fastq
EGAD00001002368 ChIP-Seq data for 3 monocyte - RPMI_BG_T=4hrs sample(s). 8 run(s), 8 experiment(s), 8 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA, unspecified;ILLUMINA 3 bam,fastq
EGAD00001002388 ChIP-Seq data for 3 monocyte - RPMI_LPS_T=24hrs sample(s). 8 run(s), 8 experiment(s), 8 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA, unspecified;ILLUMINA 3 bam,fastq
EGAD00001002448 ChIP-Seq data for 3 monocyte - RPMI_LPS_T=24hrs_RPMI_T=5days sample(s). 7 run(s), 7 experiment(s), 7 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 3 bam,fastq
EGAD00001002296 ChIP-Seq data for 3 monocyte - RPMI_LPS_T=24hrs_RPMI_T=5days_LPS_T=4hrs sample(s). 7 run(s), 7 experiment(s), 7 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 3 bam,fastq
EGAD00001002474 ChIP-Seq data for 3 monocyte - RPMI_T=24hrs sample(s). 7 run(s), 7 experiment(s), 7 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 3 bam,fastq
EGAD00001002328 ChIP-Seq data for 3 monocyte - RPMI_T=4hrs sample(s). 8 run(s), 8 experiment(s), 8 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 3 bam,fastq
EGAD00001002413 ChIP-Seq data for 3 monocyte - RPMI_T=6days sample(s). 10 run(s), 7 experiment(s), 7 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 3 bam,fastq
EGAD00001002495 ChIP-Seq data for 3 monocyte - RPMI_T=6days_LPS_T=4hrs sample(s). 8 run(s), 7 experiment(s), 7 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 3 bam,fastq
EGAD00001002411 ChIP-Seq data for 3 T-cell Prolymphocytic Leukemia sample(s). 21 run(s), 21 experiment(s), 21 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 3 bam,fastq
EGAD00001002418 ChIP-Seq data for 38 Acute Myeloid Leukemia sample(s). 244 run(s), 226 experiment(s), 226 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 38 bam,fastq
EGAD00001001533 ChIP-Seq data for 4 Acute Myeloid Leukemia - CTR sample(s). 21 run(s), 21 experiment(s), 21 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 4 fastq,bam
EGAD00001001514 ChIP-Seq data for 4 alternatively activated macrophage sample(s). 22 run(s), 22 experiment(s), 22 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 4 fastq,bam
EGAD00001000938 ChIP-Seq data for 4 alternatively activated macrophage sample(s). 29 run(s), 28 experiment(s), 28 alignment(s). Part of BLUEPRINT release August 2014. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 4 fastq
EGAD00001001511 ChIP-Seq data for 4 band form neutrophil sample(s). 18 run(s), 17 experiment(s), 17 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 4 fastq,bam
EGAD00001002454 ChIP-Seq data for 4 band form neutrophil sample(s). 26 run(s), 23 experiment(s), 23 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;, NextSeq 500; 4 bam,fastq
EGAD00001001207 ChIP-Seq data for 4 CD38-negative naive B cell sample(s). 14 run(s), 14 experiment(s), 14 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 4 fastq,bam
EGAD00001001158 ChIP-Seq data for 4 cytotoxic CD56-dim natural killer cell sample(s). 16 run(s), 16 experiment(s), 16 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 4 fastq,bam
EGAD00001001518 ChIP-Seq data for 4 cytotoxic CD56-dim natural killer cell sample(s). 17 run(s), 17 experiment(s), 17 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 4 fastq,bam
EGAD00001002442 ChIP-Seq data for 4 germinal center B cell sample(s). 24 run(s), 22 experiment(s), 22 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 4 bam,fastq
EGAD00001002379 ChIP-Seq data for 4 Multiple Myeloma sample(s). 34 run(s), 28 experiment(s), 28 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 4 bam,fastq
EGAD00001001495 ChIP-Seq data for 4 neutrophilic metamyelocyte sample(s). 18 run(s), 12 experiment(s), 12 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 4 fastq,bam
EGAD00001002435 ChIP-Seq data for 4 neutrophilic metamyelocyte sample(s). 32 run(s), 23 experiment(s), 23 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 4 bam,fastq
EGAD00001001517 ChIP-Seq data for 4 neutrophilic myelocyte sample(s). 14 run(s), 14 experiment(s), 14 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 4 fastq,bam
EGAD00001002318 ChIP-Seq data for 4 neutrophilic myelocyte sample(s). 28 run(s), 23 experiment(s), 23 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 4 bam,fastq
EGAD00001002952 ChIP-Seq data for 4 sample(s) T-cell Acute Lymphocytic Leukemia from capillary blood, on Genome GRCh38. 7 run(s), 7 experiment(s), 7 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000;ILLUMINA 4 bam,fastq
EGAD00001001588 ChIP-Seq data for 4 segmented neutrophil of bone marrow sample(s). 20 run(s), 19 experiment(s), 19 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 4 fastq,bam
EGAD00001002390 ChIP-Seq data for 4 segmented neutrophil of bone marrow sample(s). 24 run(s), 23 experiment(s), 23 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA, NextSeq 500;ILLUMINA 4 bam,fastq
EGAD00001001155 ChIP-Seq data for 5 alternatively activated macrophage sample(s). 36 run(s), 35 experiment(s), 35 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 5 fastq,bam,readme_file
EGAD00001001513 ChIP-Seq data for 5 CD8-positive, alpha-beta T cell sample(s). 26 run(s), 26 experiment(s), 26 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 5 fastq,bam
EGAD00001001154 ChIP-Seq data for 5 CD8-positive, alpha-beta T cell sample(s). 28 run(s), 28 experiment(s), 28 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 5 fastq,readme_file,bam
EGAD00001001562 ChIP-Seq data for 5 Chronic lymphocytic leukemia sample(s). 24 run(s), 23 experiment(s), 23 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 5 fastq,bam
EGAD00001002397 ChIP-Seq data for 5 Mantle Cell Lymphoma sample(s). 35 run(s), 35 experiment(s), 35 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 5 bam,fastq
EGAD00001002281 ChIP-Seq data for 5 plasma cell sample(s). 24 run(s), 23 experiment(s), 23 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 5 bam,fastq
EGAD00001002947 ChIP-Seq data for 5 sample(s) for thymocyte from thymus, on Genome GRCh38. 17 run(s), 17 experiment(s), 17 alignment(s). Part of BLUEPRINT (September 2016).Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000;ILLUMINA 5 bam,fastq
EGAD00001001138 ChIP-Seq data for 6 Acute promyelocytic leukemia sample(s). 25 run(s), 23 experiment(s), 23 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 6 fastq,bam
EGAD00001001490 ChIP-Seq data for 6 Acute promyelocytic leukemia sample(s). 29 run(s), 27 experiment(s), 27 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 6 fastq,bam
EGAD00001001594 ChIP-Seq data for 6 CD38-negative naive B cell sample(s). 20 run(s), 20 experiment(s), 20 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 6 fastq,bam
EGAD00001002463 ChIP-Seq data for 6 cytotoxic CD56-dim natural killer cell sample(s). 34 run(s), 34 experiment(s), 34 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 6 bam,fastq
EGAD00001001204 ChIP-Seq data for 6 inflammatory macrophage sample(s). 35 run(s), 35 experiment(s), 35 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 6 fastq,bam,readme_file
EGAD00001001519 ChIP-Seq data for 6 naive B cell sample(s). 34 run(s), 28 experiment(s), 28 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 6 fastq,bam
EGAD00001002340 ChIP-Seq data for 7 Acute Myeloid Leukemia - CTR sample(s). 45 run(s), 44 experiment(s), 44 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 7 bam,fastq
EGAD00001001188 ChIP-Seq data for 7 Acute myeloid leukemia sample(s). 23 run(s), 23 experiment(s), 23 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 7 fastq,bam
EGAD00001002317 ChIP-Seq data for 7 alternatively activated macrophage sample(s). 50 run(s), 49 experiment(s), 49 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 7 bam,fastq
EGAD00001001505 ChIP-Seq data for 7 CD4-positive, alpha-beta T cell sample(s). 39 run(s), 39 experiment(s), 39 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 7 fastq,bam
EGAD00001001147 ChIP-Seq data for 7 CD4-positive, alpha-beta T cell sample(s). 46 run(s), 45 experiment(s), 45 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 7 fastq,readme_file,bam
EGAD00001002455 ChIP-Seq data for 7 CD8-positive, alpha-beta T cell sample(s). 38 run(s), 38 experiment(s), 38 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 7 bam,fastq
EGAD00001001589 ChIP-Seq data for 7 inflammatory macrophage sample(s). 36 run(s), 36 experiment(s), 36 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 7 fastq,bam
EGAD00001000930 ChIP-Seq data for 7 mature neutrophil sample(s). 68 run(s), 50 experiment(s), 50 alignment(s). Part of BLUEPRINT release August 2014. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 7 fastq
EGAD00001001149 ChIP-Seq data for 7 mature neutrophil sample(s). 78 run(s), 60 experiment(s), 60 alignment(s). Part of BLUEPRINT release January 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 7 fastq,readme_file,bam
EGAD00001001552 ChIP-Seq data for 9 CD14-positive, CD16-negative classical monocyte sample(s). 56 run(s), 53 experiment(s), 53 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 9 fastq,bam
EGAD00001000913 ChIP-Seq data for 9 CD14-positive, CD16-negative classical monocyte sample(s). 59 run(s), 55 experiment(s), 55 alignment(s). Part of BLUEPRINT release August 2014. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20140811/homo_sapiens/README_chipseq_analysis_ebi_20140811 Illumina HiSeq 2000; 9 fastq
EGAD00001002524 ChIP-Seq data for 9 CD38-negative naive B cell sample(s). 48 run(s), 44 experiment(s), 44 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 9 bam,fastq
EGAD00001002444 ChIP-Seq data for 9 CD4-positive, alpha-beta T cell sample(s). 68 run(s), 63 experiment(s), 63 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 9 bam,fastq
EGAD00001002515 ChIP-Seq data for 9 inflammatory macrophage sample(s). 58 run(s), 58 experiment(s), 58 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 9 bam,fastq
EGAD00001002504 ChIP-Seq data for 9 macrophage sample(s). 55 run(s), 55 experiment(s), 55 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000; 9 bam,fastq
EGAD00001001508 ChIP-Seq data for 9 mature neutrophil sample(s). 48 run(s), 45 experiment(s), 45 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_chipseq_analysis_ebi_20150820 Illumina HiSeq 2000; 9 fastq,bam
EGAD00001002400 ChIP-Seq data for 9 T-cell Acute Lymphocytic Leukemia sample(s). 41 run(s), 41 experiment(s), 41 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 9 bam,fastq
EGAD00001003432 ChIP-Seq data for the paper titled "Orthotopic Patient-Derived Xenografts of Pediatric Solid Tumors" Illumina HiSeq 2000;ILLUMINA 20
EGAD00001000676 ChIP-seq for monocytes and neutrophils 14
EGAD00001002712 ChIP-Seq_H3K27me3 data for 131 mature neutrophil sample(s). 321 run(s), 134 experiment(s), 134 analysis(s) on human genome GRCh37. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/blueprint_Epivar/protocols/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 131 fastq,cram,bam
EGAD00001002711 ChIP-Seq_H3K4me3 data for 133 mature neutrophil sample(s). 208 run(s), 136 experiment(s), 136 analysis(s) on human genome GRCh37. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/blueprint_Epivar/protocols/README_chipseq_analysis_ebi_20160816 Illumina HiSeq 2000;ILLUMINA 133 fastq,cram,bam
EGAD00001002930 ChIPmentation data for 1 sample(s) Acute Lymphocytic Leukemia from bone marrow, on Genome GRCh38. 2 run(s), 2 experiment(s), 2 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002929 ChIPmentation data for 1 sample(s) for CD38-negative naive B cell from cord blood, on Genome GRCh38. 5 run(s), 3 experiment(s), 3 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002927 ChIPmentation data for 1 sample(s) for central memory CD4-positive, alpha-beta T cell from venous blood, on Genome GRCh38. 5 run(s), 3 experiment(s), 3 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002933 ChIPmentation data for 1 sample(s) for class switched memory B cell from venous blood, on Genome GRCh38. 2 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002940 ChIPmentation data for 1 sample(s) for conventional dendritic cell from cord blood, on Genome GRCh38. 4 run(s), 2 experiment(s), 2 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002934 ChIPmentation data for 1 sample(s) for cytotoxic CD56-dim natural killer cell from venous blood, on Genome GRCh38. 2 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002926 ChIPmentation data for 1 sample(s) for effector memory CD4-positive, alpha-beta T cell from venous blood, on Genome GRCh38. 2 run(s), 2 experiment(s), 2 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002945 ChIPmentation data for 1 sample(s) for effector memory CD8-positive, alpha-beta T cell from venous blood, on Genome GRCh38. 2 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002943 ChIPmentation data for 1 sample(s) for effector memory CD8-positive, alpha-beta T cell, terminally differentiated from venous blood, on Genome GRCh38. 5 run(s), 3 experiment(s), 3 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002932 ChIPmentation data for 1 sample(s) for germinal center B cell from tonsil, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001002925 ChIPmentation data for 1 sample(s) for immature conventional dendritic cell GM-CSF_IL4_T=6_days from venous blood, on Genome GRCh38. 2 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002941 ChIPmentation data for 1 sample(s) for mature conventional dendritic cell GM-CSF_IL4_T=6_days_R848_T=24hrs from venous blood, on Genome GRCh38. 2 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 1 bam,fastq
EGAD00001002937 ChIPmentation data for 1 sample(s) for naive B cell from tonsil, on Genome GRCh38. 1 run(s), 1 experiment(s), 1 alignment(s). Part of BLUEPRINT (September 2016). Illumina HiSeq 2000;ILLUMINA 1 bam,fastq
EGAD00001002944 ChIPmentation data for 2 sample(s) Activated B-Cell-Like Diffuse Large B-Cell Lymphoma from lymph node, on Genome GRCh38. 3 run(s), 3 experiment(s), 3 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002935 ChIPmentation data for 2 sample(s) Acute Myeloid Leukemia for blast cell from bone marrow, on Genome GRCh38. 12 run(s), 6 experiment(s), 6 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002924 ChIPmentation data for 2 sample(s) for central memory CD8-positive, alpha-beta T cell from venous blood, on Genome GRCh38. 11 run(s), 7 experiment(s), 7 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002923 ChIPmentation data for 2 sample(s) for memory B cell from venous blood, on Genome GRCh38. 6 run(s), 4 experiment(s), 4 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002942 ChIPmentation data for 2 sample(s) for regulatory T cell from venous blood, on Genome GRCh38. 14 run(s), 9 experiment(s), 9 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002946 ChIPmentation data for 2 sample(s) Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma from lymph node, on Genome GRCh38. 6 run(s), 6 experiment(s), 6 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002938 ChIPmentation data for 2 sample(s) T-cell Acute Lymphocytic Leukemia from capillary blood, on Genome GRCh38. 2 run(s), 2 experiment(s), 2 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 2 bam,fastq
EGAD00001002939 ChIPmentation data for 3 sample(s) Burkitt Lymphoma from lymph node, on Genome GRCh38. 10 run(s), 8 experiment(s), 8 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 3 bam,fastq
EGAD00001002931 ChIPmentation data for 3 sample(s) Lymphoma_Follicular from lymph node, on Genome GRCh38. 7 run(s), 6 experiment(s), 6 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 3 bam,fastq
EGAD00001002936 ChIPmentation data for 5 sample(s) Acute Lymphocytic Leukemia for precursor B cell from venous blood, on Genome GRCh38. 7 run(s), 7 experiment(s), 7 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 5 bam,fastq
EGAD00001002928 ChIPmentation data for 7 sample(s) Acute Lymphocytic Leukemia for precursor B cell from bone marrow, on Genome GRCh38. 13 run(s), 13 experiment(s), 13 alignment(s). Part of BLUEPRINT (September 2016). NextSeq 500;ILLUMINA 7 bam,fastq
EGAD00001002135 ChIPseq data of Atypical teratoid/rhabdoid tumors (ATRT) Illumina HiSeq 2000;, Illumina HiSeq 2500; 15 fastq
EGAD00001002012 ChIPseq data of whole blood samples from smoking and non-smoking mothers and their children at gestation/birth and follow-up years. 16 bam
EGAD00001001988 Cholangiocarcinoma whole genome sequencing data HiSeq X Ten (ILLUMINA), Illumina HiSeq 2000 (ILLUMINA), Illumina HiSeq 2500 (ILLUMINA) 118
EGAD00010000488 Chondroblastoma case sample genotype using Affymetrix SNP6.0 Affymetrix_SNP6- 7
EGAD00001001063 Chondromxoid fibroma is a benign tumour of bone with unknown underlying pathogenesis. To determine pathognomic genomic event in chondromyxoid fibroma whole genome sequencing will be undertaken to reconstruct rearrangements and find underlying mutations. Illumina HiSeq 2000; 2 bam,cram
EGAD00001000358 Chondrosarcoma (CHS) is a heterogeneous collection of malignant bone tumours and is the second most common primary malignancy of bone after osteosarcoma. Recent work has identified frequent, recurrent mutations in IDH1/2 in nearly half of central CHS. However, there has been little systematic genomic analysis of this tumour type and thus the contribution of other genes is unclear. Here we report comprehensive genomic analyses of 49 cases of CHS. We identified hypermutability of the major cartilage collagen COL2A1 with insertions, deletions and rearrangements identified in 37% of cases. The patterns of mutation were consistent with selection for variants likely to impair normal collagen biosynthesis. In addition we identified mutations in IDH1/2 (59%), TP53 (20%), the RB1 pathway (27%) and hedgehog signaling (22%). Illumina HiSeq 2000; 17 bam
EGAD00010000452 Chondrosarcoma case sample genotype using Affymetrix SNP6.0 Affymetrix_SNP6 36
EGAD00001000125 Chondrosarcoma Exome Illumina HiSeq 2000, Illumina HiSeq 2000; 104 bam
EGAD00001000119 Chordoma Exome Sequencing Illumina HiSeq 2000, Illumina Genome Analyzer II, Illumina HiSeq 2000; 50 bam
EGAD00001000226 Chordoma is a rare malignant bone tumor that expresses the transcription factor T. We conducted an association study of 40 patients with chordoma and 358 ancestry-matched, unaffected individuals with replication in an independent cohort. Whole-exome and Sanger sequencing of T exons reveals a strong risk association ( allelic odds ratio (OR) = 4.9, P = 3.3x10-11, CI= 2.9-8.1) with the common (minor allelic frequency >5%) non-synonymous SNP rs2305089 in chordoma, which is exceptional in cancer genetics. Illumina Genome Analyzer II;, Illumina HiSeq 2000; 18 bam
EGAD00001002110 Chronic lymphocytic leukemia (CLL) is characterized by substantial clinical heterogeneity, despite relatively few genetic alterations. To provide a basis for studying epigenome deregulation in CLL, we established genome-wide chromatin accessibility maps for 88 CLL samples from 55 patients using the ATAC-seq assay, and we also performed ChIPmentation and RNA-seq profiling for ten representative samples. Based on the resulting dataset, we devised and applied a bioinformatic method that links chromatin profiles to clinical annotations. Our analysis identified sample-specific variation on top of a shared core of CLL regulatory regions. IGHV mutation status – which distinguishes the two major subtypes of CLL – was accurately predicted by the chromatin profiles, and gene regulatory networks inferred for IGHV-mutated vs. IGHV-unmutated samples identified characteristic differences between these two disease subtypes. In summary, we discovered widespread heterogeneity in the chromatin landscape of CLL, established a community resource for studying epigenome deregulation in leukemia, and demonstrated the feasibility of chromatin accessibility mapping in cancer cohorts and clinical research. Illumina HiSeq 3000; 138 bam
EGAD00001003445 Clear cell renal cancer is characterized by near-universal loss of the short arm of chromosome 3 (3p). This event arises through unknown mechanisms, but critically results in the loss of several tumor suppressor genes. We analyzed whole genomes from 95 biopsies across 33 patients with clear cell renal cancer (ccRCC) recruited into the Renal TRACERx study. We find novel hotspots of point mutations in the 5'-UTR of TERT, targeting a MYC-MAX repressor, that result in telomere lengthening. The most common structural abnormality generates simultaneous 3p loss and 5q gain (36% patients), typically through chromothripsis. Using molecular clocks, we estimate this occurs in childhood or adolescence, generally preceding emergence of the most recent common ancestor by years to decades. Similar genomic changes recent common ancestor by years to decades. Similar genomic changes are seen in inherited kidney cancers. Modeling differences in age-incidence between inherited and sporadic cancers suggests that the number of cells with 3p loss capable of initiating sporadic tumors is no more than a few hundred. Targeting essential genes in deleted regions of chromosome 3p could represent a potential preventative strategy for renal cancer. HiSeq X Ten;ILLUMINA 164
EGAD00001003328 Clinical and genetic information of an individual with RVOT-VT and a KCNK2 (TREK1) gene mutation obtained after whole exome sequencing. 1
EGAD00001001421 Clinical Implications of Genomic Alterations in the Tumour and Circulation of Pancreatic Cancer Patients Illumina MiSeq; 125 fastq
EGAD00010000871 CLL and normal B cell samples using 450K 226
EGAD00001000004 CLL cancer Sample Sequencing Illumina Genome Analyzer II, Illumina Genome Analyzer 5 srf
EGAD00001000013 CLL Cancer Whole Genome Sequencing Illumina Genome Analyzer II 19 srf
EGAD00010000280 CLL Expression array Affymetrix snp 6.0 4
EGAD00010000238 CLL Expression array Affymetrix GeneChip Human Genome U133 plus 2.0 64
EGAD00010000472 CLL Expression Array Affymetrix U219 219
EGAD00010000470 CLL Expression Array GPL570 20
EGAD00010000642 CLL Expression Array 144
EGAD00010000875 CLL Expression Array Affymetrix U219 1,008
EGAD00010000252 CLL Expression Arrays Affymetrix U219 137
EGAD00010000254 CLL Methylation Arrays Illumina HumanMethylation450 165
EGAD00001001256 Clonal hematopoiesis was investigated in patients with aplastic anemia using next-generation sequencing and single-nucleotide polymorphism (SNP) array-based karyotyping. Illumina HiSeq 2000; 186 bam
EGAD00001002726 Cluster headache is a relatively rare headache disorder, typically characterized by multiple daily, short-lasting attacks of excruciating, unilateral (peri-)orbital or temporal pain associated with autonomic symptoms and restlessness. To better understand the pathophysiology of cluster headache, we used RNA sequencing to identify differentially expressed genes and pathways in whole blood of patients with episodic (n = 19) or chronic (n = 20) cluster headache in comparison with headache-free controls (n = 20). Illumina HiSeq 4000;ILLUMINA 60
EGAD00001000136 CML blast phase rearrangement screen Illumina HiSeq 2000 6 bam
EGAD00001000111 CML Discovery Project Illumina Genome Analyzer II 6 bam
EGAD00010001240 CN/LOH-profile of Translocation-negative FL_1 Affymetrix SNP 6.0 1
EGAD00010001237 CN/LOH-profile of Translocation-negative FL_10 Affymetrix SNP 6.0 1
EGAD00010001235 CN/LOH-profile of Translocation-negative FL_11 Affymetrix SNP 6.0 1
EGAD00010001238 CN/LOH-profile of Translocation-negative FL_2 Affymetrix SNP 6.0 1
EGAD00010001236 CN/LOH-profile of Translocation-negative FL_4 Affymetrix SNP 6.0 1
EGAD00010001233 CN/LOH-profile of Translocation-negative FL_5 Affymetrix SNP 6.0 1
EGAD00010001239 CN/LOH-profile of Translocation-negative FL_6 Affymetrix SNP 6.0 1
EGAD00010001241 CN/LOH-profile of Translocation-negative FL_7 Affymetrix SNP 6.0 1
EGAD00010001232 CN/LOH-profile of Translocation-negative FL_8 Affymetrix SNP 6.0 1
EGAD00010001234 CN/LOH-profile of Translocation-negative FL_9 Affymetrix SNP 6.0 1
EGAD00010001425 Codelink Human Whole Genome from Blood taken at 72 hours after birht Codelink Human Whole Genome Bioarray 9
EGAD00010001424 Codelink Human Whole Genome from Blood taken at 72 hours after birht Codelink Human Whole Genome Bioarray 11
EGAD00010000246 Coeliac disease cases and control samples. (1958BC samples excluded) Illumina ImmunoBeadChip - Illuminus, GenoSNP 10,758
EGAD00001003103 Cohort of 19 ADPKD patients characterized using long-read sequencing. The variant identification provided high sensitivity in identifying PKD1 pathogenic variants, with a diagnostic yield of 94.7%. This dataset includes all sequencing data (BAM files) of the 19 patients, in addition to their raw variants (unfiltered) obtained from the long-read sequencing as well as Sanger sequencing (VCF file). PacBio RS II;PACBIO_SMRT 19
EGAD00000000055 COLO-829 is a publicly available immortal cancer cell line and COLO-829BL is a lymphoblastoid cell line derived from the same patient Illumina Genome Analyzer II 2
EGAD00010000274 Colon matched tumour samples Illumina_2.5M 74
EGAD00010000272 Colon tumour samples Illumina_2.5M 75
EGAD00001000363 Common variable immunodeficiency (CVID) is the most common form of primary immunodeficiency with an estimated incidence of 1:10,000. It has been apparent for many years that CVID has a genetic component, occurs frequently in families and can have both a recessive or dominant mode of inheritance. In recent years, 4 genes underlying CVID have been identified; however, mutations within in them are estimated to account for no more than 10% of all cases of CVID. We have identified a multi-generational family with autosomal dominant CVID. Genome-wide linkage analysis has mapped the locus underlying CVID in this family to an approximately 9.2 Mb interval on chromosome 3q27.3-q29, between the markers D3S3570 and D3S1265. This locus is distinct from any of the previously mapped susceptibility loci suggesting a novel genetic variant is responsible for disease in this family. The aim of this study is to use exome sequencing of affected (n = 4) and unaffected (n = 4) individuals, in tandem with the available genetic mapping data, to identify the causal variant underlying CVID in this family. Illumina HiSeq 2000; 8 bam
EGAD00001001041 Comparison of genomic rearrangements and DNA methylation patterns between different foci of multiple synchronous (multifocal and multicentric) invasive breast cancers. Illumina Genome Analyzer II;, Illumina HiSeq 2000; 305
EGAD00001002069 Complete genomics data for VCaP and PC346c. 2 other
EGAD00001000702 Complete set of bam files associated with study EGAS00001000622 190 bam
EGAD00001000877 Complete WGS and RNA-Seq dataset for Australian ICGC ovarian cancer sequencing project 2014-07-07, representing 93 donors. Sequencing was performed on Illumina HiSeq. Alignment of the lane-level fastq data was performed with bwa (WGS data) and RSEM (transcriptome data). For this dataset lane-level .bam files have been merged and de-duplicated to create a single bam file for each sample type (tumour/normal) for each donor. This dataset supersedes all previous datasets for this study. 331 bam
EGAD00001002228 Congenital anosmias can be complete (the lack of a sense of smell) or specific (the inability to detect specific smells). Here we obtained genomic DNA from families with multiple individuals with anosmia, suggesting they are congenital. These include those inherited in a manner consistent with dominant and recessive alleles. We have sequenced the exomes of both affected and unaffected family members on the Illumina platform. Illumina HiSeq 2000; 24 cram
EGAD00001002210 Congenital anosmias can be complete (the lack of a sense of smell) or specific (the inability to detect specific smells). To date, only a single recessive gene underlying complete anosmia has been identified. Here we sequenced the exomes of 10 individuals from a single family, including three with complete anosmia, across three generations to identify the genetic basis of congenital anosmia in this family. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/ Illumina HiSeq 2000; 10 cram
EGAD00010000654 Control samples using SNP 6.0 Arrays 0
EGAD00010000504 Control samples using SNP Array 6.0 Affymetrix_U133plus2- 35
EGAD00010000620 Controls 3,683
EGAD00010000458 Controls using 450K DNA methylation 151
EGAD00010000494 Controls_Human660W-Quad_v1_A Illumina_Human660W-Quad_v1_A-Not supplied 4
EGAD00000000017 Cord blood control samples from Gambia 0
EGAD00001002256 Corresponding data set is composed of whole exome sequencing of Korean ER positive breast cancer under 35. This set provides 100 alignment files from normal-tumor paired whole exome sequencing of 50 patients. This is a part of total project data set. Illumina HiSeq 2500;ILLUMINA, Illumina HiSeq 2500; 100 bam
EGAD00001000605 CR products were obtained from each target loci using genomic DNA from human iPS cells. Subsequently, PCR products are pooled and subjected to Illumina library preparation. The library will be sequenced either by HiSeq or MiSeq. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/ Illumina MiSeq;, Illumina HiSeq 2000; 10 bam
EGAD00001000076 CRLF2 sequencing project Illumina HiSeq 2000 13 bam
EGAD00001000077 CRLF2 sequencing project Exomes Illumina HiSeq 2000 26 bam
EGAD00010001155 Crohn's disease DNA samples genotyped using UK Biobank Axiom array Axiom UKB 1,676
EGAD00010000542 Cusihg's syndrome normal samples using 250K Affymetrix 250K Nsp-GTYPE 16
EGAD00010000544 Cusihg's syndrome tumor samples using 250K Affymetrix 250K Nsp-GTYPE 16
EGAD00001000654 DATA FILES FOR BALL-PAX5 Illumina HiSeq 2000; 153 bam
EGAD00001001352 Data files for CONSERTING (WGS) Illumina HiSeq 2000; 38 bam
EGAD00001003134 DATA FILES FOR GRUBER SJAMLM7 EXOME Illumina HiSeq 2000;ILLUMINA 114
EGAD00001003135 DATA FILES FOR GRUBER SJAMLM7 RNASEQ Illumina HiSeq 2000;ILLUMINA 86
EGAD00001000657 DATA FILES FOR Histone Capture bams Illumina HiSeq 2000; 962 bam
EGAD00001000655 DATA FILES FOR Histone-NSD2_RNASeq Illumina HiSeq 2000; 8 bam
EGAD00001002692 DATA FILES FOR MULLIGHAN MEF2D RNASEQ STRANDED Illumina HiSeq 2000;ILLUMINA 200 bam
EGAD00001002704 DATA FILES FOR MULLIGHAN MEF2D RNASEQ UNSTRANDED Illumina HiSeq 2000;ILLUMINA 217 bam
EGAD00001001418 DATA FILES FOR PCGP Dyer_iPSC 5hmc Illumina HiSeq 2000; 8 bam
EGAD00001001416 DATA FILES FOR PCGP Dyer_iPSC TEBS Illumina HiSeq 2000; 18 bam
EGAD00001001415 DATA FILES FOR PCGP Dyer_iPSC WGS Illumina HiSeq 2000; 2 bam
EGAD00001001864 DATA FILES FOR PCGP MB WGS - Supersedes (EGAD00001000269) Illumina HiSeq 2000; 76 bam
EGAD00001002676 DATA FILES FOR PCGP SJERG (WGS) Illumina HiSeq 2000;ILLUMINA 44 bam
EGAD00001002677 DATA FILES FOR PCGP SJERG (WXS) Illumina HiSeq 2000;ILLUMINA 42 bam
EGAD00001001248 DATA FILES FOR PCGP SJETP WXS Illumina HiSeq 2000; 13 bam
EGAD00001001245 DATA FILES FOR PCGP SJINF WES Illumina HiSeq 2000; 40 bam
EGAD00001001247 DATA FILES FOR PCGP SJMEL RNASEQ Illumina HiSeq 2000; 7 bam
EGAD00001001246 DATA FILES FOR PCGP SJMEL WXS Illumina HiSeq 2000; 28 bam
EGAD00001001054 DATA FILES FOR Ph-likeALL WES Illumina HiSeq 2000; 23 bam
EGAD00001000160 DATA FILES FOR SJACT Illumina HiSeq 2000 16 bam
EGAD00001000259 DATA FILES FOR SJAMLM7 Illumina HiSeq 2000; 8 bam
EGAD00001000268 DATA FILES FOR SJCBF Illumina HiSeq 2000; 34 bam
EGAD00001000162 DATA FILES FOR SJEPD Illumina HiSeq 2000 44 bam
EGAD00001000853 DATA FILES FOR SJEPD Illumina HiSeq 2000; 37 bam
EGAD00001000854 DATA FILES FOR SJEPD Illumina HiSeq 2000; 77 bam
EGAD00001001020 DATA FILES FOR SJEWS-WGS Illumina HiSeq 2000; 38 bam
EGAD00001000165 DATA FILES FOR SJINF Illumina HiSeq 2000 46 bam
EGAD00001001098 DATA FILES FOR SJINF RNASeq Illumina HiSeq 2000; 63 bam
EGAD00001000352 DATA FILES FOR SJLGG Illumina HiSeq 2000; 7 bam
EGAD00001000353 DATA FILES FOR SJLGG Illumina HiSeq 2000; 45 bam
EGAD00001000161 DATA FILES FOR SJLGG Illumina HiSeq 2000 33 bam
EGAD00001000695 DATA FILES FOR SJLGG Illumina HiSeq 2000; 46 bam
EGAD00001001032 DATA FILES FOR SJMEL-WGS Illumina HiSeq 2000; 12 bam
EGAD00001000159 DATA FILES FOR SJOS Illumina HiSeq 2000 37 bam
EGAD00001001053 DATA FILES FOR SJOS-WGS-2ndBatch Illumina HiSeq 2000; 27 bam
EGAD00001000163 DATA FILES FOR SJPHALL Illumina HiSeq 2000 18 bam
EGAD00001001016 DATA FILES FOR SJPhLike-RNASeq Illumina HiSeq 2000; 125 bam
EGAD00001001045 DATA FILES FOR SJRB Illumina HiSeq 2000; 20 bam
EGAD00001000164 DATA FILES FOR SJRHB Illumina HiSeq 2000, Illumina HiSeq 2000; 29 bam
EGAD00001000878 DATA FILES FOR SJRHB RNA-Seq Illumina HiSeq 2000; 42 bam
EGAD00001001059 DATA FILES FOR SJRHB-WES Illumina HiSeq 2000; 56 bam
EGAD00001001052 DATA FILES FOR SJTALL Illumina HiSeq 2000; 24 bam
EGAD00001002201 Data for paper: Epigenetic dynamics of monocyte to macrophage differentiation with Chip Seq, NOMe, mRNA, total RNA, noncoding RNA, whole genome bisulfite seq, Illumina HiSeq 2000; 8 readme_file,fastq,bam
EGAD00001001668 Data from the paper Context-specific Effects of TGFβ/SMAD3 in Cancer Are Modulated by the Epigenome. Tufegdzic et al, Cell Reports 2015 Illumina HiSeq 2500; 12 bam
EGAD00001001667 Data from the paper Context-specific Effects of TGFβ/SMAD3 in Cancer Are Modulated by the Epigenome. Tufegdzic et al, Cell Reports 2015 Illumina MiSeq; 12 bam
EGAD00001001669 Data from the paper Context-specific Effects of TGFβ/SMAD3 in Cancer Are Modulated by the Epigenome. Tufegdzic et al, Cell Reports 2015 Illumina HiSeq 2500; 42 bam
EGAD00001001345 Data from the study of subclonal metastatic expansion in prostate cancer. RNA-seq of twelve samples, tumour and benign tissue, from the four initial patients. Illumina HiSeq 2000; 12 fastq
EGAD00001001343 Data from the study of subclonal metastatic expansion in prostate cancer. Whole genome shotgun sequencing of fifteen samples, tumour and whole blood, from the four initial patients. Illumina HiSeq 2000; 15 fastq
EGAD00001001344 Data from the study of subclonal metastatic expansion in prostate cancer. Whole genome shotgun sequencing of six samples, tumour and whole blood, from the three additional patients whose somatic variants were examined in depth. Illumina HiSeq 2000; 6 fastq
EGAD00001001399 Data represent genome-wide DNA methylation profiles obtained by MethylCap-seq (Diagenode’s MethylCap-kit based purification followed by Illumina GAIIx sequencing), for 70 brain tissue samples, including 65 glioblastoma samples and 5 non-tumoral tissues (obtained from epilepsy surgery). Illumina Genome Analyzer IIx; 70 fastq
EGAD00001000275 Data set for Whole-genome-Sequencing of adult medulloblastoma Illumina HiSeq 2000; 10 bam
EGAD00001000745 Data supporting the paper Transcriptional diversity during lineage commitment of human blood progenitors Illumina HiSeq 2000; 26 bam,phenotype_file,readme_file
EGAD00001003602 Dataset consisting of: (1) N=234 genome-wide chromatin accessibility (ATAC-seq) profiles for distinct N=21 healthy old and N=28 healthy young subjects. ATAC-seq biological samples provided for the following tissues: PBMC (N=24), CD14+ monocytes (N=18), CD8+ memory T cells (N=7), CD8+ naive T cells (N=7), CD4+ memory T cells (N=7), CD4+ naive T cells (N=7), and naive B cells (N=7). (2) N=39 genome-wide transcription (RNA-seq) data for distinct N=15 healthy old and N=24 healthy young subjects' PBMCs. Illumina HiSeq 2500;ILLUMINA 273
EGAD00001001359 Dataset contains Exome-seq and RNA-seq from 2 GBM patients, as well as RNA-seq from the derived cultured cells (GNS). 6 bam
EGAD00001000777 Dataset contains MeDIP-Seq, MRE-Seq and H3K4me3 ChIP-Seq data on 5 GBM patients. 16 bam
EGAD00001003311 Dataset contains one sample derived from gDNA of human fibroblasts. Files are in FASTQ format and were generated using the Agilent SureSelect Human All Exon 50Mb Kit and followed by Next Generation Sequencing on a HighSeq2000 instrument (Illumina). Illumina HiSeq 2000;ILLUMINA 1
EGAD00001001305 Dataset contains WES data from 3 astrocytoma patients: blood as control, primary tumor and recurrent tumor 9 bam
EGAD00001002133 Dataset contains Whole Exome Sequencing(WES) data from 37 individuals as aligned bam-files. The reads have been aligned using bowtie2 to human genome hg19 build. Illumina HiSeq 2000; 37 bam
EGAD00001000758 dataset for BGI bladder cancer project Illumina Genome Analyzer II; 198 fastq
EGAD00001000760 dataset for esophageal cancer, 17pairs for whole-genome sequencing and 71pairs for whole-exome sequencing Illumina HiSeq 2000; 176 fastq
EGAD00001001006 Dataset for whole exome sequencing of 113 pairs of tumor and normal DNA samples along with 8 cell lines. Illumina HiSeq 2000; 234 fastq
EGAD00001000810 Dataset for whole exome sequencing of 49 tumor-blood pairs and transcriptome sequencing of 44 tumors for adrenocortical tumors Illumina HiSeq 2000; 106 fastq
EGAD00001003121 Dataset is composed of FASTQ files from 165 samples of small round cell sarcomas which were RNA-sequenced (whole transcriptome) with either Illumina HiSeq 2500 (120 million reads per sample, paired-end 100 pb) or Illumina NextSeq 500 (110 million reads per sample, paired-end 150) Illumina HiSeq 2500;ILLUMINA, NextSeq 500;ILLUMINA 165
EGAD00001000709 Dataset of CageKid Blood DNA samples 95 bam
EGAD00001000719 Dataset of CageKid Normal RNA samples 45 bam
EGAD00001000717 Dataset of CageKid Tumor DNA samples 95 bam
EGAD00001000718 Dataset of CageKid Tumor RNA samples 91 bam
EGAD00001000720 Dataset of CageKid tumor-normal paired RNA samples 90 bam
EGAD00001000176 DATA_SET_Comparing_sequencing_four_proto-typical_Burkitt_lymphomas_BL_IG-MYC_translocation Illumina HiSeq 2000;, Illumina Genome Analyzer IIx; 8 bam
EGAD00001000174 DATA_SET_Coverage_bias_sensitivity_of_variant_calling_for_4_WG_seq_tech Complete Genomics;, unspecified; 4 bam
EGAD00001000270 DATA_SET_EOP-PCA-LargeAndSmallTumors1 Illumina HiSeq 2000; 18 bam
EGAD00001000122 DATA_SET_ICGC_PedBrainTumor_Medulloblastoma Illumina HiSeq 2000, Illumina Genome Analyzer IIx 206 bam
EGAD00001000274 DATA_SET_TRANSCIPTOME_Comparing_sequencing_four_proto-typical_Burkitt_lymphomas_BL_IG-MYC_translocation Illumina HiSeq 2000; 4 bam
EGAD00010000096 DBA case samples using 250K Nsp Affymetrix_250K(Nsp) - gtype 27
EGAD00001001100 DCC Project Code: SKCA-BR Skin Adenocarcinoma - BR Brazil Illumina HiSeq 2500;ILLUMINA 200
EGAD00001003390 DCM-cases (149 human DCM samples) human heart biopsies from 149 patients with dilated cardiomyopathy (DCM) were subjected to RNA sequencing in order to assess transcriptome variation. We used Illumina HiSeq2000 technology. Each sample-dataset contains the output from tophat-1.4.1 (one *.bam file with the aligned reads and two *.fq files one with the not aligned forward read and one with the revers unaligned reads). We reveal extensive differences of gene expression and splicing between dilated cardiomyopathy patients and controls. Illumina HiSeq 2000;ILLUMINA 149
EGAD00001003391 DCM-controls (113 human non-DCM samples) human heart biopsies from 113 non-diseased controls were subjected to RNA sequencing in order to assess transcriptome variation. We used Illumina HiSeq2000 technology. Each sample-dataset contains the output from tophat-1.4.1 (one *.bam file with the aligned reads and two *.fq files one with the not aligned forward read and one with the revers unaligned reads). We reveal extensive differences of gene expression and splicing between dilated cardiomyopathy patients and controls. Illumina HiSeq 2000;ILLUMINA 113
EGAD00001001114 DDD DATAFREEZE 2013-12-18: 1133 trios - exome sequence BAM files (Ref: DDD Nature 2015) 3,335 bam,tab
EGAD00001001413 DDD DATAFREEZE 2013-12-18: 1133 trios - README, family trios, phenotypes, validated DNMs (Ref: DDD Nature 2015) 3,335 readme_file,tab
EGAD00001001355 DDD DATAFREEZE 2013-12-18: 1133 trios - VCF files (Ref: DDD Nature 2015) 3,335 readme_file,tab,vcf
EGAD00001002748 DDD DATAFREEZE 2014-11-04: 4293 trios - exome sequence CRAM files 12,548 cram,bam
EGAD00001001977 DDD DATAFREEZE 2014-11-04: 4293 trios - phenotypic and family descriptions 12,539 phenotype_file
EGAD00001001848 DDD DATAFREEZE 2014-11-04: 4293 trios - VCF files 12,539 vcf
EGAD00001000251 De novo mutations in schizophrenia Illumina HiSeq 2000; 611 bam
EGAD00001003122 December 2016 data update (bam/fastq for WGBS on samples CEMT0062, CEMT0068, CEMT0072, CEMT0086, CEMT0087) for reference epigenomes generated at Centre for Epigenome Mapping Technologies (Canadian Epigenetics, Environment and Health Research Consortium), Genome Sciences Center, B.C. Cancer Agency, Vancouver, Canada as part of the International Human Epigenome Consortium. Illumina HiSeq 2500;ILLUMINA 5
EGAD00001001214 Deep (>25x mean coverage) whole genome sequencing on 5-10 families drawn from the Scottish Family Health Study with four or more children. Illumina HiSeq 2000; 19 bam
EGAD00001003211 Deep (>25x mean coverage) whole genome sequencing on 5-10 families drawn from the Scottish Family Health Study with four or more children. HiSeq X Ten;ILLUMINA 57
EGAD00001002527 DEEP (German Epigenome Project) sequence data of following samples (Sequencing Types: Chip-Seq, WGBS-Seq, RNA-Seq, sncRNA-Seq, NOMe-Se, DNase-Seq): 41_Hf01_LiHe_Ct, 41_Hf02_LiHe_Ct, 41_Hf03_LiHe_Ct, 01_HepG2_LiHG_Ct1, 01_HepG2_LiHG_Ct2, 01_HepaRG_LiHR_D31, 01_HepaRG_LiHR_D32, 01_HepaRG_LiHR_D33, 43_Hm01_BlMo_Ct, 43_Hm03_BlMo_Ct, 43_Hm05_BlMo_Ct, 43_Hm03_BlMa_Ct, 43_Hm05_BlMa_Ct, 43_Hm03_BlMa_TO, 43_Hm05_BlMa_TO, 43_Hm03_BlMa_TE, 43_Hm05_BlMa_TE, 51_Hf01_BlCM_Ct, 51_Hf03_BlCM_Ct, 51_Hf04_BlCM_Ct, 51_Hf02_BlCM_Ct, 51_Hf05_BlCM_Ct, 51_Hf06_BlCM_Ct, 51_Hf06_BlCM_T1, 51_Hf06_BlCM_T2, 51_Hf03_BlEM_Ct, 51_Hf04_BlEM_Ct, 51_Hf02_BlEM_Ct, 51_Hf05_BlEM_Ct, 51_Hf06_BlEM_Ct, 51_Hf06_BlEM_T1, 51_Hf06_BlEM_T2, 51_Hf03_BlTN_Ct, 51_Hf04_BlTN_Ct, 51_Hf02_BlTN_Ct, 51_Hf05_BlTN_Ct, 51_Hf06_BlTN_Ct, 51_Hf06_BlTN_T1, 51_Hf06_BlTN_T2, 51_Hf07_BmTM4_Ct, 51_Hf08_BlTM4_Ct, 51_Hf08_BmTM4_SP1, 51_Hf08_BmTM4_SP2, 51_Hf05_BlTA_Ct, 44_Mm01_WEAd_C2, 44_Mm03_WEAd_C2, 44_Mm02_WEAd_C2, 44_Mm07_WEAd_C2, 44_Mm04_WEAd_C1, 44_Mm05_WEAd_C1 Illumina HiSeq 2000;ILLUMINA, Illumina HiSeq 2500;ILLUMINA 50 fastq
EGAD00001000258 Deep RNA sequencing in CLL Illumina Genome Analyzer II; 107 fastq
EGAD00001001870 Deep sequencing of 151 cancer genes in 6 synchronous CRC of 3 patients Illumina MiSeq; 6 bam
EGAD00001000220 Deep sequencing of CTCs 454 GS FLX Titanium;, Illumina MiSeq; 3 bam
EGAD00001000225 Deep sequencing of KRAS 454 GS FLX Titanium; 8 fastq
EGAD00001001445 Deep sequencing of melanoma for driver mutations Illumina MiSeq; 3 cram
EGAD00001001123 Deep sequencing of two skin biopsies to study the landscape of somatic mutations in human adult tissues. Illumina HiSeq 2000; 2 cram
EGAD00010000960 Definite and borderline rheumatic heart disease cases and patients with mild non-diagnostic valvulopathy recruited in Samoa HumanCore-24 BeadChip 126
EGAD00001001441 Despite the established role of the transcription factor MYC in cancer, little is known about the impact of a new class of transcriptional regulators, the long non-coding RNAs (lncRNAs), on the way MYC is able to influence cellular transcriptome. To this aim we have intersected RNA-sequencing data from two MYC-inducible cell lines and from a cohort of 91 mature B-cell lymphomas carrying, or not carrying, genetic variants resulting in MYC over-expression. By this approach, we identified 13 lncRNAs differentially expressed in IG-MYC-positive Burkitt lymphoma and regulated in the same direction by MYC in the model cell lines. Among them we focused on a lncRNA that we named MINCR, for MYC-Induced long Non-Coding RNA, showing a strong correlation with MYC expression in MYC-positive lymphomas and also in pancreatic ductal adenocarcinomas. To understand its cellular role we performed RNA interference (RNAi) experiments and found that MINCR knock-down is associated with a reduction in cellular viability, due to an impairment in cell cycle progression. Differential gene expression analysis following RNAi showed a strongly significant enrichment of cell cycle genes among the genes down-regulate following MINCR knock-down. Interestingly these genes are enriched in MYC binding sites in their promoters, suggesting that MINCR acts as a modulator of MYC transcriptional program. Accordingly, following MINCR knock-down, we observed a reduction in the binding of MYC to the promoters of selected cell cycle genes. Finally we provide evidences that down-regulation of AURKA, AURKB and CTD1 may explain the reduction in cellular proliferation observed upon MINCR knock-down. We therefore suggest that MINCR is a newly identified player in the MYC transcriptional network able to control the expression of cell cycle genes. Illumina HiSeq 2000;, Illumina HiSeq 2500; 49 fastq
EGAD00001002229 Detection of BAP1 mutations in DNA from uveal melanoma and mesothelioma samples. Illumina HiSeq 2000; 22 cram
EGAD00001000025 Determination of the molecular nature of the Vel blood group by exome sequencing Illumina Genome Analyzer II 4 srf
EGAD00001001332 Development of a method for separation and parallel sequencing of the genomes and transcriptomes of single cells. Illumina MiSeq;, HiSeq X Ten;, Illumina HiSeq 2500; 700 bam,cram
EGAD00010001400 Difference in gene expression values between case and control, log2 values. Blood transcriptome from women participating in the Norwegian Women and Cancer study (NOWAC) Post-genome Cohort taken up to eight years before brest cancer diagnosis. Illumina HumanWG-6 version 3 or Illumina HumanHT-12 expression bead chip, combined on identical nucleotide universal identifiers. Illumina HumanWG-6 467
EGAD00001003305 Diffuse Intrinsic Pontine Glioma (DIPG) is a fatal brain cancer that arises in the brainstem of children with no effective treatment. To understand what drives DIPGs we integrated whole-genome-sequencing with methylation, expression and copy-number profiling. AB SOLiD System (ABI_SOLID), Illumina HiSeq 2500 (ILLUMINA) 23
EGAD00010001099 Digital images of ovarian cancer metastases Aperio 127
EGAD00010000881 Digital images of ovarian cancer sections Aperio 91
EGAD00001000200 Dilgom Exome Illumina HiSeq 2000; 130 bam
EGAD00001002148 Directed differentiation of stem cells offers a scalable solution to the need for human cell models recapitulating islet biology and T2D pathogenesis. We profiled mRNA expression at six stages of an induced pluripotent stem cell (iPSC) model of endocrine pancreas development from two donors, and characterized the distinct transcriptomic profiles associated with each stage. Established regulators of endodermal lineage commitment, such as SOX17 (log2 fold change [FC] compared to iPSCs=14.2, p-value=4.9x10-5) and the pancreatic agenesis gene GATA6 (log2 FC=12.1, p-value=8.6x10-5), showed transcriptional variation consistent with their known developmental roles. However, these analyses highlighted many other genes with stage-specific expression patterns, some of which may be novel drivers or markers of islet development. For example, the leptin receptor gene, LEPR, was most highly expressed in published data from in vivo-matured cells compared to the endocrine pancreas-like cells (log2 FC=5.5, p-value=2.0x10-12), suggesting a role for the leptin pathway in the maturation process. Endocrine pancreas-like cells showed significant stage-selective expression of adult islet genes, including INS, ABCC8, and GLP1R, and enrichment of relevant GO-terms (e.g. “insulin secretion”; odds ratio=4.2, p-value=1.9x10-3): however, principal component analysis indicated that in vitro-differentiated cells were more immature than adult islets. Integration of the stage-specific expression information with genetic data from T2D genome-wide association studies revealed that 46 of 82 T2D-associated loci harbor genes present in at least one developmental stage, facilitating refinement of potential effector transcripts. Together, these data show that expression profiling in an iPSC islet development model can further understanding of islet biology and T2D pathogenesis. Illumina HiSeq 2000; 12 bam
EGAD00001000707 Discovery of resistance mechanisms to the BRAF inhibitor vemurafenib in metastatic BRAF mutant melanoma by massively-parallel sequencing of tumour samples. Comparison of genomic characteristics of pretreatment 'sensitive' to recurrence 'resistant' tumours to identify the genetics of drug resistance. Illumina HiSeq 2000; 57 cram
EGAD00001000946 Divergent clonal selection dominates medulloblastoma at recurrence 125 bam
EGAD00010000658 DLBCL 148 SNP 6.0 Cohort 0
EGAD00001001028 DNA belonging to 16 tumour/normal samples were treated with bisulfite, then up to 5 different bisulfite PCRs were performed in each one of the samples. Amplicons form the same sample were pooled and submitted to sequencing on a MiSeq platform. Illumina MiSeq; 18 cram
EGAD00001001017 DNA extracted from multiple biopsies taken from different areas of primary lung tumours will be subjected to targeted re-sequencing and analysed in order to assess intra-tumour heterogeneity with respect to mutations in a selection of cancer related genes. Illumina HiSeq 2000; 31 bam,cram
EGAD00001001938 DNA from each sample (100ng) was sheared on Covaris S220 (Covaris): duty cycle - 10%, intensity -5.0, bursts per sec - 200, duration - 300 sec, mode - frequency sweeping, power - 23V, temperature -5:5 ?C to 6 ?C, water level - 13. Libraries were prepared with the TruSeq Nano DNA LT Sample Prep Kit (Illumina) using a modi?ed protocol - Sample Puri?cation Beads were replaced by Agencourt AMPure XP beads (Beckman Coultier) and size selection after the End Repair was done to remove only the short fragments. Quality and quantity for contructed libraries were assessed with DNA 7500 kit on Agilent 2100 Bioanalyzer and with Kapa Quanti?cation kit (KAPA Biosystems) on 7900HT Fast Real-Time PCR System (Applied Biosystems) according to the supplier's recommendations, respectively. Libraries from 18 barcoded samples were pooled together in equimolar amounts and each pool was loaded on a single lane of a HiSeq Single End Flowcell (Illumina), followed by cluster generation on a cBot (Illumina) and sequencing on a HiSeq 2500 (Illumina) in a single-read 50bp mode. Reads were aligned using bwa-mem v0.7.12-r1039 [10] to the 1000 genomes version of human genome build GRCh37. Picard (http://picard.sourceforge.net) was used to remove duplicate reads. Illumina HiSeq 2500; 60 bam
EGAD00010001296 DNA methylation analysis from primary human JMML and normal blood samples using 450K Illumina_450K 0
EGAD00010000379 DNA methylation analysis of 2 peripheral blood samples HumanMethylation450k Bead Chip - Genome Studio 2
EGAD00010000646